0001792044-23-000008 | 10-K | XBRL Viewer

Print Document View Excel Document

Employee Benefit Plans (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized net actuarial losses exceed higher of market value of plan assets or the projected benefit obligation at the beginning of the year	10.00%
Accumulated benefit obligation	$ 1,310.0	$ 1,860.0
Defined benefit plan, ultimate health care cost trend rate	6.30%
Defined benefit plan, ultimate health care cost trend rate, projected	4.00%
Total employer contributions	$ 111.5	$ 107.4	$ 115.5
Fiscal Year 2017
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined benefit plan, ultimate health care cost trend rate	6.90%
Defined benefit plan, ultimate health care cost trend rate, projected	4.00%
Deferred Base Salary
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, maximum annual contribution per employee, percent	50.00%
Deferred Bonus
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined contribution plan, maximum annual contribution per employee, percent	100.00%

Equity Method Investments

12 Months Ended

Dec. 31, 2022

Equity Method Investments and Joint Ventures [Abstract]

Equity Method Investments

The Company had three equity method investments in limited liability companies that owned refined coal production plants whose activities qualified for income tax credits under Section 45 of the Code. The Company did not consolidate these entities as we had determined that we were not the primary beneficiary of these entities and did not have the power to individually direct the activities of these entities. Accordingly, these investments were accounted for under the equity method of accounting. For each of the clean energy investments, the Company had entered into notes payable with the respective project sponsor, which in part were paid to the sponsor as certain production levels were met. The law that provided for IRC Section 45 tax credits expired during the year ended December 31, 2021for all three clean energy investments and all of the clean energy investments have wound down operations.

During the years ended December 31, 2021 and 2020, the Company reduced its long-term obligations for its three investments as a result of lower than anticipated production levels and lower expected future variable debt payments to the respective project sponsor. The Company recognized a net gain of approximately $5.7 million and $21.4 million, respectively, which was recognized as a component of Other (income) expense, net in the consolidated statements of operations.

The carrying values and respective balance sheet location of the Company’s clean energy investments were as follows at December 31, 2021:


(In millions)									December 31, 2021

Other current liabilities									10.9

Summarized financial information, in the aggregate, for the Company’s three equity method, clean energy investments on a 100% basis as of December 31, 2021 and for the years ended December 31, 2021 and 2020 are as follows:


(In millions)	December 31, 2021
Current assets	$	4.2
Noncurrent assets	0.5
Total assets	4.7
Current liabilities	2.8

Total liabilities	2.8
Net assets	$	1.9


	Year Ended December 31,
(In millions)	2021		2020
Total revenues	$	326.7	$	374.5
Gross loss	(4.6)		(4.6)
Operating and non-operating expense	16.8		19.0
Net loss	$	(21.4)	$	(23.6)

The Company’s net losses from its equity method investments included amortization expense related to the excess of the cost basis of the Company’s investment over the underlying assets of each individual investee. For the years ended December 31, 2021 and 2020, the Company recognized net losses from equity method investments of $61.9 million, and $48.4 million, respectively, which were recognized as a component of Other (income) expense, net in the consolidated statements of operations. The Company recognized the income tax credits and benefits from the clean energy investments as part of its provision for income taxes.

Commitments	12 Months Ended
Commitments	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments	Commitments The Company has entered into employment and other agreements with certain executives and other employees that provide for compensation, retirement and certain other benefits. These agreements provide for severance payments under certain circumstances. Additionally, the Company has split-dollar life insurance agreements with certain retired executives. In conjunction with the Combination, Viatris entered into a TSA with Pfizer pursuant to which each party provides certain limited transition services to the other party generally for an initial period of 24 months from the closing date of the Combination. In addition to the monthly service fees under the TSA, Viatris has agreed to reimburse Pfizer for fifty percent of the costs, up to the first $380 million incurred, to establish and wind down the TSA services. Viatris will be required to fully reimburse Pfizer for total costs in excess of $380 million. During the years ended December 31, 2022 and 2021, the Company incurred $54.5 million and $30.4 million, respectively, related to this provision of the TSA, and approximately $138.0 million during the period beginning on the closing date of the Combination and ended December 31, 2022. We expect to incur future costs related to the completion of the services. As of December 31, 2022, the Company has exited substantially all transition services with Pfizer. In conjunction with the Combination, during the year ended December 31, 2020, the Company accrued approximately $26.9 million due to change in control clauses in employment arrangements for certain former Mylan employees, which was paid during 2021. In addition, the Company entered into retention agreements with certain key employees, whereby they agreed to continue to provide service to the Company for a period of time after the Combination. The Company is recording the expense for these agreements over the applicable service periods. In conjunction with the Biocon Biologics Transaction, Viatris and Biocon Biologics also entered an agreement pursuant to which Viatris is providing commercialization and certain other transition services on behalf of Biocon Biologics, including billings, collections and the remittance of rebates, to ensure business continuity for patients, customers and colleagues. In the normal course of business, Viatris periodically enters into employment, legal settlement and other agreements which incorporate indemnification provisions. While the maximum amount to which Viatris may be exposed under such agreements cannot be reasonably estimated, the Company maintains insurance coverage, which management believes will effectively mitigate the Company’s obligations under these indemnification provisions. No amounts have been recorded in the consolidated financial statements with respect to the Company’s obligations under such agreements.

Leases

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Leases

The Company has operating leases of real estate, consisting primarily of administrative offices, manufacturing and distribution facilities, and R&D facilities. We also have operating leases of certain equipment, primarily automobiles, and certain limited supply arrangements.

We elected to apply the practical expedient to not separate lease and non-lease components for our leases except for those related to certain limited supply arrangements. We have also elected to apply the short-term lease recognition exemption which means we will not recognize ROU assets or lease liabilities for leases with an initial term of 12 months of less.

As of December 31, 2022, the Company recognized ROU assets of $259.3 million and total lease liabilities of $262.0 million. The Company’s ROU assets are recorded in other assets. The related lease liability balances are recorded in other current liabilities and other long-term obligations in the consolidated balance sheets. Refer to Note 6 Balance Sheet Components for additional information.

ROU assets and liabilities are recognized at the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not provide an implicit rate, we use an applicable incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Options to extend or terminate the ROU assets are reviewed at lease inception and these options are accounted for when they are reasonably certain of being exercised.

Other information related to leases was as follows:


	As of December 31, 2022
Remaining lease terms	1 year to 22 years
Weighted-average remaining lease term	6 years
Weighted-average discount rate	3.0	%

As of December 31, 2022, maturities of lease liabilities were as follows:


(In millions)
Year ending December 31,
2023	$	76.4
2024	63.4
2025	38.6
2026	30.2
2027	23.1
Thereafter	52.3
Total lease payments	$	284.0
Less imputed interest	22.0
Total lease liability	$	262.0

As of December 31, 2022, the Company did not have any significant leases that have not yet commenced. For the years ended December 31, 2022, 2021 and 2020, the Company had operating lease expense of approximately $90.9 million, $97.6 million and $80.7 million, respectively. Operating lease costs are classified primarily as SG&A and cost of sales in the consolidated statements of operations.

Financial Instruments and Risk Management (Financial Assets and Liabilities Carried at Fair Value) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	$ 42.6	$ 51.0
Fair Value	35.3	38.2
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	688.8	50.9
Equity securities	42.6
Total assets at recurring fair value measurement	731.4	101.9
Level 1 \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	688.8	50.9
Level 1 \| Equity securities — exchange traded funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	42.4	50.3
Level 1 \| Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		51.0
Level 1 \| Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	0.2
Level 1 \| Marketable Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities		0.7
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at recurring fair value measurement	170.0	182.8
Total liabilities at recurring fair value measurement	187.0	61.0
Level 2 \| Foreign Exchange Contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative assets	134.7	144.6
Level 2 \| Foreign Exchange Contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign exchange derivative liabilities	187.0	61.0
Level 2 \| Available-for-sale fixed income investments
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	35.3	38.2
Level 2 \| Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	13.2	16.6
Level 2 \| U.S. Treasuries
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	11.7	14.6
Level 2 \| Agency mortgage-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	4.7	2.0
Level 2 \| Asset backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	5.1	4.6
Level 2 \| Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	0.6	0.4
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets at recurring fair value measurement	997.4
Total liabilities at recurring fair value measurement	375.0	199.7
Level 3 \| Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	375.0	$ 199.7
Level 3 \| Convertible Preferred Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	$ 997.4

Share-Based Incentive Plan (Valuation Assumptions) (Details) - Long Term Incentive Plan 2003 - Stock options	12 Months Ended
	Dec. 31, 2020 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	46.70%
Risk-free interest rate	1.00%
Expected term (years)	6 years 6 months
Forfeiture rate	5.50%
Weighted average grant date fair value per option	$ 8.07
Dividend yield	0.00%

Employee Benefit Plans (Fair Values of Plan Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 1,067.1	$ 1,366.4
Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	35.1	65.0
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	396.3	551.1
Fixed income securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	453.1	616.9
Assets held by insurance companies and other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	182.6	133.4
Level 1
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	335.6	338.6
Level 1 \| Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	34.2	63.1
Level 1 \| Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	42.9	53.9
Level 1 \| Fixed income securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	181.6	211.4
Level 1 \| Assets held by insurance companies and other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	76.9	10.2
Level 2
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	723.7	946.2
Level 2 \| Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0.9	1.9
Level 2 \| Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	353.4	497.2
Level 2 \| Fixed income securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	271.5	405.5
Level 2 \| Assets held by insurance companies and other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	97.9	41.6
Level 3
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	7.8	81.6
Level 3 \| Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0.0	0.0
Level 3 \| Equity securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0.0	0.0
Level 3 \| Fixed income securities
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	0.0	0.0
Level 3 \| Assets held by insurance companies and other
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 7.8	$ 81.6

- Definition

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

+ References + Details

Debt (Short-term borrowings) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Short-term Debt [Line Items]
Short-term borrowings	$ 0	$ 1,493,000
Commercial Paper
Short-term Debt [Line Items]
Short-term borrowings	0	1,173,400
Receivables Facility
Short-term Debt [Line Items]
Short-term borrowings	0	318,500
Other Current Portion of Long-term Debt
Short-term Debt [Line Items]
Short-term borrowings	$ 0	$ 1,100

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Summary Of Significant Accounting Policies

Summary of Significant Accounting Policies

Principles of Consolidation. The consolidated financial statements include the accounts of Viatris and those of its wholly owned and majority-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Investments in equity method affiliates are recorded at cost and adjusted for the Company’s share of the affiliates’ cumulative results of operations, capital contributions and distributions.

Use of Estimates in the Preparation of Financial Statements. The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Because of the uncertainty inherent in such estimates, actual results could differ from those estimates.

Foreign Currencies. The consolidated financial statements are presented in U.S. Dollars, the reporting currency of Viatris. Statements of Operations and Cash Flows of all of the Company’s subsidiaries that have functional currencies other than U.S. Dollars are translated at a weighted average exchange rate for the period for inclusion in the consolidated statements of operations and cash flows, whereas assets and liabilities are translated at the end of the period exchange rates for inclusion in the consolidated balance sheets. Translation differences are recorded directly in shareholders’ equity as foreign currency translation adjustments. Gains or losses on transactions denominated in a currency other than the subsidiaries’ functional currency, which arise as a result of changes in foreign currency exchange rates, are recorded in the consolidated statements of operations.

Under ASC 830, Foreign Currency Matters (“ASC 830”), a highly inflationary economy is one that has cumulative inflation of approximately 100% or more over a three-year period. Effective April 1, 2022, we classified Turkey as highly inflationary and began to utilize the U.S. dollar as our functional currency in Turkey, which historically utilized the Turkish lira as the functional currency. Application of the guidance in ASC 830 did not have a material impact on our consolidated financial statements for the year ended December 31, 2022. The impacted net sales for the year ended December 31, 2022 and total assets at December 31, 2022 represented less than 1% of our consolidated net sales and total assets, respectively.

Cash and Cash Equivalents. Cash and cash equivalents are comprised of highly liquid investments with an original maturity of three months or less at the date of purchase.

Debt and Equity Securities. Debt securities classified as available-for-sale on the date of purchase are recorded at fair value, with net unrealized gains and losses, net of income taxes, reflected in accumulated other comprehensive loss as a component of shareholders’ equity. Net realized gains and losses on sales of available-for-sale debt securities are computed on a specific security basis and are included in Other (income) expense, net in the consolidated statements of operations. Debt securities classified as trading securities are valued using the quoted market price from broker or dealer quotations or transparent pricing sources at the reporting date, with gains and losses included in Other (income) expense, net in the consolidated statements of operations. Fair value is determined based on observable market quotes or valuation models using assessments of counterparty credit worthiness, credit risk or underlying security and overall capital market liquidity. Debt securities are reviewed for impairment by assessing if the decline in market value of the investment below the carrying value is other than temporary.

Investments in equity securities with readily determinable fair values are recorded at fair value with changes in fair value recorded in Other (income) expense, net in the consolidated statements of operations. Investments in equity securities without readily determinable fair values are recorded at cost minus any impairment, plus or minus changes in their estimated fair value resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Investments in entities are accounted for using the equity method of accounting when the ability to exercise significant influence over the operating and financial decisions of the investee is maintained. The share of net income or losses of equity method investments are included in Other (income) expense, net in the consolidated statements of operations. Investments in equity securities without readily determinable fair values and investments in equity accounted for using the equity method are assessed for potential impairment on a quarterly basis based on qualitative factors.

Concentrations of Credit Risk. Financial instruments that potentially subject the Company to credit risk consist principally of interest-bearing investments, derivatives and accounts receivable.

Viatris invests its excess cash in high-quality, liquid money market instruments, principally overnight deposits and highly rated money market funds. The Company maintains deposit balances at certain financial institutions in excess of federally insured amounts. Periodically, the Company reviews the creditworthiness of its counterparties to derivative transactions, and it does not expect to incur a loss from failure of any counterparties to perform under agreements it has with such counterparties.

Inventories. Inventories are stated at the lower of cost and net realizable value, with cost principally determined by the weighted average cost method. Provisions for potentially obsolete or slow-moving inventory, including pre-launch inventory, are made based on our analysis of product dating, inventory levels, historical obsolescence and future sales forecasts. Included as a component of cost of sales is expense related to the net realizable value of inventories.

Property, Plant and Equipment. Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed and recorded on a straight-line basis over the assets’ estimated service lives (3 to 18 years for machinery and equipment and other fixed assets and 15 to 39 years for buildings and improvements). Capitalized software is included in property, plant and equipment and is amortized over estimated useful lives ranging from 3 to 7 years.

Intangible Assets and Goodwill. Intangible assets are stated at cost less accumulated amortization. Amortization is generally recorded on a straight-line basis over estimated useful lives ranging from 3 to 20 years. The Company periodically reviews the estimated useful lives of intangible assets and makes adjustments when events indicate that a shorter life is appropriate.

The Company accounts for acquired businesses using the acquisition method of accounting in accordance with the provisions of ASC 805, Business Combinations, which requires that the assets acquired and liabilities assumed be recorded at the date of acquisition at their respective estimated fair values. The cost to acquire businesses is allocated to the underlying net assets of the acquired business based on estimates of their respective fair values. Amounts allocated to acquired IPR&D are capitalized at the date of acquisition and, at that time, such IPR&D assets have indefinite lives. As products in development are approved for sale, amounts are allocated to product rights and licenses and will be amortized over their estimated useful lives. Finite-lived intangible assets are amortized over the expected life of the asset. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.

Purchases of developed products and licenses that are accounted for as asset acquisitions are capitalized as intangible assets and amortized over an estimated useful life.

The Company reviews goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable based on management's assessment of the fair value of the Company's reporting units as compared to their related carrying value. Under the authoritative guidance issued by the FASB, we have the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If we choose to use qualitative factors and determine that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test would be required. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the carrying amount is less than its fair value, then no impairment is recognized. If the carrying amount recorded exceeds the fair value calculated, an impairment charge is recorded for the difference. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company’s financial condition and results of operations.

Indefinite-lived intangible assets, principally IPR&D acquired as part of business combinations, are tested at least annually for impairment or upon the occurrence of a triggering event. The impairment test for IPR&D consists of a comparison of the asset’s fair value with its carrying value. Impairment is determined to exist when the fair value of IPR&D assets, which is based upon updated forecasts and commercial development plans, is less than the carrying value of the assets being tested.

Acquired IPR&D. IPR&D assets acquired as part of an asset acquisition are expensed immediately if they have no alternative future uses and are recorded in Acquired IPR&D in the consolidated statements of operations.

Contingent Consideration. Viatris records contingent consideration resulting from business acquisitions or divestitures at its estimated fair value on the acquisition date. Each reporting period thereafter, the Company revalues these obligations and records increases or decreases in their fair value as adjustments to litigation settlements and other contingencies, net within the consolidated statements of operations. Changes in the fair value of the contingent consideration obligations can result from adjustments to the discount rates, payment periods and adjustments in the probability of achieving future development steps, regulatory approvals, market launches, operating results, sales targets and profitability. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market.

Significant judgment is employed in determining the assumptions utilized as of the acquisition or divestiture date and for each subsequent measurement period. Accordingly, changes in the assumptions described above could have a material impact on the Company’s consolidated financial condition and results of operations.

Impairment of Long-Lived Assets. The carrying values of long-lived assets, which include property, plant and equipment and intangible assets with finite lives, are evaluated periodically in relation to the expected future undiscounted cash flows of the underlying assets and monitored for other potential triggering events. The assessment for impairment is based on our ability to recover the carrying value of the long-lived assets or asset grouping by analyzing the expected future undiscounted pre-tax cash flows specific to the asset or asset grouping. If the carrying amount is greater than the undiscounted cash flows, the Company recognizes an impairment loss for the excess of the carrying amount over the estimated fair value based on discounted cash flows.

Divestitures. For businesses that are divested, the Company records the net gain or loss on the sale within Other (income) expense, net. For divestitures of businesses, including divestitures of products that qualify as a business, the Company allocates the relative fair value of goodwill associated with the businesses in the determining the gain or loss on sale. The Company records amounts received as part of TSAs within Other (income) expense, net.

Short-Term Borrowings. The Company’s subsidiaries in India have working capital facilities with several banks which are secured by its current assets. The Company also has the CP Notes, Receivables Facility and the Note Securitization Facility. Under the terms of each of the Receivables Facility and Note Securitization Facility, certain of our accounts receivable secure the amounts borrowed and cannot be used to pay our other debts or liabilities. As the accounts receivable do not transfer to the banks, any amounts outstanding under the facilities are recorded as borrowings and the underlying receivables continue to be included in accounts receivable, net, in the consolidated balance sheets.

Revenue Recognition. The Company recognizes revenues in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, the Company recognizes net revenue for product sales when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, governmental rebate programs, price adjustments, returns, chargebacks, promotional programs and other sales allowances. Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net sales and as a contra asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Amounts recorded for revenue deductions can result from a complex series of judgements about future events and uncertainties and can rely heavily on estimates and assumptions. The following section briefly describes the nature of our provisions for variable consideration and how such provisions are estimated:

•Chargebacks: the Company has agreements with certain indirect customers, such as independent pharmacies, retail pharmacy chains, managed care organizations, hospitals, nursing homes, governmental agencies and pharmacy benefit managers, which establish contract prices for certain products. The indirect customers then independently select a wholesaler from which to purchase the products at these contracted prices. Alternatively, certain wholesalers may enter into agreements with indirect customers that establish contract pricing for certain products, which the wholesalers provide. Under either arrangement, Viatris will provide credit to the wholesaler for any difference between the contracted price with the indirect party and the wholesaler’s invoice price. Such credits are called chargebacks. The provision for chargebacks is based on expected sell-through levels by our wholesaler customers to indirect customers, as well as estimated wholesaler inventory levels.

•Rebates, promotional programs and other sales allowances: this category includes rebate and other programs to assist in product sales. These programs generally provide that the customer receives credit directly related to the amount of purchases or credits upon the attainment of pre-established volumes. Also included in this category are prompt pay discounts, administrative fees and price adjustments to reflect decreases in the selling prices of products.

•Returns: consistent with industry practice, Viatris maintains a return policy that allows customers to return a product, which varies country by country in accordance with local practices, generally within a specified period prior (six months) and subsequent (twelve months) to the expiration date. The Company’s estimate of the provision for returns is generally based upon historical experience with actual returns. Generally, returned products are destroyed and customers are refunded the sales price in the form of a credit.

•Governmental rebate programs: government reimbursement programs in the U.S. include Medicare, Medicaid, and State Pharmacy Assistance Programs established according to statute, regulations and policy. Manufacturers of pharmaceutical products that are covered by the Medicaid program are required to pay rebates to each state based on a statutory formula set forth in the Social Security Act. Medicare beneficiaries are eligible to obtain discounted prescription drug coverage from private sector providers. In addition, certain states have also implemented supplemental rebate programs that obligate manufacturers to pay rebates in excess of those required under federal law. Our estimate of these rebates is based on the historical trends of rebates paid as well as on changes in wholesaler inventory levels and increases or decreases in the level of sales. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare “coverage gap” based on historical experience of prescriptions and utilization expected to result in the discount of the “coverage gap”.

Outside the U.S., the majority of our pharmaceutical sales are contractually or legislatively governed. In certain European countries, certain rebates are calculated on the governments total pharmaceutical spending or on specific product sale thresholds. We utilize historical data and obtain third party information to determine the adequacy of these accruals. Also, this provision includes price reductions that are mandated by law outside of the U.S.

Our net sales may be impacted by wholesaler and distributor inventory levels of our products, which can fluctuate throughout the year due to the seasonality of certain products, pricing, the timing of product demand, purchasing decisions and other factors. Such fluctuations may impact the comparability of our net sales between periods.

Consideration received from licenses of intellectual property is recorded as other revenues. Royalty or profit share amounts, which are based on sales of licensed products or technology, are recorded when the customer’s subsequent sales or usages occur. Such consideration is included in other revenues in the consolidated statements of operations.

Receivables, including deferred consideration, with terms in excess of one year are initially recorded at their net present value using discount rates reflecting the relative credit risk.

Research and Development. R&D expenses are charged to operations as incurred.

Income Taxes. Income taxes have been provided for using an asset and liability approach in which deferred income taxes reflect the tax consequences on future years of events that the Company has already recognized in the financial statements or tax returns. Changes in enacted tax rates or laws may result in adjustments to the recorded tax assets or liabilities in the period that the new tax law is enacted.

Earnings per Share. Basic earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period. Diluted earnings per share is computed by dividing net earnings attributable to holders of Viatris Inc. common stock by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding related to potentially dilutive securities or instruments, if the impact is dilutive.

Basic and diluted earnings per share attributable to Viatris Inc. are calculated as follows:


	Year Ended December 31,
(In millions, except per share amounts)	2022		2021		2020
Basic earnings (loss) attributable to Viatris Inc. common shareholders (numerator):
Net earnings (loss) attributable to Viatris Inc. common shareholders	$	2,078.6	$	(1,269.1)	$	(669.9)
Shares (denominator):
Weighted average shares outstanding	1,212.1		1,208.8		601.2
Basic earnings (loss) per share attributable to Viatris Inc. shareholders	$	1.71	$	(1.05)	$	(1.11)

Diluted earnings (loss) attributable to Viatris Inc. common shareholders (numerator):
Net earnings (loss) attributable to Viatris Inc. common shareholders	$	2,078.6	$	(1,269.1)	$	(669.9)
Shares (denominator):
Weighted average shares outstanding	1,212.1		1,208.8		601.2
Share-based awards	5.3		—		—
Total dilutive shares outstanding	1,217.4		1,208.8		601.2
Diluted earnings (loss) per share attributable to Viatris Inc. shareholders	$	1.71	$	(1.05)	$	(1.11)

The weighted average shares outstanding used in the computation of earnings per share for the year ended December 31, 2020 includes the effect of the 689.9 million shares issued for the closing of the Combination.

Additional stock awards and restricted ordinary shares were outstanding during the years ended December 31, 2022, 2021 and 2020 but were not included in the computation of diluted earnings per share for each respective period because the effect would be anti-dilutive. Excluded shares also include certain share-based compensation awards and restricted shares whose performance conditions had not been fully met. Such excluded shares and anti-dilutive awards represented 11.8 million, 12.7 million and 10.3 million shares for the years ended December 31, 2022, 2021 and 2020, respectively.

The Company paid quarterly cash dividends of $0.11 per share on the Company’s issued and outstanding common stock on June 16, 2021, September 16, 2021, and December 16, 2021. The Company paid quarterly dividends of $0.12 per share on the Company’s issued and outstanding common stock on March 16, 2022, June 16, 2022, September 16, 2022 and December 16, 2022. On February 24, 2023, the Company’s Board of Directors declared a quarterly cash dividend of $0.12 per share on the Company’s issued and outstanding common stock, which will be payable on March 17, 2023 to shareholders of record as of the close of business on March 9, 2023. The declaration and payment of future dividends to holders of the Company’s common stock will be at the discretion of the Board of Directors, and will depend upon factors, including but not limited to, the Company’s financial condition, earnings, capital requirements of its businesses, legal requirements, regulatory constraints, industry practice, and other factors that the Board of Directors deems relevant.

On May 6, 2022, the Company announced that its Board of Directors had authorized a DRIP. The DRIP allows shareholders to automatically reinvest all or a portion of the cash dividends paid on their shares of the Company’s common stock and to make certain additional optional cash investments in the Company’s common stock.

On February 28, 2022, the Company announced that its Board of Directors had authorized a share repurchase program for the repurchase of up to $1.0 billion of the Company’s shares of common stock. Such repurchases may be made from time-to-time at the Company’s discretion and effected by any means, including but not limited to, open market repurchases, pursuant to plans in accordance with Rules 10b5-1 or 10b-18 under the Exchange Act, privately negotiated transactions (including accelerated stock repurchase programs) or any combination of such methods as the Company deems appropriate. The program does not have an expiration date. During 2022, the Company did not repurchase any shares of common stock under the share repurchase program. In January and February 2023, the Company repurchased approximately 21.2 million shares of common stock at a cost of approximately $250 million. The share repurchase program does not obligate the Company to acquire any particular amount of common stock.

Share-Based Compensation. The fair value of share-based compensation is recognized as expense in the consolidated statements of operations over the vesting period.

Derivatives. From time to time the Company may enter into derivative financial instruments (mainly foreign currency exchange forward contracts, interest rate swaps and purchased equity call options) designed to: 1) hedge the cash flows resulting from existing assets and liabilities and transactions expected to be entered into over the next 24 months in currencies other than the functional currency, 2) hedge the variability in interest expense on floating rate debt, 3) hedge the fair value of fixed-rate notes, 4) hedge against changes in interest rates that could impact future debt issuances, 5) hedge cash or share payments required on conversion of issued convertible notes, 6) hedge a net investment in a foreign operation, or 7) economically hedge the foreign currency exposure associated with the purchase price of non-U.S. acquisitions. Derivatives are recognized as assets or liabilities in the consolidated balance sheets at their fair value. When the derivative instrument qualifies as a cash flow hedge, changes in the fair value are deferred through other comprehensive earnings. If a derivative instrument qualifies as a fair value hedge, the changes in the fair value, as well as the offsetting changes in the fair value of the hedged items, are generally included in within the same line item on the consolidated statements of operations as the hedged item. When such instruments do not qualify for hedge accounting the changes in fair value are recorded in the consolidated statements of operations within Other (income) expense, net.

Financial Instruments. The Company’s financial instruments consist primarily of short-term and long-term debt, interest rate swaps, forward contracts and option contracts. The Company’s financial instruments also include cash and cash equivalents as well as accounts and other receivables and accounts payable, the fair values of which approximate their carrying values. As a policy, the Company does not engage in speculative or leveraged transactions.

The Company carries derivative instruments in the consolidated balance sheets at fair value, determined by reference to market data such as forward rates for currencies, implied volatility, and interest rate swap yield curves. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, if so, the reason for holding it. In addition, the Company has designated certain long-term debt instruments as net investment hedges.

Recent Accounting Pronouncements.

Adoption of New Accounting Standards

In November 2021, the FASB issued Accounting Standards Update 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance (“ASU 2021-10”), which requires entities to provide annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. We adopted the ASU prospectively on January 1, 2022. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and disclosures.

Accounting Standards Issued Not Yet Adopted

In March 2020, the FASB issued Accounting Standards Update 2020-04, Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”), which for a limited period of time adds ASC 848 to provide optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2020-04 applies only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. On December 21, 2022, the FASB issued ASU 2022-06 to defer the sunset date of ASC 848 until December 31, 2024. ASU 2022-06 became effective upon issuance. Entities can apply the provisions of ASU 2020-04 immediately, as applicable, and generally the provisions of the guidance are available through December 31, 2024 as entities transition away from reference rates that are expected to be discontinued. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.

In October 2021, the FASB issued Accounting Standards Update 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which requires entities (acquirers) to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606. The ASU will be effective for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2022 with early adoption permitted. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.

In September 2022, the FASB issued Accounting Standards Update 2022-04, Liabilities—Supplier Finance Programs (Subtopic 405-50), which requires entities to provide qualitative and quantitative disclosures about their supplier finance programs, including a rollforward of related obligations. The ASU will be effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the rollforward requirement, which becomes effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company is currently assessing the impact of the adoption of this guidance on its consolidated financial statements and disclosures.

Balance Sheet Components (Other Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Schedule of Other Assets [Line Items]
Operating lease right-of-use assets	$ 259.3	$ 290.8
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets	Other assets
Other long-term assets	$ 753.3	$ 798.5
Other assets	2,403.5	1,170.7
Biocon Biologics
Schedule of Other Assets [Line Items]
Deferred consideration due from Biocon Biologics	299.5	0.0
Convertible Preferred Stock
Schedule of Other Assets [Line Items]
Equity Securities, FV-NI, Cost	997.4	0.0
Private Equity Securities
Schedule of Other Assets [Line Items]
Equity Securities, FV-NI, Cost	$ 94.0	$ 81.4

Financial Instruments and Risk Management (Schedule of Available-for-sale Securities Reconciliation) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 38.0	$ 38.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0.0	0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	(2.7)	0.0
Fair Value	35.3	38.2
Available-for-sale fixed income investments
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	38.0	38.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	0.0	0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	(2.7)	0.0
Fair Value	$ 35.3	$ 38.2

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Cash Flow Hedging Relationships) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	$ 84.7	$ 26.6	$ 0.3
Cash flow hedging relationships \| Foreign Exchange Contract \| Net sales
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	34.2	45.8	20.6
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	89.2	30.9	4.8
Cash flow hedging relationships \| Interest rate swaps \| Interest Expense
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	(3.5)	(3.4)	0.0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	$ (4.5)	$ (4.3)	$ (4.5)

Revenue Recognition and Accounts Receivable

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Revenue Recognition and Accounts Receivable

The following table presents the Company’s net sales by product category for each of our reportable segments for the years ended December 31, 2022, 2021, and 2020, respectively:


(In millions)	2022 Net Sales
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	5,160.4		2,190.7		922.6		1,615.9		9,889.6
Complex Gx and Biosimilars	1,218.0		0.6		44.1		50.7		1,313.4
Generics	3,390.5		9.9		665.7		949.0		5,015.1
Total Viatris	$	9,768.9	$	2,201.2	$	1,632.4	$	2,615.6	$	16,218.1


(In millions)	2021 Net Sales
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	5,759.2		2,207.8		1,197.1		1,677.2		10,841.3
Complex Gx and Biosimilars	1,241.6		0.2		46.5		53.8		1,342.1
Generics	3,427.9		4.8		783.8		1,413.7		5,630.2
Total Viatris	$	10,428.7	$	2,212.8	$	2,027.4	$	3,144.7	$	17,813.6


(In millions)	2020 Net Sales
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	3,920.7		253.9		617.0		443.3		5,234.9
Complex Gx and Biosimilars	1,202.6		0.7		42.8		49.4		1,295.5
Generics	3,387.6		5.3		535.5		1,361.1		5,289.5
Total Viatris	$	8,510.9	$	259.9	$	1,195.3	$	1,853.8	$	11,819.9

____________

(a)Amounts for the year ended December 31, 2022 include the unfavorable impact of foreign currency translations compared to the prior year period.

(b)Amounts for the year ended December 31, 2022 reflect a decrease of approximately $63.5 million related to the year over year impact of the sale of the biosimilars business in November 2022. The Company has not recognized the results of the biosimilars business in its consolidated financial statements subsequent to November 29, 2022.

The following table presents net sales on a consolidated basis for select key products for the years ended December 31, 2022 and 2021, respectively:


	Year Ended December 31,
(In millions)	2022		2021

Select Key Global Products
Lipitor ®	$	1,635.2	$	1,663.2
Norvasc ®	775.1		824.7
Lyrica ®	623.8		728.5
Viagra ®	458.9		533.8
EpiPen® Auto-Injectors	378.0		391.7
Celebrex ®	338.1		344.4
Creon ®	304.0		309.8
Effexor ®	279.6		316.8
Zoloft ®	246.2		284.3
Xalabrands	195.1		226.0

Select Key Segment Products
Influvac ®	$	225.5	$	299.3
Yupelri ®	202.1		161.9
Dymista ®	179.8		168.0
Amitiza ®	167.9		201.5
Xanax ®	156.5		185.9

____________

(a)The Company does not disclose net sales for any products considered competitively sensitive.

(b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.

(c)Amounts for the year ended December 31, 2022 include the unfavorable impact of foreign currency translations compared to the prior year period.

(d)Amounts for the year ended December 31, 2020 are not presented due to the significance of products acquired as part of the Combination.

Variable Consideration and Accounts Receivable

The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the years ended December 31, 2022, 2021 and 2020, respectively:


	Year Ended December 31,
(In millions)	2022		2021		2020
Gross sales	$	27,662.1	$	30,553.4	$	19,899.1
Gross to net adjustments:
Chargebacks	(6,192.2)		(5,530.1)		(3,656.2)
Rebates, promotional programs and other sales allowances	(4,346.2)		(6,135.6)		(3,765.5)
Returns	(296.7)		(384.6)		(329.7)
Governmental rebate programs	(608.9)		(689.5)		(327.8)
Total gross to net adjustments	$	(11,444.0)	$	(12,739.8)	$	(8,079.2)
Net sales	$	16,218.1	$	17,813.6	$	11,819.9

The following is a rollforward of the categories of variable consideration during 2022:


(In millions)	Balance at December 31, 2021		Current Provision Related to Sales Made in the Current Period		Balances Divested		Checks/ Credits Issued to Third Parties		Effects of Foreign Exchange		Balance at December 31, 2022
Chargebacks	$	591.7	$	6,192.2	$	(53.4)	$	(6,205.6)	$	(1.5)	$	523.4
Rebates, promotional programs and other sales allowances	1,373.0		4,346.2		(215.1)		(4,177.5)		(42.4)		1,284.2
Returns	686.8		296.7		(16.0)		(447.6)		(6.5)		513.4
Governmental rebate programs	399.2		608.9		(34.1)		(602.4)		(5.1)		366.5
Total	$	3,050.7	$	11,444.0	$	(318.6)	$	(11,433.1)	$	(55.5)	$	2,687.5

Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net revenues and as a contra-asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2022 and 2021, respectively:


(In millions)	December 31, 2022		December 31, 2021
Accounts receivable, net	$	1,798.7	$	1,688.6
Other current liabilities	888.8		1,362.1
Total	$	2,687.5	$	3,050.7

We have not made and do not anticipate making any significant changes to the methodologies that we use to measure provisions for variable consideration; however, the balances within these reserves can fluctuate significantly through the consistent application of our methodologies. Historically, we have not recorded in any current period any material amounts related to adjustments made to prior period reserves.

Accounts receivable, net was comprised of the following at December 31, 2022 and 2021, respectively:


(In millions)	December 31, 2022		December 31, 2021
Trade receivables, net	$	3,243.8	$	3,774.4
Other receivables	570.7		492.0
Accounts receivable, net	$	3,814.5	$	4,266.4

Total allowances for doubtful accounts were $114.7 million and $154.5 million at December 31, 2022 and 2021, respectively. Viatris performs ongoing credit evaluations of its customers and generally does not require collateral. Approximately 23% and 18% of the accounts receivable balances represent amounts due from three customers at December 31, 2022 and 2021, respectively.

Accounts Receivable Factoring Arrangements

We have entered into accounts receivable factoring agreements with financial institutions to sell certain of our non-U.S. accounts receivable. These transactions are accounted for as sales and result in a reduction in accounts receivable because the agreements transfer effective control over and risk related to the receivables to the buyers. Our factoring agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. We derecognized $34.7 million and $29.6 million of accounts receivable as of December 31, 2022 and 2021 under these factoring arrangements, respectively.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

Revenue Recognition and Accounts Receivable (Accounts Receivable, Net) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	$ 3,243.8	$ 3,774.4
Other receivables	570.7	492.0
Accounts receivable, net	3,814.5	4,266.4
Variable Consideration
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net	1,798.7	1,688.6
Other receivables	888.8	1,362.1
Accounts receivable, net	$ 2,687.5	$ 3,050.7

Employee Benefit Plans (Weighted Average Assumptions) (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2021
Pension Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	4.80%			2.30%
Expected return on plan assets	5.00%			5.10%
Rate of compensation increase	3.70%			3.10%
Discount rate	2.30%	1.90%	1.60%
Expected return on plan assets	5.00%	5.10%	4.30%
Rate of compensation increase	3.10%	2.90%	2.70%
Other Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	5.40%			2.50%
Expected return on plan assets	0.00%			0.00%
Rate of compensation increase	0.00%			0.00%
Discount rate	2.50%	1.90%	3.30%
Expected return on plan assets	0.00%	0.00%	0.00%
Rate of compensation increase	0.00%	0.00%	0.00%

Restructuring

12 Months Ended

Dec. 31, 2022

Restructuring and Related Activities [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

Restructuring

2020 Restructuring Program

During the fourth quarter of 2020, Viatris announced a significant global restructuring program in order to achieve synergies and ensure that the organization is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers, and other stakeholders. As part of the restructuring, the Company is optimizing its commercial capabilities and enabling functions, and closing, downsizing or divesting certain manufacturing facilities globally that are deemed to be no longer viable either due to surplus capacity, challenging market dynamics or a shift in its product portfolio toward more complex products.

For the committed restructuring actions, the Company expects to incur total pre-tax charges of up to approximately $1.4 billion. Such charges are expected to include up to approximately $450 million of non-cash charges mainly related to accelerated depreciation and asset impairment charges, including inventory write-offs. The remaining estimated cash costs of up to approximately $950 million are expected to be primarily related to severance and employee benefits expense, as well as other costs, including those related to contract terminations and other plant disposal costs. In addition, management believes the potential annual savings related to these committed restructuring activities to be up to approximately $900 million once fully implemented, with most of these savings expected to improve operating cash flow.

The following table summarizes the restructuring charges and the reserve activity for the 2020 restructuring program:


(In millions)	Employee Related Costs		Other Exit Costs		Total
Charges (3)	$	195.6	$	75.7	$	271.3
Acquired in the Combination	91.7		0.3		92.0
Cash payment	(25.1)		(0.4)		(25.5)
Utilization	—		(70.8)		(70.8)
Foreign currency translation	0.4		—		0.4
Balance at December 31, 2020	$	262.6	$	4.8	$	267.4
Charges (2)	396.1		496.1		892.2
Reimbursable restructuring charges	26.4		—		26.4
Cash payment	(385.5)		(151.7)		(537.2)
Utilization	—		(345.0)		(345.0)
Foreign currency translation	(7.0)		(0.1)		(7.1)
Balance at December 31, 2021	$	292.6	$	4.1	$	296.7
Charges (1)	38.2		48.3		86.5
Cash payment	(170.1)		(15.3)		(185.4)
Utilization	—		(34.9)		(34.9)
Foreign currency translation	(5.1)		(0.3)		(5.4)
Balance at December 31, 2022	$	155.6	$	1.9	$	157.5

2016 Restructuring Program

Mylan previously announced a restructuring program representing a series of actions in certain locations to further streamline its operations globally. We incurred total restructuring related costs of approximately $733.0 million through December 31, 2020. The 2016 Restructuring Program was substantially completed at December 31, 2020.

In April 2018, the FDA completed an inspection at Mylan’s plant in Morgantown, West Virginia and made observations through a Form 483. In the fourth quarter of 2018, Mylan received a warning letter related to the previously disclosed observations at the plant. The issues raised in the warning letter were addressed within the context of the Mylan’s comprehensive restructuring and remediation activities. On May 11, 2020, Mylan received the close-out of the warning letter. On December 11, 2020, the Company announced that the Morgantown plant will be closed or divested as part of the 2020 Restructuring Program. The Morgantown plant was closed during the third quarter of 2021.

The following table summarizes the restructuring charges and the reserve activity for the 2016 restructuring program from December 31, 2019 to December 31, 2020:


(In millions)	Employee Related Costs		Other Exit Costs		Total






Balance at December 31, 2019:	$	26.4	$	2.8	$	29.2
Charges (3)	9.9		40.6		50.5
Cash payment	(18.1)		(7.6)		(25.7)
Utilization	—		(32.9)		(32.9)
Foreign currency translation	1.8		(0.1)		1.7
Balance at December 31, 2020:	$	20.0	$	2.8	$	22.8

(1) For the year ended December 31, 2022, total restructuring charges for the 2020 restructuring program, in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $74.6 million, $2.5 million, $0.9 million, $8.2 million, and $0.3 million, respectively.

(2) For the year ended December 31, 2021, total restructuring charges, for the 2020 restructuring program, in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $623.8 million, $5.8 million, $138.1 million, $94.1 million, and $30.4 million, respectively.

(3) For the year ended December 31, 2020, total restructuring charges for both programs, in Developed Markets, Greater China, JANZ, and Emerging Markets were approximately $292.1 million, $18.4 million, $2.9 million, and $8.4 million, respectively.

At December 31, 2022 and 2021, accrued liabilities for restructuring and other cost reduction programs were primarily included in other current liabilities and other long-term obligations in the consolidated balance sheets.

Nature of Operations (Narrative) (Details)	Dec. 31, 2022 molecule site
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number Of Molecules \| molecule	1,400
Number Of Manufacturing Sites \| site	40

Income Taxes

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Income Taxes

The income tax provision (benefit) consisted of the following components:


	Year Ended December 31,
(In millions)	2022		2021		2020
U.S. Federal:
Current	$	115.3	$	12.6	$	(6.4)
Deferred	263.7		(182.7)		(277.0)
	379.0		(170.1)		(283.4)
U.S. State:
Current	26.5		7.7		(0.1)
Deferred	20.3		(10.8)		7.7
	46.8		(3.1)		7.6
Non-U.S.:
Current	618.7		(91.3)		168.7
Deferred	(309.9)		869.2		55.8
	308.8		777.9		224.5
Income tax provision (benefit)	$	734.6	$	604.7	$	(51.3)
Earnings before income taxes:

United States	794.8		(1,982.5)		(945.5)
Foreign - Other	2,018.4		1,318.1		224.3
Total earnings (loss) before income taxes	$	2,813.2	$	(664.4)	$	(721.2)

For all periods presented, the allocation of earnings before income taxes between U.S. and non-U.S. operations includes intercompany interest allocations between certain domestic and foreign subsidiaries. These amounts are eliminated on a consolidated basis.

Temporary differences and carry-forwards that result in deferred tax assets and liabilities were as follows:


(In millions)	December 31, 2022		December 31, 2021
Deferred tax assets:
Employee benefits	$	129.6	$	271.3
Litigation reserves	20.5		94.4
Accounts receivable allowances	446.2		425.9
Inventory	159.3		187.8
Tax credit and loss carry-forwards	760.3		1,256.0
Operating lease assets	56.2		63.6
Interest expense	94.8		111.6
Intangible assets	149.3		151.1
Other	209.3		327.8
	2,025.5		2,889.5
Less: Valuation allowance	(387.0)		(780.4)
Total deferred tax assets	1,638.5		2,109.1
Deferred tax liabilities:
Plant and equipment	56.6		19.6
Operating lease liabilities	56.2		63.6
Intangible assets and goodwill	2,880.3		3,468.3
Other	151.5		39.9
Total deferred tax liabilities	3,144.6		3,591.4
Deferred tax liabilities, net	$	(1,506.1)	$	(1,482.3)

For those foreign subsidiaries whose investments are permanent in duration, income and foreign withholding taxes have not been provided on the unremitted earnings of those subsidiaries. This amount may become taxable upon a repatriation of assets from the subsidiary or a sale or liquidation of the subsidiary. The amount of such unremitted earnings is approximately $2.6 billion at December 31, 2022. Determination of the amount of any unrecognized deferred income tax liability on these unremitted earnings is not practicable as such determination involves material uncertainties about the potential extent and timing of any distributions, the availability and complexity of calculating foreign tax credits, and the potential indirect tax consequences of such distributions, including withholding taxes.

Our effective tax rate from continuing operations differs from the applicable United States statutory federal income tax rate of 21.0%, due to the following:


	Year Ended December 31,
	2022		2021		2020
Statutory tax rate	21.0	%	21.0	%	21.0	%


Clean energy and research credits	—	%	9.8	%	12.8	%
Foreign rate differential	(3.6)	%	31.4	%	8.6	%
Expiration of attributes	9.8	%	—	%	—	%
Goodwill impairment	6.5	%	—	%	—	%
State income taxes and credits	1.3	%	(0.6)	%	(1.6)	%
Tax settlements and resolution of certain tax positions	1.0	%	0.9	%	(3.8)	%

Impact of the Combination and divestitures	(6.7)	%	(109.7)	%	(35.5)	%
Incremental U.S. tax on foreign earnings	2.0	%	(36.9)	%	(3.6)	%
Valuation allowance	(13.6)	%	(8.4)	%	24.6	%
Deferred tax impact of tax law changes	5.4	%	7.0	%	—	%
Withholding taxes	1.5	%	(1.3)	%	(1.6)	%
Waived deductions under IRC § 59A	—	%	—	%	(3.3)	%
















Other items	1.5	%	(4.2)	%	(10.5)	%
Effective tax rate	26.1	%	(91.0)	%	7.1	%

In all years, our effective tax rate is impacted by the jurisdictional location of earnings and the corresponding tax rates in those jurisdictions. Subsequent to the Combination, the Company realizes benefits from lower tax rates in Singapore and Puerto Rico due to manufacturing and other incentives.

Prior to the Combination, Mylan was a U.K. tax resident, with its Corporate seat in the Netherlands. As of the date of the Combination, Viatris is domiciled in the U.S., and the applicable income tax rate to Viatris is the U.S. statutory federal income tax rate of 21.0%. The effective tax rate reconciliations of the years ended December 31, 2021 and December 31, 2020 have been recast to reflect this change.

During the year ended December 31, 2022, a Puerto Rico net operating loss, which was recorded in conjunction with the Combination, expired unutilized resulting in a $274.4 million write-off of deferred tax asset and corresponding valuation allowance. The expiration and valuation allowance impacts are reflected in the above table.

Valuation Allowance

A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. At December 31, 2022, a valuation allowance has been applied to certain deferred tax assets in the amount of $387.0 million.

When assessing the realizability of deferred tax assets, management considers all available evidence, including historical information, long-term forecasts of future taxable income and possible tax planning strategies. Amounts recorded for valuation allowances can result from a complex series of estimates, assumptions and judgments about future events. Due to the inherent uncertainty involved in making these estimates, assumptions and judgments, actual results could differ materially. Any future increases to the Company’s valuation allowances could materially impact the Company’s consolidated financial condition and results of operations.

Net Operating Losses

As of December 31, 2022, the Company had the following carryforwards and attributes:

•U.S. federal net operating loss carryforwards of $4.6 million.

•U.S. state income tax loss carryforwards of approximately $2.90 billion, which are largely offset by a valuation allowance.

•Non-U.S. net operating loss carryforwards of approximately $1.01 billion, of which $810.8 million can be carried forward indefinitely, with the remaining $195.1 million expiring in years 2023 through 2042.

•Foreign deductible attributes of $37.3 million that can be carried forward indefinitely, which are offset by a full valuation allowance.

•U.S. and foreign credit carryovers of $213.3 million, expiring in various amounts through 2042.

•Anticipatory foreign tax credits of $196.1 million which will generate from the reversal of future taxable income in certain non-U.S. jurisdictions which are taxed both in their local jurisdictions and in the U.S.

On November 16, 2020, the Company had a change in ownership pursuant to Section 382 of the Code. Under this provision of the Code, the utilization of any NOL or tax credit carryforwards incurred prior to the date of ownership change may be limited. Analyses of the limits for each ownership change indicates the annual limitation would not impair the Company's ability to utilize our U.S. federal credit carryovers. While state loss carryforwards may be limited by Section 382 of the Code, the carryforwards are largely offset by a valuation allowance.

CARES Act

On March 27, 2020, the CARES Act was enacted and signed into law. The CARES Act includes several provisions, including increasing the amount of deductible interest, allowing companies to carryback certain NOLs, and increasing the amount of NOLs that corporations can use to offset income. During the year ended December 31, 2020, the CARES Act reduced the Company’s 2020 income tax expense by $22.1 million resulting from additional deductible interest.

Tax Examinations

The Company is subject to income taxes and tax audits in many jurisdictions. A certain degree of estimation is thus required in recording the assets and liabilities related to income taxes. Tax audits and examinations can involve complex issues, interpretations, and judgments and the resolution of matters that may span multiple years, particularly if subject to litigation or negotiation.

Although the Company believes that adequate provisions have been made for these uncertain tax positions, the Company’s assessment of uncertain tax positions, including those arising from legal entity restructuring transactions in connection with the Combination, is based on estimates and assumptions that the Company believes are reasonable but the estimates for unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variations from such estimates could materially affect the Company’s financial condition, results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire.

The Company is subject to ongoing IRS examinations. The years 2015 through 2019 are open years under examination. The years 2012, 2013 and 2014 have one matter open, and a Tax Court petition was filed regarding the matter and a trial was held in December 2018 and is discussed further below.

Several international audits are currently in progress. In some cases, the tax auditors have proposed adjustments or issued assessments to our tax positions, including with respect to intercompany transactions, and we are in ongoing discussions with some of the auditors regarding the validity of their positions.

In instances where assessments have been issued, we disagree with these assessments and believe they are without merit and incorrect as a matter of law. As a result, we anticipate that certain of these matters may become the subject of litigation before tax courts where we intend to vigorously defend our position.

In Australia, the tax authorities have issued notices of assessments to the Company for the years ended December 2009 to December 2020, subject to additional interest and penalties, concerning our tax position with respect to certain intercompany transactions. The tax authorities denied our objections to the assessments for the years ended December 2009 to December 2020 and we have commenced litigation in the Australian Federal Court challenging those decisions. The Company made a partial payment of $56.0 million in 2021 and $5.2 million in 2022 in order to stay potential interest and penalties resulting from this litigation.

In France, the tax authorities have issued notices of assessments to the Company for the years ended December 2013 to December 2015 concerning our tax position with respect to whether income earned by a Company entity not domiciled in France should be subject to French tax. We have commenced litigation before the French tax courts where the tax authorities will seek unpaid taxes, penalties, and interest.

In India, the tax authorities have issued notices of assessments to the Company seeking unpaid taxes and interest for the financial years covering 2013 to 2018 concerning our tax position with respect to certain corporate tax deductions and certain intercompany transactions. Some of these assessments remain in the audit phase where we are challenging them before the tax authorities while we are challenging some of the other assessments in the Indian tax courts.

The Company has recorded a net reserve for uncertain tax positions of $298.1 million and $315.6 million, including interest and penalties, in connection with its international audits at December 31, 2022 and 2021, respectively. In connection with our international tax audits, it is possible that we will incur material losses above the amounts reserved.

The Company’s major U.S. state taxing jurisdictions remain open from fiscal year 2013 through 2021, with several state audits currently in progress. The Company’s major international taxing jurisdictions remain open from 2012 through 2021.

Tax Court Proceedings

The Company's U.S. federal income tax returns for 2012 through 2014 had been subject to proceedings in U.S. Tax Court involving a dispute with the IRS regarding whether certain costs related to ANDAs were eligible to be expensed and deducted immediately or required to be amortized over longer periods. A trial was held in U.S. Tax Court in December 2018 and on April 27, 2021, the Court affirmed Mylan’s position and held that patent litigation expenses related to ANDAs are immediately deductible. The IRS has appealed this decision.

Accounting for Uncertainty in Income Taxes

The impact of an uncertain tax position that is more likely than not of being sustained upon audit by the relevant taxing authority must be recognized at the largest amount that is more likely than not to be sustained. No portion of an uncertain tax position will be recognized if the position has less than a 50% likelihood of being sustained.

As of December 31, 2022 and 2021, the Company’s consolidated balance sheets reflect net liabilities for unrecognized tax benefits of $296.7 million and $322.9 million, respectively, of which $210.7 million as of December 31, 2022 would affect the Company’s effective tax rate if recognized, with the remainder being offset by potential correlative adjustments. Related accrued interest and penalties included in the consolidated balance sheets were $106.4 million and $96.8 million as of December 31, 2022 and 2021, respectively. For the years ended December 31, 2022, 2021 and 2020, the Company recognized $21.1 million of tax expense, $18.5 million of tax expense, and $6.0 million of tax benefits, respectively, related to interest and penalties on uncertain tax positions. Interest and penalties related to income taxes are included in the tax provision.

A reconciliation of the unrecognized tax benefits is as follows:


	Year Ended December 31,
(In millions)	2022		2021		2020
Unrecognized tax benefit — beginning of year	$	322.9	$	391.1	$	92.1
Additions for current year tax positions	8.2		—		13.4
Additions for prior year tax positions	1.0		—		35.7
Reductions for prior year tax positions	(5.8)		(9.1)		(5.2)
Settlements	(0.4)		(47.3)		(8.9)
Reductions due to expirations of statute of limitations	(1.9)		(7.0)		—
(Reduction) addition due to acquisition	(27.3)		(4.8)		264.0
Unrecognized tax benefit — end of year	$	296.7	$	322.9	$	391.1

The Company believes that it is reasonably possible that the amount of unrecognized tax benefits will decrease in the next twelve months by approximately $55.0 million, involving international and state audits and settlements and expiring statutes of limitations. The Company does not anticipate significant increases to the reserve within the next twelve months.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Consolidated Statements of Comprehensive Earnings - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net loss	$ 2,078.6	$ (1,269.1)	$ (669.9)
Other comprehensive (loss) earnings, before tax:
Foreign currency translation adjustment	(1,583.5)	(1,340.9)	1,213.0
Change in unrecognized gain (loss) and prior service cost related to defined benefit plans	279.1	73.9	(14.0)
Net unrealized (loss) gain on marketable securities	(2.8)	(1.1)	0.6
Other comprehensive (loss) earnings, before tax	(884.0)	(775.2)	912.6
Income tax provision (benefit)	132.9	111.1	(26.6)
Other comprehensive (loss) earnings, net of tax	(1,016.9)	(886.3)	939.2
Comprehensive earnings	1,061.7	(2,155.4)	269.3
Cash flow hedging relationships
Other comprehensive (loss) earnings, before tax:
Net unrecognized gain (loss) on derivatives in hedging relationships	(36.9)	36.1	18.2
Net Investment Hedging
Other comprehensive (loss) earnings, before tax:
Net unrecognized gain (loss) on derivatives in hedging relationships	$ 460.1	$ 456.8	$ (305.2)

Goodwill and Other Intangible Assets (Changes in Carrying Amount Of Goodwill) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Apr. 01, 2021
Goodwill [Line Items]
Goodwill	$ 10,425.8	$ 12,113.7	$ 12,347.0
Goodwill			295.6
Foreign currency translation		(651.2)	(528.9)
Goodwill, Transfers	(919.7)
Impairment of goodwill	(117.0)	0.0	0.0
Goodwill, net, ending balance	10,425.8	12,113.7	12,347.0
Accumulated impairment losses	385.0	385.0	385.0
Developed Markets
Goodwill [Line Items]
Goodwill	7,461.5	8,723.4	9,184.5
Goodwill			67.7
Foreign currency translation		(518.0)	(528.8)
Goodwill, Transfers	(743.9)
Impairment of goodwill	0.0
Goodwill, net, ending balance	7,461.5	8,723.4	9,184.5
Greater China
Goodwill [Line Items]
Goodwill	940.6	969.5	738.3	$ 970.0
Goodwill			220.4
Foreign currency translation		(26.2)	10.8
Goodwill, Transfers	(2.7)
Impairment of goodwill	0.0
Goodwill, net, ending balance	940.6	969.5	738.3
JANZ
Goodwill [Line Items]
Goodwill	689.0	776.3	864.0	780.0
Goodwill			(30.9)
Foreign currency translation		(54.7)	(56.8)
Goodwill, Transfers	(32.6)
Impairment of goodwill	0.0
Goodwill, net, ending balance	689.0	776.3	864.0
Emerging Markets
Goodwill [Line Items]
Goodwill	1,334.7	1,644.5	1,560.2	$ 1,640.0
Goodwill			38.4
Foreign currency translation		(52.3)	45.9
Goodwill, Transfers	(140.5)
Goodwill, net, ending balance	1,334.7	$ 1,644.5	$ 1,560.2
Emerging Markets \| Disposal Group, Held-for-sale, Not Discontinued Operations \| Upjohn Distributor Markets
Goodwill [Line Items]
Impairment of goodwill	$ (117.0)

Goodwill and Other Intangible Assets (Narrative) (Details)		12 Months Ended
	Apr. 01, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Intangible Assets Excluding Goodwill [Line Items]
Finite-lived intangible assets, net		$ 22,566,900,000	$ 26,087,700,000
In-process research and development		40,200,000	46,500,000
Goodwill		10,425,800,000	12,113,700,000	$ 12,347,000,000
Goodwill, Derecognized		919,700,000
Impairment of goodwill		(117,000,000.0)	0	0
Disposal Group, Held-for-sale, Not Discontinued Operations \| Upjohn Distributor Markets
Intangible Assets Excluding Goodwill [Line Items]
Assets held-for-sale, intangible assets		230,300,000
In-process research and development
Intangible Assets Excluding Goodwill [Line Items]
IPR&D intangible asset impairment charges		600,000	19,400,000	37,400,000
Product rights and licenses
Intangible Assets Excluding Goodwill [Line Items]
Finite-lived intangible assets, net		22,565,900,000	26,084,500,000
Finite-lived intangible asset disposal & impairment charges		172,900,000	83,400,000	45,000,000.0
Europe Segment
Intangible Assets Excluding Goodwill [Line Items]
Reporting Unit, Amount of Fair Value in Excess of Carrying Amount	$ 797,000,000
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount	5.30%
Goodwill	$ 4,950,000,000
Europe Segment \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input, Term	10 years
North America Segment
Intangible Assets Excluding Goodwill [Line Items]
Goodwill		3,610,000,000
JANZ
Intangible Assets Excluding Goodwill [Line Items]
Reporting Unit, Amount of Fair Value in Excess of Carrying Amount	$ 231,000,000
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount	7.40%
Goodwill	$ 780,000,000	689,000,000.0	776,300,000	864,000,000.0
Impairment of goodwill		0
JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input, Term	10 years
JANZ \| Product rights and licenses
Intangible Assets Excluding Goodwill [Line Items]
Finite-lived intangible assets, net		1,325,500,000	1,495,800,000
Greater China
Intangible Assets Excluding Goodwill [Line Items]
Goodwill	$ 970,000,000	940,600,000	969,500,000	738,300,000
Impairment of goodwill		0
Greater China \| Product rights and licenses
Intangible Assets Excluding Goodwill [Line Items]
Finite-lived intangible assets, net		5,642,900,000	6,115,000,000
Emerging Markets
Intangible Assets Excluding Goodwill [Line Items]
Reporting Unit, Amount of Fair Value in Excess of Carrying Amount	$ 816,000,000
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount	10.30%
Goodwill	$ 1,640,000,000	1,334,700,000	1,644,500,000	$ 1,560,200,000
Emerging Markets \| Disposal Group, Held-for-sale, Not Discontinued Operations \| Upjohn Distributor Markets
Intangible Assets Excluding Goodwill [Line Items]
Impairment of goodwill		(117,000,000)
Emerging Markets \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input, Term	10 years
Emerging Markets \| Product rights and licenses
Intangible Assets Excluding Goodwill [Line Items]
Finite-lived intangible assets, net		$ 3,386,400,000	$ 4,160,100,000
Measurement Input, Discount Rate \| In-process research and development \| Minimum
Intangible Assets Excluding Goodwill [Line Items]
Rate used to discount net cash inflows to present values		0.105	0.070	0.090
Measurement Input, Discount Rate \| In-process research and development \| Maximum
Intangible Assets Excluding Goodwill [Line Items]
Rate used to discount net cash inflows to present values			0.090	0.110
Measurement Input, Discount Rate \| Product rights and licenses \| Minimum
Intangible Assets Excluding Goodwill [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 0.090
Measurement Input, Discount Rate \| Europe Segment \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.095
Measurement Input, Discount Rate \| JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.060
Measurement Input, Discount Rate \| Emerging Markets \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.105
Measurement Input, Long-term Revenue Growth Rate \| Europe Segment \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.005
Measurement Input, Long-term Revenue Growth Rate \| JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.048
Measurement Input, Long-term Revenue Growth Rate \| Emerging Markets \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.016
Measurement Input, Estimated Tax Rate \| Europe Segment \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.153
Measurement Input, Estimated Tax Rate \| JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.304
Measurement Input, Estimated Tax Rate \| Emerging Markets \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.184
Measurement Input, EBITDA Multiple \| Europe Segment \| Minimum \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	7.5
Measurement Input, EBITDA Multiple \| Europe Segment \| Maximum \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	8.0
Measurement Input, EBITDA Multiple \| JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	6.0
Measurement Input, EBITDA Multiple \| Emerging Markets \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	7.5
Measurement Input, Control Premium \| Europe Segment \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.150
Measurement Input, Control Premium \| JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.150
Measurement Input, Control Premium \| Emerging Markets \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.150
Measurement Input, Terminal Year Revenue Growth Rate \| Europe Segment \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.010
Measurement Input, Terminal Year Revenue Growth Rate \| JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0
Measurement Input, Terminal Year Revenue Growth Rate \| Emerging Markets \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.008
Measurement Input, Reduction in Terminal Year Revenue Growth Rate \| Europe Segment \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	(0.030)
Measurement Input, Reduction in Terminal Year Revenue Growth Rate \| JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	(0.035)
Measurement Input, Reduction in Terminal Year Revenue Growth Rate \| Emerging Markets \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	(0.085)
Measurement Input, Increase in Discount Rate \| Europe Segment \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.015
Measurement Input, Increase in Discount Rate \| JANZ \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.020
Measurement Input, Increase in Discount Rate \| Emerging Markets \| Valuation Technique, Discounted Cash Flow
Intangible Assets Excluding Goodwill [Line Items]
Goodwill Impairment, Measurement Input	0.030

Income Taxes (Statutory Tax Rate to Effective Tax Rate Reconciliation) (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Contingency [Line Items]
Statutory tax rate	21.00%	21.00%	21.00%
Expiration of attributes	9.80%	0.00%	0.00%
Goodwill impairment	6.50%	0.00%	0.00%
Incremental U.S. tax on foreign earnings	2.00%	36.90%	3.60%
Waived deductions under IRC § 59A	0.00%	0.00%	(3.30%)
Impact of the Combination and divestitures	(6.70%)	(109.70%)	(35.50%)
Effective tax rate	26.10%	(91.00%)	7.10%
United States
Income Tax Contingency [Line Items]
Clean energy and research credits	0.00%	9.80%	12.80%
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent	(3.60%)	31.40%	8.60%
State income taxes and credits	1.30%	(0.60%)	(1.60%)
Valuation allowance	(13.60%)	(8.40%)	24.60%
Tax settlements and resolution of certain tax positions	1.00%	0.90%	(3.80%)
Other Foreign Operations
Income Tax Contingency [Line Items]
Other U.S. items	1.50%	(4.20%)	(10.50%)
Deferred tax impact of tax law changes	5.40%	7.00%	0.00%
Withholding taxes	1.50%	(1.30%)	(1.60%)

Employee Benefit Plans

12 Months Ended

Dec. 31, 2022

Retirement Benefits [Abstract]

Employee Benefits

Employee Benefit Plans

Defined Benefit Plans

The Company sponsors various defined benefit pension plans in several countries. Benefits provided generally depend on length of service, pay grade and remuneration levels. Employees in the U.S., Puerto Rico and certain international locations are also provided retirement benefits through defined contribution plans.

The Company also sponsors other postretirement benefit plans including plans that provide for postretirement supplemental medical coverage. Benefits from these plans are provided to employees and their spouses and dependents who meet various minimum age and service requirements. In addition, the Company sponsors other plans that provide for life insurance benefits and postretirement medical coverage for certain officers and management employees.

Accounting for Defined Benefit Pension and Other Postretirement Plans

The Company recognizes on its balance sheet an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension and other postretirement plan. Actuarial gains or losses and prior service costs or credits that arise during the period are not recognized as components of net periodic benefit cost, but are recognized, net of tax, as a component of other comprehensive (loss) earnings.

Included in accumulated other comprehensive loss as of December 31, 2022 and 2021 are:


	Pension Benefits				Other Postretirement Benefits
	December 31,				December 31,
(In millions)	2022		2021		2022		2021
Unrecognized actuarial (gain) loss	$	(293.6)	$	(59.9)	$	(22.0)	$	21.7
Unrecognized prior service cost (credit)	4.0		6.6		(3.7)		(3.7)
Total	$	(289.6)	$	(53.3)	$	(25.7)	$	18.0

The unrecognized net actuarial (gains) losses exceeded 10% of the higher of the market value of plan assets or the projected benefit obligation at the beginning of the year for certain of the plans, therefore, amortization of such excess has been included in net periodic benefit costs for pension and other postretirement benefits in each of the last three years. The amortization period is the average remaining service period that active employees are expected to receive benefits, unless a plan is mostly inactive in which case the amortization period is the average remaining life expectancy of the plan participants. Unrecognized prior service cost is amortized over the future service periods of those employees who are active at the dates of the plan amendments and who are expected to receive benefits. If all or almost all of a plan's participants are inactive, unrecognized prior service cost is amortized over the remaining life expectancy of those participants.

The change in accumulated other comprehensive loss in 2022 relating to pension benefits and other postretirement benefits consists of:


(In millions)	Pension Benefits		Other Postretirement Benefits
Unrecognized actuarial (gain) loss	$	(236.9)	$	(43.4)
Amortization of actuarial gain/(loss)	3.5		(0.3)
Unrecognized prior service credit (cost)	(1.4)		(0.5)
Amortization of prior service costs	(0.9)		0.5
Impact of foreign currency translation	(0.6)		—
Net change	$	(236.3)	$	(43.7)

Components of net periodic benefit cost, change in projected benefit obligation, change in plan assets, funded status, fair value of plan assets, assumptions used to determine net periodic benefit cost, funding policy and estimated future benefit payments are summarized below for the Company’s pension plans and other postretirement plans.

Net Periodic Benefit Cost

Components of net periodic benefit cost for the years ended December 31, 2022, 2021 and 2020 were as follows:


	Pension Benefits						Other Postretirement Benefits
	December 31,						December 31,
(In millions)	2022		2021		2020		2022		2021		2020
Service cost	$	32.6	$	38.6	$	23.5	$	3.4	$	3.4	$	1.2
Interest cost	36.8		31.6		13.5		3.7		2.6		1.4
Expected return on plan assets	(64.6)		(66.1)		(19.9)		—		—		—
Plan curtailment, settlement and termination	2.3		(16.5)		1.1		(3.9)		—		—
Amortization of prior service costs	0.9		0.9		—		(0.6)		—		—
Recognized net actuarial losses (gains)	(0.2)		1.3		0.4		0.3		0.2		0.3
Net periodic benefit cost	$	7.8	$	(10.2)	$	18.6	$	2.9	$	6.2	$	2.9

During the year ended December 31, 2021, the Company recognized a settlement gain as a result of cash payments from lump sum elections related to the U.S. and Puerto Rico pension plans.

Change in Projected Benefit Obligation, Change in Plan Assets and Funded Status

The table below presents components of the change in projected benefit obligation, change in plan assets and funded status at December 31, 2022 and 2021.


	Pension Benefits				Other Postretirement Benefits
(In millions)	2022		2021		2022		2021
Change in Projected Benefit Obligation
Projected benefit obligation, beginning of year	$	1,946.6	$	2,145.8	$	188.4	$	188.8
Service cost	32.6		38.6		3.4		3.4
Interest cost	36.8		31.6		3.7		2.6
Participant contributions	3.3		2.0		4.5		2.4
Acquisitions	2.8		4.0		—		—

Plan settlements and terminations	(82.0)		(128.6)		(4.5)		(4.3)
Actuarial (gains) losses	(439.4)		(26.1)		(43.3)		16.2
Benefits paid	(54.1)		(52.8)		(14.7)		(20.7)
Impact of foreign currency translation	(67.6)		(67.9)		—		—
Projected benefit obligation, end of year	$	1,379.0	$	1,946.6	$	137.5	$	188.4

Change in Plan Assets
Fair value of plan assets, beginning of year	$	1,366.4	$	1,354.6	$	—	$	—
Actual return on plan assets	(138.1)		141.7		—		—
Company contributions	25.6		97.0		10.2		18.3
Participant contributions	3.3		2.0		4.5		2.4
Acquisitions	—		(2.1)		—		—

Plan settlements	(85.9)		(128.9)		—		—
Benefits paid	(54.1)		(52.8)		(14.7)		(20.7)

Impact of foreign currency translation	(50.1)		(45.1)		—		—
Fair value of plan assets, end of year	1,067.1		1,366.4		—		—
Funded status of plans	$	(311.9)	$	(580.2)	$	(137.5)	$	(188.4)

Net accrued benefit costs for pension plans and other postretirement benefits are reported in the following components of the Company’s consolidated balance sheets at December 31, 2022 and 2021:


	Pension Benefits				Other Postretirement Benefits
	December 31,				December 31,
(In millions)	2022		2021		2022		2021
Noncurrent assets	$	118.3	$	117.2	$	—	$	—
Current liabilities	(14.6)		(14.6)		(15.4)		(16.1)
Noncurrent liabilities	(415.6)		(682.8)		(122.1)		(172.3)
Net accrued benefit costs	$	(311.9)	$	(580.2)	$	(137.5)	$	(188.4)

The projected benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, including the effects of estimated future pay increases. The accumulated benefit obligation is the actuarial present value of benefits attributable to employee service rendered to date, but does not include the effects of estimated future pay increases. The accumulated benefit obligation for the Company’s pension plans was $1.31 billion and $1.86 billion at December 31, 2022 and 2021, respectively.

The projected benefit obligation, accumulated benefit obligation and fair value of plan assets for pension plans with an accumulated benefit obligation in excess of the fair value of plan assets at December 31, 2022 and 2021 were as follows:


	December 31,
(In millions)	2022		2021
Plans with accumulated benefit obligation in excess of plan assets:
Projected benefit obligation	$	1,026.5	$	1,591.8
Accumulated benefit obligation	999.3		1,546.4
Fair value of plan assets	604.9		904.1

Fair Value of Plan Assets

The Company measures the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy described in Note 10 Financial Instruments and Risk Management. The table below presents total plan assets by investment category as of December 31, 2022 and 2021 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value:


	December 31, 2022
(In millions)	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	34.2	$	0.9	$	—	$	35.1
Equity securities	42.9		353.4		—		396.3
Fixed income securities	181.6		271.5		—		453.1
Assets held by insurance companies and other	76.9		97.9		7.8		182.6
Total	$	335.6	$	723.7	$	7.8	$	1,067.1


	December 31, 2021
(In millions)	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	63.1	$	1.9	$	—	$	65.0
Equity securities	53.9		497.2		—		551.1
Fixed income securities	211.4		405.5		—		616.9
Assets held by insurance companies and other	10.2		41.6		81.6		133.4
Total	$	338.6	$	946.2	$	81.6	$	1,366.4

Risk tolerance on invested pension plan assets is established through careful consideration of plan liabilities, plan funded status and corporate financial condition. Investment risk is measured and monitored on an ongoing basis through annual liability measures, periodic asset/liability studies and investment portfolio reviews. The Company’s investment strategy is to maintain, where possible, a diversified investment portfolio across several asset classes that, when combined with the Company’s contributions to the plans, will ensure that required benefit obligations are met.

Assumptions

The following weighted average assumptions were used to determine the benefit obligations for the Company’s defined benefit pension and other postretirement plans as of December 31, 2022 and 2021:


	Pension Benefits				Other Postretirement Benefits
	2022		2021		2022		2021
Discount rate	4.8	%	2.3	%	5.4	%	2.5	%
Expected return on plan assets	5.0	%	5.1	%	—	%	—	%
Rate of compensation increase	3.7	%	3.1	%	—	%	—	%

The following weighted average assumptions were used to determine the net periodic benefit cost for the Company’s defined benefit pension and other postretirement benefit plans for the three years in the period ended December 31, 2022:


	Pension Benefits						Other Postretirement Benefits
	2022		2021		2020		2022		2021		2020
Discount rate	2.3	%	1.9	%	1.6	%	2.5	%	1.9	%	3.3	%
Expected return on plan assets	5.0	%	5.1	%	4.3	%	—	%	—	%	—	%
Rate of compensation increase	3.1	%	2.9	%	2.7	%	—	%	—	%	—	%

The assumptions for each plan are reviewed on an annual basis. The discount rate reflects the current rate at which the pension and other benefit liabilities could be effectively settled at the measurement date. In setting the discount rates, we utilize comparable corporate bond indices as an indication of interest rate movements and levels. Corporate bond indices were selected based on individual plan census data and duration. The expected return on plan assets was determined using historical market returns and long-term historical relationships between equities and fixed income securities. The Company compares the expected return on plan assets assumption to actual historic returns to ensure reasonableness. Current market factors such as inflation and interest rates are also evaluated.

The weighted-average healthcare cost trend rate used for 2022 was 6.3% declining to a projected 4.0% in the year 2045. For 2023, the assumed weighted-average healthcare cost trend rate used will be 6.9% declining to a projected 4.0% in the year 2046. In selecting rates for current and long-term healthcare cost assumptions, the Company takes into consideration a number of factors including the Company’s actual healthcare cost increases, the design of the Company’s benefit programs, the demographics of the Company’s active and retiree populations and external expectations of future medical cost inflation rates.

Estimated Future Benefit Payments

The Company’s funding policy for its funded pension plans is based upon local statutory requirements. The Company’s funding policy is subject to certain statutory regulations with respect to annual minimum and maximum company contributions. Plan benefits for the non-qualified plans are paid as they come due.

Estimated benefit payments over the next ten years for the Company’s pension plans and retiree health plan are as follows:


(In millions)	Pension Benefits		Other Postretirement Benefits
2023	$	93.1	$	15.4
2024	96.1		15.8
2025	97.9		15.8
2026	98.3		15.7
2027	102.0		15.1
Thereafter	518.1		64.5
Total	$	1,005.5	$	142.3

Defined Contribution Plans

The Company sponsors defined contribution plans covering its employees in the U.S. and Puerto Rico, as well as certain employees in a number of countries outside the U.S. The Company’s domestic defined contribution plans consist primarily of a Profit Sharing 401(k) Plan and a 401(k) retirement plan for union-represented employees. Profit sharing contributions are made at the discretion of the Board of Directors. The Company’s non-domestic plans vary in form depending on local legal requirements. The Company’s contributions are based upon employee contributions, service hours, or pre-determined amounts depending upon the plan. Obligations for contributions to defined contribution plans are recognized as expense in the consolidated statements of operations when they are earned.

The Company maintains a Restoration Plan, which permits employees who earn compensation in excess of the limits imposed by Section 401(a)(17) of the Code to (i) defer a portion of base salary and bonus compensation, (ii) be credited with a Company matching contribution in respect of deferrals under the Restoration Plan, and (iii) be credited with Company non-elective contributions (to the extent so made by the Company), in each case, to the extent that participants otherwise would be able to defer or be credited with such amounts, as applicable, under the Profit Sharing 401(k) Plan if not for the limits on contributions and deferrals imposed by the Code.

The Company maintains an Income Deferral Plan, which permits certain management or highly compensated employees who are designated by the plan administrator to participate in the Income Deferral Plan to elect to defer up to 50% of base salary and up to 100% of bonus compensation, in each case, in addition to any amounts that may be deferred by such participants under the Profit Sharing 401(k) Plan and the Restoration Plan. In addition, under the Income Deferral Plan, eligible participants may be granted employee deferral awards, which awards will be subject to the terms and conditions (including vesting) as determined by the plan administrator at the time such awards are granted.

Total employer contributions to defined contribution plans were approximately $111.5 million, $107.4 million and $115.5 million for the years ended December 31, 2022, 2021 and 2020, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI https://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Restructuring (Tables)

12 Months Ended

Dec. 31, 2022

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs [Table Text Block]

The following table summarizes the restructuring charges and the reserve activity for the 2020 restructuring program:


(In millions)	Employee Related Costs		Other Exit Costs		Total
Charges (3)	$	195.6	$	75.7	$	271.3
Acquired in the Combination	91.7		0.3		92.0
Cash payment	(25.1)		(0.4)		(25.5)
Utilization	—		(70.8)		(70.8)
Foreign currency translation	0.4		—		0.4
Balance at December 31, 2020	$	262.6	$	4.8	$	267.4
Charges (2)	396.1		496.1		892.2
Reimbursable restructuring charges	26.4		—		26.4
Cash payment	(385.5)		(151.7)		(537.2)
Utilization	—		(345.0)		(345.0)
Foreign currency translation	(7.0)		(0.1)		(7.1)
Balance at December 31, 2021	$	292.6	$	4.1	$	296.7
Charges (1)	38.2		48.3		86.5
Cash payment	(170.1)		(15.3)		(185.4)
Utilization	—		(34.9)		(34.9)
Foreign currency translation	(5.1)		(0.3)		(5.4)
Balance at December 31, 2022	$	155.6	$	1.9	$	157.5

The following table summarizes the restructuring charges and the reserve activity for the 2016 restructuring program from December 31, 2019 to December 31, 2020:


(In millions)	Employee Related Costs		Other Exit Costs		Total






Balance at December 31, 2019:	$	26.4	$	2.8	$	29.2
Charges (3)	9.9		40.6		50.5
Cash payment	(18.1)		(7.6)		(25.7)
Utilization	—		(32.9)		(32.9)
Foreign currency translation	1.8		(0.1)		1.7
Balance at December 31, 2020:	$	20.0	$	2.8	$	22.8

Leases (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
Leases (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2021
Leases [Abstract]
Right-of-use asset	$ 259,300			$ 290,800
Total lease liability	$ 262,000
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other Liabilities, Current			Other Liabilities, Current
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other Liabilities, Noncurrent			Other Liabilities, Noncurrent
Payments for rent	$ 90,900	$ 97,600	$ 80,700

Acquisitions and Other Transactions (Tables)

12 Months Ended

Dec. 31, 2022

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

During the year ended December 31, 2021, adjustments were made to the preliminary purchase price recorded at December 31, 2020, and are reflected as “Measurement Period and Other Adjustments” in the table below. The allocation of the $10.73 billion purchase price to the assets acquired and liabilities assumed under the Combination is as follows:


(In millions)	Preliminary Purchase Price Allocation as of December 31, 2020 (a)		Measurement Period and Other Adjustments (b)		Purchase Price Allocation as of December 31, 2021 (as adjusted)
Current assets (excluding inventories and net of cash acquired)	$	2,841.9	$	(38.7)	$	2,803.2
Inventories	2,588.9		(34.2)		2,554.7
Property, plant and equipment	1,394.1		(5.0)		1,389.1
Identified intangible assets	18,040.0		—		18,040.0
Goodwill	2,107.5		295.6		2,403.1
Deferred income tax benefit	1,481.9		196.3		1,678.2
Other assets	792.1		(7.4)		784.7
Total assets acquired	$	29,246.4	$	406.6	$	29,653.0
Current liabilities	2,760.2		419.7		3,179.9
Long-term debt, including current portion	13,076.2		—		13,076.2
Deferred tax liabilities	1,656.9		1.0		1,657.9
Other noncurrent liabilities	1,441.5		(14.1)		1,427.4
Net assets acquired (net of $415.8 of cash acquired)	$	10,311.6	$	—	$	10,311.6

____________

(a)As previously reported in Viatris’ Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

(b)The measurement period adjustments are primarily for 1) certain working capital adjustments, an increase in litigation reserves to reflect facts and circumstances that existed as of the date of the Combination, and other adjustments and 2) the tax implications of these and other adjustments. These adjustments did not have a significant impact on the Company’s previously reported consolidated financial statements and accordingly, the Company has not retrospectively adjusted those consolidated financial statements.

Business Acquisition, Pro Forma Information

Accordingly, the unaudited pro forma results are not necessarily indicative of the results that actually would have occurred had the acquisitions been completed on the stated date above, nor are they indicative of the future operating results of Viatris and its subsidiaries.


	Year Ended December 31,
(Unaudited, in millions, except per share amounts)	2020
Total revenues	$	18,284.8
Net earnings	$	1,483.7
Earnings per share:
Basic	$	1.23
Diluted	$	1.23
Weighted average shares outstanding:
Basic	1,206.8
Diluted	1,207.7

Share-Based Incentive Plan (Narrative) (Details) - USD ($) $ in Millions		12 Months Ended
	Nov. 16, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares exercised				27,615
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		4,449,642	5,576,490	6,711,731	6,347,709
Restricted stock \| Vest ratably in five years or less [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years		3 years
Number of restricted stock awards, granted		11,471,308
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock awards, granted		16,880,145
Long Term Incentive Plan 2003
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares exercised	6,757,640
Common stock shares reserved for issuance to employees	13,535,627
Total unrecognized compensation expense, net of estimated forfeitures		$ 171.2
Weighted-average period over which total unrecognized compensation expense expected to be recognized (years)		1 year 6 months
Intrinsic value of stock-based awards exercised and restricted stock units converted		$ 51.8	$ 78.1
Long Term Incentive Plan 2003 \| Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award expiration period, in years		10 years
Average remaining contractual term for options outstanding, in years		4 years 1 month 6 days
Average remaining contractual term for options vested and expected to vest, in years		4 years 1 month 6 days
Average remaining contractual term for options exercisable, in years		3 years 10 months 24 days
Long Term Incentive Plan 2003 \| Minimum \| Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years		3 years
Long Term Incentive Plan 2003 \| Maximum \| Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years		4 years
2020 Stock Incentive Plan and 2003 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount of common stock shares authorized	72,500,000
Not subject to market conditions \| Performance Shares \| Vest after three years
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock awards, granted		290,173
Subject to Market Conditions \| Performance Shares \| Vest after three years
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option award vesting period, in years		3 years
Number of restricted stock awards, granted		5,118,664

Restructuring (Narrative) (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

60 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Restructuring Cost and Reserve [Line Items]

Expected total pre-tax charges for restructuring

^[1]

$ 50.5

Potential annual savings relating to committed restructuring activities

$ 900.0

2016 Restructuring Program

Restructuring Cost and Reserve [Line Items]

Expected total pre-tax charges for restructuring

$ 733.0

2020 Restructuring Plan

Restructuring Cost and Reserve [Line Items]

Expected total pre-tax charges for restructuring

86.5

892.2

$ 271.3

2020 Restructuring Plan | Maximum

Restructuring Cost and Reserve [Line Items]

Expected total pre-tax charges for restructuring

$ 1,400.0

Non-cash charges mainly related to accelerated depreciation and asset impairment charges

450.0

Approximate expected severance and employee benefit expense

$ 950.0

950.0

Employee Severance

Restructuring Cost and Reserve [Line Items]

Expected total pre-tax charges for restructuring

^[1]

9.9

Employee Severance | 2020 Restructuring Plan

Restructuring Cost and Reserve [Line Items]

Expected total pre-tax charges for restructuring

38.2

396.1

195.6

Other Restructuring

Restructuring Cost and Reserve [Line Items]

Expected total pre-tax charges for restructuring

^[1]

40.6

Other Restructuring | 2020 Restructuring Plan

Restructuring Cost and Reserve [Line Items]

Expected total pre-tax charges for restructuring

48.3

496.1

75.7

Developed Markets | Operating Segments

Restructuring Cost and Reserve [Line Items]

Expected total pre-tax charges for restructuring

74.6

623.8

292.1

JANZ | Operating Segments

Restructuring Cost and Reserve [Line Items]

Expected total pre-tax charges for restructuring

0.9

138.1

2.9

Greater China | Operating Segments

Restructuring Cost and Reserve [Line Items]

Expected total pre-tax charges for restructuring

$ 2.5

$ 5.8

$ 18.4

[1]

For the year ended December 31, 2022, total restructuring charges for the 2020 restructuring program, in Developed Markets, Greater China, JANZ, Emerging Markets, and Corporate/Other were approximately $74.6 million, $2.5 million, $0.9 million, $8.2 million, and $0.3 million, respectively.

Employee Benefit Plans (Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Pension Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized actuarial (gain) loss	$ (293.6)	$ (59.9)
Unrecognized prior service cost (credit)	4.0	6.6
Total	(289.6)	(53.3)
Other Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized actuarial (gain) loss	(22.0)	21.7
Unrecognized prior service cost (credit)	(3.7)	(3.7)
Total	$ (25.7)	$ 18.0

Segment Information (Third Party Net Sales by Major Customers) (Details) - Third party net sales - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
McKesson Corporation
Revenue, Major Customer [Line Items]
Concentration risk, percentage	11.00%	9.00%	13.00%
AmeriSourceBergen Corporation
Revenue, Major Customer [Line Items]
Concentration risk, percentage	10.00%	9.00%	10.00%
Cardinal Health Inc
Revenue, Major Customer [Line Items]
Concentration risk, percentage	5.00%	5.00%	8.00%

Equity Method Investments (Tables)

12 Months Ended

Dec. 31, 2022

Equity Method Investments and Joint Ventures [Abstract]

Equity Method Investments

The carrying values and respective balance sheet location of the Company’s clean energy investments were as follows at December 31, 2021:


(In millions)									December 31, 2021

Other current liabilities									10.9


(In millions)	December 31, 2021
Current assets	$	4.2
Noncurrent assets	0.5
Total assets	4.7
Current liabilities	2.8

Total liabilities	2.8
Net assets	$	1.9


	Year Ended December 31,
(In millions)	2021		2020
Total revenues	$	326.7	$	374.5
Gross loss	(4.6)		(4.6)
Operating and non-operating expense	16.8		19.0
Net loss	$	(21.4)	$	(23.6)

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Comprehensive Earnings Derivatives in Cash Flow Hedging Relationships) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax	$ 0.0	$ 0.0	$ 7.1
Foreign Exchange Contract \| Cash flow hedging relationships \| Other income
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax	$ 0.0	$ 0.0	$ 7.1

Income Taxes (Schedule of Unrecognized Tax Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Unrecognized tax benefit — beginning of year	$ 296.7	$ 322.9	$ 391.1		$ 92.1
Additions for current year tax positions	8.2		0.0	$ 13.4
Additions for prior year tax positions	1.0		0.0	35.7
Reductions for prior year tax positions	(5.8)		(9.1)	(5.2)
Settlements	(0.4)		(47.3)	(8.9)
Reductions due to expirations of statute of limitations	(1.9)		(7.0)	$ 0.0
Unrecognized Tax Benefits, Decrease Resulting from Acquisition	(27.3)	(4.8)
(Reduction) addition due to acquisition			264.0
Unrecognized tax benefit — end of year	$ 296.7	$ 322.9	$ 391.1

Financial Instruments and Risk Management (Tables)

12 Months Ended

Dec. 31, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Summary of notional amounts of net investment hedges

The following table summarizes the principal amounts of the Company’s outstanding Euro and Yen borrowings and the notional amounts of the Euro and Yen borrowings designated as net investment hedges:


			Notional Amount Designated as a Net Investment Hedge
(in millions)	Principal Amount		December 31, 2022		December 31, 2021
Euro
2.250% Euro Senior Notes due 2024	€	1,000.0	€	1,000.0	€	1,000.0
3.125% Euro Senior Notes due 2028	750.0		750.0		750.0
2.125% Euro Senior Notes due 2025	500.0		500.0		500.0
0.816% Euro Senior Notes due 2022 (1)	750.0		—		750.0
1.023% Euro Senior Notes due 2024	750.0		750.0		750.0
1.362% Euro Senior Notes due 2027	850.0		850.0		850.0
1.908% Euro Senior Notes due 2032	1,250.0		1,250.0		1,250.0

Euro Total	€	5,850.0	€	5,100.0	€	5,850.0

Yen
YEN Term Loan	¥	40,000.0	¥	40,000.0	¥	40,000.0
Yen Total	¥	40,000.0	¥	40,000.0	¥	40,000.0

____________

(1)The Senior Notes were repaid at maturity during the second quarter of 2022.

Summary of classification and fair values of derivative instruments in consolidated balance sheets

The following table summarizes the classification and fair values of derivative instruments in our consolidated balance sheets:


	Asset Derivatives					Liability Derivatives
(In millions)	Balance Sheet Location	December 31, 2022 Fair Value		December 31, 2021 Fair Value		Balance Sheet Location	December 31, 2022 Fair Value		December 31, 2021 Fair Value

Derivatives designated as hedges:

Foreign currency forward contracts	Prepaid expenses & other current assets	$	30.4	$	62.0	Other current liabilities	$	26.4	$	4.3
Total derivatives designated as hedges		30.4		62.0			26.4		4.3
Derivatives not designated as hedges:
Foreign currency forward contracts	Prepaid expenses & other current assets	104.3		82.6		Other current liabilities	160.6		56.7
Total derivatives not designated as hedges		104.3		82.6			160.6		56.7
Total derivatives		$	134.7	$	144.6		$	187.0	$	61.0

Effect of Derivative Instruments on the Consolidated Statements of Operations

The following tables summarize information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:


		Amount of Gains/(Losses) Recognized in Earnings						Amount of Gain Excluded from the Assessment of Hedge Effectiveness
		Year Ended December 31,						Year Ended December 31,
(In millions)	Location of Gain/(Loss)	2022		2021		2020		2022		2021		2020
Derivative Financial Instruments in Fair Value Hedge Relationships (1) :
Interest rate swaps	Interest expense (3)	$	—	$	—	$	22.1	$	—	$	—	$	—
2023 Senior Notes (3.125% coupon)	Interest expense (3)	—		—		(22.1)		—		—		—
Derivative Financial Instruments in Cash Flow Hedging Relationships :
Foreign currency forward contracts	Other (income) expense, net (4)	—		—		—		—		—		7.1
Derivative Financial Instruments Not Designated as Hedging Instruments:
Foreign currency option and forward contracts	Other (income) expense, net (3)	(82.1)		39.3		(10.1)		—		—		—
Total		$	(82.1)	$	39.3	$	(10.1)	$	—	$	—	$	7.1

		Amount of Gains/(Losses) Recognized in AOCE (Net of Tax) on Derivatives						Amount of Gains/(Losses) Reclassified from AOCE into Earnings
		Year Ended December 31,						Year Ended December 31,
(In millions)	Location of Gain/(Loss)	2022		2021		2020		2022		2021		2020
Derivative Financial Instruments in Cash Flow Hedging Relationships (2) :
Foreign currency forward contracts	Net sales (5)	$	34.2	$	45.8	$	20.6	$	89.2	$	30.9	$	4.8
Interest rate swaps	Interest expense (5)	(3.5)		(3.4)		—		(4.5)		(4.3)		(4.5)
Non-derivative Financial Instruments in Net Investment Hedging Relationships:
Foreign currency borrowings		360.1		436.6		(346.4)		—		—		—
Total		$	390.8	$	479.0	$	(325.8)	$	84.7	$	26.6	$	0.3

____________

(1)In the first quarter of 2020, the Company terminated interest rate swaps designated as a fair value hedge resulting in net proceeds of approximately $45 million. The amount included in the above tables represents the fair value adjustment recognized at the date the interest rate swaps were settled.

(2)At December 31, 2022, the Company expects that approximately $8.0 million of pre-tax net losses on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months.

(3)Represents the location of the gain/(loss) recognized in earnings on derivatives.

(4)Represents the location of the gain excluded from the assessment of hedge effectiveness.

(5)Represents the location of the gain/(loss) reclassified from AOCE into earnings.

Financial Assets and Liabilities Carried at Fair Value

Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above:


	December 31, 2022						December 31, 2021
(In millions)	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Recurring fair value measurements
Financial Assets
Cash equivalents:
Money market funds	$	688.8	$	—	$	—	$	50.9	$	—	$	—
Total cash equivalents	688.8		—		—		50.9		—		—
Equity securities:
Exchange traded funds	42.4		—		—		50.3		—		—
Marketable securities	0.2		—		—		0.7		—		—
Total equity securities	42.6		—		—		51.0		—		—
CCPS in Biocon Biologics	—		—		997.4		—		—		—
Available-for-sale fixed income investments:
Corporate bonds	—		13.2		—		—		16.6		—
U.S. Treasuries	—		11.7		—		—		14.6		—
Agency mortgage-backed securities	—		4.7		—		—		2.0		—
Asset backed securities	—		5.1		—		—		4.6		—
Other	—		0.6		—		—		0.4		—
Total available-for-sale fixed income investments	—		35.3		—		—		38.2		—
Foreign exchange derivative assets	—		134.7		—		—		144.6		—

Total assets at recurring fair value measurement	$	731.4	$	170.0	$	997.4	$	101.9	$	182.8	$	—
Financial Liabilities
Foreign exchange derivative liabilities	$	—	$	187.0	$	—	$	—	$	61.0	$	—
Contingent consideration	—		—		375.0		—		—		199.7
Total liabilities at recurring fair value measurement	$	—	$	187.0	$	375.0	$	—	$	61.0	$	199.7

Schedule of Business Acquisitions by Acquisition, Contingent Consideration

A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2020 to December 31, 2022 is as follows:


(In millions)	Current Portion (1)		Long-Term Portion (2)		Total Contingent Consideration
Balance at December 31, 2020	$	100.5	$	123.1	$	223.6

Payments	(83.2)		—		(83.2)
Reclassifications	49.4		(49.4)		—
Accretion	—		9.0		9.0
Fair value loss (3)	—		50.3		50.3

Balance at December 31, 2021	$	66.7	$	133.0	$	199.7
Payments	(64.1)		—		(64.1)
Biocon Biologics Transaction	—		220.0		220.0
Reclassifications	61.8		(61.8)		—
Accretion	—		8.2		8.2
Fair value loss (3)	—		11.2		11.2
Balance at December 31, 2022	$	64.4	$	310.6	$	375.0

____________

(1)Included in other current liabilities in the consolidated balance sheets.

(2)Included in other long-term obligations in the consolidated balance sheets.

(3)Included in litigation settlements and other contingencies, net in the consolidated statements of operations.

Schedule of Available-for-Sale Securities Reconciliation

The amortized cost and estimated fair value of available-for-sale securities were as follows:


(In millions)	Balance Sheet Location	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
December 31, 2022
Available-for-sale fixed income investments	Prepaid expenses and other current assets	$	38.0	$	—	$	(2.7)	$	35.3
		$	38.0	$	—	$	(2.7)	$	35.3
December 31, 2021
Available-for-sale fixed income investments	Prepaid expenses and other current assets	$	38.1	$	0.1	$	—	$	38.2
		$	38.1	$	0.1	$	—	$	38.2

Maturities Of Available-for-Sale Debt Securities At Fair Value

Maturities of available-for-sale fixed income investments at fair value as of December 31, 2022, were as follows:


(In millions)
Mature within one year	$	1.0
Mature in one to five years	18.4
Mature in five years and later	15.9
	$	35.3

Financial Instruments and Risk Management

12 Months Ended

Dec. 31, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial Instruments And Risk Management

Financial Instruments and Risk Management

The Company is exposed to certain financial risks relating to its ongoing business operations. The primary financial risks that are managed by using derivative instruments are foreign currency risk and interest rate risk.

Foreign Currency Risk Management

In order to manage certain foreign currency risks, the Company enters into foreign exchange forward contracts to mitigate risk associated with changes in spot exchange rates of mainly non-functional currency denominated assets or liabilities. The foreign exchange forward contracts are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. Any gains or losses on the foreign exchange forward contracts are recognized in earnings in the period incurred in the consolidated statements of operations.

The Company has also entered into forward contracts to hedge forecasted foreign currency denominated sales from certain international subsidiaries and a portion of forecasted intercompany inventory sales denominated in Euro, Japanese Yen, Chinese Renminbi and Indian Rupee for up to twenty-four months. These contracts are designated as cash flow hedges to manage foreign currency transaction risk and are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. Any changes in the fair value of designated cash flow hedges are deferred in AOCE and are reclassified into earnings when the hedged item impacts earnings.

Net Investment Hedges

The Company may hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries by either borrowing directly in foreign currencies and designating all or a portion of the foreign currency debt as a hedge of the applicable net investment position or entering into foreign currency swaps that are designated as hedges of net investments.

The Company has designated certain Euro and Yen borrowings as a hedge of its investment in certain Euro-functional and Yen-functional currency subsidiaries in order to manage foreign currency translation risk. Borrowings designated as net investment hedges are marked-to-market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of AOCE until the sale or substantial liquidation of the underlying net investments. In addition, the Company manages the related foreign exchange risk of the Euro and Yen borrowings not designated as net investment hedges through certain Euro and Yen denominated financial assets and forward currency swaps.


			Notional Amount Designated as a Net Investment Hedge
(in millions)	Principal Amount		December 31, 2022		December 31, 2021
Euro
2.250% Euro Senior Notes due 2024	€	1,000.0	€	1,000.0	€	1,000.0
3.125% Euro Senior Notes due 2028	750.0		750.0		750.0
2.125% Euro Senior Notes due 2025	500.0		500.0		500.0
0.816% Euro Senior Notes due 2022 (1)	750.0		—		750.0
1.023% Euro Senior Notes due 2024	750.0		750.0		750.0
1.362% Euro Senior Notes due 2027	850.0		850.0		850.0
1.908% Euro Senior Notes due 2032	1,250.0		1,250.0		1,250.0

Euro Total	€	5,850.0	€	5,100.0	€	5,850.0

Yen
YEN Term Loan	¥	40,000.0	¥	40,000.0	¥	40,000.0
Yen Total	¥	40,000.0	¥	40,000.0	¥	40,000.0

____________

(1)The Senior Notes were repaid at maturity during the second quarter of 2022.

At December 31, 2022, the principal amount of the Company’s outstanding Yen borrowings and the notional amount of the Yen borrowings designated as net investment hedge was $305.1 million.

Interest Rate Risk Management

The Company enters into interest rate swaps from time to time in order to manage interest rate risk associated with the Company’s fixed-rate and floating-rate debt. Interest rate swaps that meet specific accounting criteria are accounted for as fair value or cash flow hedges. All derivative instruments used to manage interest rate risk are measured at fair value and reported as current assets or current liabilities in the consolidated balance sheets. For fair value hedges, the changes in the fair value of both the hedging instrument and the underlying debt obligations are included in interest expense. For cash flow hedges, the change in fair value of the hedging instrument is deferred through AOCE and is reclassified into earnings when the hedged item impacts earnings.

Cash Flow Hedging Relationships

The Company’s interest rate swaps designated as cash flow hedges fix the interest rate on a portion of the Company’s variable-rate debt or hedge part of the Company’s interest rate exposure associated with the variability in the future cash flows attributable to changes in interest rates. Any changes in fair value are included in earnings or deferred through AOCE, depending on the nature and effectiveness of the offset. Any ineffectiveness in a cash flow hedging relationship is recognized immediately in earnings in the consolidated statements of operations.

Fair Value Hedging Relationships

The Company's interest rate swaps designated as fair value hedges convert the fixed rate on a portion of the Company's fixed-rate senior notes to a variable rate. Any changes in the fair value of these derivative instruments, as well as the offsetting change in fair value of the portion of the fixed-rate debt being hedged, is included in interest expense. The Company’s fair value hedge was terminated during 2020.

Credit Risk Management

The Company regularly reviews the creditworthiness of its financial counterparties and does not expect to incur a significant loss from the failure of any counterparties to perform under any agreements. The Company is not subject to any obligations to post collateral under derivative instrument contracts. Certain derivative instrument contracts entered into by the

Company are governed by master agreements, which contain credit-risk-related contingent features that would allow the counterparties to terminate the contracts early and request immediate payment should the Company trigger an event of default on other specified borrowings. The Company records all derivative instruments on a gross basis in the consolidated balance sheets. Accordingly, there are no offsetting amounts that net assets against liabilities.

The following table summarizes the classification and fair values of derivative instruments in our consolidated balance sheets:


	Asset Derivatives					Liability Derivatives
(In millions)	Balance Sheet Location	December 31, 2022 Fair Value		December 31, 2021 Fair Value		Balance Sheet Location	December 31, 2022 Fair Value		December 31, 2021 Fair Value

Derivatives designated as hedges:

Foreign currency forward contracts	Prepaid expenses & other current assets	$	30.4	$	62.0	Other current liabilities	$	26.4	$	4.3
Total derivatives designated as hedges		30.4		62.0			26.4		4.3
Derivatives not designated as hedges:
Foreign currency forward contracts	Prepaid expenses & other current assets	104.3		82.6		Other current liabilities	160.6		56.7
Total derivatives not designated as hedges		104.3		82.6			160.6		56.7
Total derivatives		$	134.7	$	144.6		$	187.0	$	61.0

The following tables summarize information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:


		Amount of Gains/(Losses) Recognized in Earnings						Amount of Gain Excluded from the Assessment of Hedge Effectiveness
		Year Ended December 31,						Year Ended December 31,
(In millions)	Location of Gain/(Loss)	2022		2021		2020		2022		2021		2020
Derivative Financial Instruments in Fair Value Hedge Relationships (1) :
Interest rate swaps	Interest expense (3)	$	—	$	—	$	22.1	$	—	$	—	$	—
2023 Senior Notes (3.125% coupon)	Interest expense (3)	—		—		(22.1)		—		—		—
Derivative Financial Instruments in Cash Flow Hedging Relationships :
Foreign currency forward contracts	Other (income) expense, net (4)	—		—		—		—		—		7.1
Derivative Financial Instruments Not Designated as Hedging Instruments:
Foreign currency option and forward contracts	Other (income) expense, net (3)	(82.1)		39.3		(10.1)		—		—		—
Total		$	(82.1)	$	39.3	$	(10.1)	$	—	$	—	$	7.1

		Amount of Gains/(Losses) Recognized in AOCE (Net of Tax) on Derivatives						Amount of Gains/(Losses) Reclassified from AOCE into Earnings
		Year Ended December 31,						Year Ended December 31,
(In millions)	Location of Gain/(Loss)	2022		2021		2020		2022		2021		2020
Derivative Financial Instruments in Cash Flow Hedging Relationships (2) :
Foreign currency forward contracts	Net sales (5)	$	34.2	$	45.8	$	20.6	$	89.2	$	30.9	$	4.8
Interest rate swaps	Interest expense (5)	(3.5)		(3.4)		—		(4.5)		(4.3)		(4.5)
Non-derivative Financial Instruments in Net Investment Hedging Relationships:
Foreign currency borrowings		360.1		436.6		(346.4)		—		—		—
Total		$	390.8	$	479.0	$	(325.8)	$	84.7	$	26.6	$	0.3

____________

(2)At December 31, 2022, the Company expects that approximately $8.0 million of pre-tax net losses on cash flow hedges will be reclassified from AOCE into earnings during the next twelve months.

(3)Represents the location of the gain/(loss) recognized in earnings on derivatives.

(4)Represents the location of the gain excluded from the assessment of hedge effectiveness.

(5)Represents the location of the gain/(loss) reclassified from AOCE into earnings.

Fair Value Measurement

Fair value is based on the price that would be received from the sale of an identical asset or paid to transfer an identical liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, a fair value hierarchy has been established that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as considers counterparty credit risk in its assessment of fair value.

Financial assets and liabilities carried at fair value are classified in the tables below in one of the three categories described above:


	December 31, 2022						December 31, 2021
(In millions)	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Recurring fair value measurements
Financial Assets
Cash equivalents:
Money market funds	$	688.8	$	—	$	—	$	50.9	$	—	$	—
Total cash equivalents	688.8		—		—		50.9		—		—
Equity securities:
Exchange traded funds	42.4		—		—		50.3		—		—
Marketable securities	0.2		—		—		0.7		—		—
Total equity securities	42.6		—		—		51.0		—		—
CCPS in Biocon Biologics	—		—		997.4		—		—		—
Available-for-sale fixed income investments:
Corporate bonds	—		13.2		—		—		16.6		—
U.S. Treasuries	—		11.7		—		—		14.6		—
Agency mortgage-backed securities	—		4.7		—		—		2.0		—
Asset backed securities	—		5.1		—		—		4.6		—
Other	—		0.6		—		—		0.4		—
Total available-for-sale fixed income investments	—		35.3		—		—		38.2		—
Foreign exchange derivative assets	—		134.7		—		—		144.6		—

Total assets at recurring fair value measurement	$	731.4	$	170.0	$	997.4	$	101.9	$	182.8	$	—
Financial Liabilities
Foreign exchange derivative liabilities	$	—	$	187.0	$	—	$	—	$	61.0	$	—
Contingent consideration	—		—		375.0		—		—		199.7
Total liabilities at recurring fair value measurement	$	—	$	187.0	$	375.0	$	—	$	61.0	$	199.7

For financial assets and liabilities that utilize Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including the LIBOR yield curve, foreign exchange forward prices, and bank price quotes. For the years ended December 31, 2022 and 2021, there were no transfers between Level 1 and 2 of the fair value hierarchy. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities:

•Cash equivalents — valued at observable net asset value prices.

•Equity securities, exchange traded funds — valued at the active quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in Other (income) expense, net, in the consolidated statements of operations.

•Equity securities, marketable securities — valued using quoted stock prices from public exchanges at the reporting date. Unrealized gains and losses attributable to changes in fair value are included in Other (income) expense, net, in the consolidated statements of operations.

•CCPS in Biocon Biologics — valued using a Monte Carlo simulation model using Level 3 inputs. The fair value of the CCPS is sensitive to changes in the forecasts of operating metrics and changes in volatility and discount rates. The Company elected the fair value option for the CCPS under ASC 825. The fair value is reassessed quarterly and any change in the fair value estimate is recorded in Other (income) expense, net, in the consolidated statements of operations for that period.

•Available-for-sale fixed income investments — valued at the quoted market prices from broker or dealer quotations or transparent pricing sources at the reporting date. Unrealized gains and losses attributable to changes in fair value, net of income taxes, are included in accumulated other comprehensive loss as a component of shareholders’ equity.

•Foreign exchange derivative assets and liabilities — valued using quoted forward foreign exchange prices and spot rates at the reporting date. Counterparties to these contracts are highly rated financial institutions.

Contingent Consideration

In December 2011, the Company completed the acquisition of the exclusive worldwide rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline’s Advair Diskus® incorporating Pfizer’s Respiratory Delivery Platform. The Company accounted for this transaction as a purchase of a business and utilized the acquisition method of accounting. On January 30, 2019, the Company received FDA approval of Wixela Inhub® (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of GlaxoSmithKline’s Advair Diskus®. The commercial launch of the Wixela Inhub® occurred in February 2019.

As of December 31, 2022, the Company has a contingent consideration liability of $132.0 million related to the Respiratory Delivery Platform and $221.2 million related to the Biocon Biologics Transaction. The contingent consideration liability related to the Biocon Biologics Transaction represents the amount of the closing working capital target to which the parties have agreed that may become payable to Biocon Biologics in connection with certain events in the future, depending on the valuations attributable to such events. The measurement of these contingent consideration liabilities is calculated using unobservable Level 3 inputs based on the Company’s own assumptions primarily related to the probability and timing of future events and payments which are discounted using a market rate of return. At December 31, 2022 and 2021, discount rates ranging from 6.4% to 9.0% were utilized in the valuations. Significant changes in unobservable inputs could result in material changes to the contingent consideration liabilities.

A rollforward of the activity in the Company’s fair value of contingent consideration from December 31, 2020 to December 31, 2022 is as follows:


(In millions)	Current Portion (1)		Long-Term Portion (2)		Total Contingent Consideration
Balance at December 31, 2020	$	100.5	$	123.1	$	223.6

Payments	(83.2)		—		(83.2)
Reclassifications	49.4		(49.4)		—
Accretion	—		9.0		9.0
Fair value loss (3)	—		50.3		50.3

Balance at December 31, 2021	$	66.7	$	133.0	$	199.7
Payments	(64.1)		—		(64.1)
Biocon Biologics Transaction	—		220.0		220.0
Reclassifications	61.8		(61.8)		—
Accretion	—		8.2		8.2
Fair value loss (3)	—		11.2		11.2
Balance at December 31, 2022	$	64.4	$	310.6	$	375.0

____________

(1)Included in other current liabilities in the consolidated balance sheets.

(2)Included in other long-term obligations in the consolidated balance sheets.

(3)Included in litigation settlements and other contingencies, net in the consolidated statements of operations.

Although the Company has not elected the fair value option for financial assets and liabilities other than the CCPS, any future transacted financial asset or liability will be evaluated for the fair value election.

Available-for-Sale Securities

The amortized cost and estimated fair value of available-for-sale securities were as follows:


(In millions)	Balance Sheet Location	Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
December 31, 2022
Available-for-sale fixed income investments	Prepaid expenses and other current assets	$	38.0	$	—	$	(2.7)	$	35.3
		$	38.0	$	—	$	(2.7)	$	35.3
December 31, 2021
Available-for-sale fixed income investments	Prepaid expenses and other current assets	$	38.1	$	0.1	$	—	$	38.2
		$	38.1	$	0.1	$	—	$	38.2

Maturities of available-for-sale fixed income investments at fair value as of December 31, 2022, were as follows:


(In millions)
Mature within one year	$	1.0
Mature in one to five years	18.4
Mature in five years and later	15.9
	$	35.3

Nature of Operations	12 Months Ended
Nature of Operations	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	Nature of Operations Viatris is a global healthcare company formed in November 2020 whose mission is to empower people worldwide to live healthier at every stage of life, regardless of geography or circumstance. Improving the ability of patients to gain access to sustainable and high-quality healthcare is our relentless pursuit. One that rests on visionary thinking, determination and best-in-class capabilities that were strategically built to remove barriers across the health spectrum and advance access globally. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generics, and complex generics, including biosimilars prior to the Biocon Biologics Transaction. The Company operates approximately 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and APIs. We conduct our business through four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China and Hyderabad, India. Certain reclassifications were made to conform the prior period consolidated financial statements to the current period presentation. Upfront and milestone-related charges in connection with collaboration and licensing arrangements made prior to regulatory approval of a development product that were previously presented in Research and Development are now presented in Acquired IPR&D in the consolidated statements of operations. In accordance with ASC 805, Business Combinations, Mylan is considered the accounting acquirer of the Upjohn Business and all historical financial information of the Company prior to November 16, 2020 represents Mylan’s historical results and the Company’s thereafter.

Debt (Issuance of 2018 Senior Notes) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Long-term debt	$ 18,015.2	$ 19,717.1
Senior Notes \| 2028 Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	4.55%
Senior Notes \| 2048 Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	5.20%

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets

Goodwill and Intangible Assets

Goodwill

The changes in the carrying amount of goodwill for the years ended December 31, 2022 and 2021 are as follows:


(In millions)	Developed Markets (1)		Greater China		JANZ		Emerging Markets (2)		Total



Balance at December 31, 2020:	$	9,184.5	$	738.3	$	864.0	$	1,560.2	$	12,347.0
Measurement period and other adjustments	67.7		220.4		(30.9)		38.4		295.6
Foreign currency translation	(528.8)		10.8		(56.8)		45.9		(528.9)
Balance at December 31, 2021:	$	8,723.4	$	969.5	$	776.3	$	1,644.5	$	12,113.7




Disposition (3)	(743.9)		(2.7)		(32.6)		(140.5)		(919.7)
Impairment	—		—		—		(117.0)		(117.0)
Foreign currency translation	(518.0)		(26.2)		(54.7)		(52.3)		(651.2)
Balance at December 31, 2022	$	7,461.5	$	940.6	$	689.0	$	1,334.7	$	10,425.8

____________

(1)Balances as of December 31, 2022, 2021 and 2020 include accumulated impairment losses of $385.0 million.

(2)Balance as of December 31, 2022 includes accumulated impairment loss of $117.0 million.

(3)Reflects goodwill relating to the biosimilars portfolio. Refer to Note 5 Divestitures for additional information.

The Company reviews goodwill for impairment annually on April 1st or more frequently if events or changes in circumstances indicate that the carrying value of goodwill may not be recoverable. As a result of the Biocon Biologics Transaction (refer to Note 5 Divestitures for additional information) and the decline in the Company’s share price during the first quarter of 2022, the Company performed an interim goodwill impairment test as of March 31, 2022. The Company performed the annual goodwill impairment test as of April 1, 2022. There were no significant changes from the interim goodwill test performed at March 31, 2022 and the results were consistent with the interim goodwill impairment test.

The Company performed both its interim and annual goodwill impairment tests on a quantitative basis for its five reporting units, North America, Europe, Emerging Markets, JANZ, and Greater China. In estimating each reporting unit’s fair value, the Company performed an extensive valuation analysis, utilizing both income and market-based approaches. The determination of the fair value of the reporting units requires the Company to make significant estimates and assumptions that affect the reporting unit’s expected future cash flows. These estimates and assumptions, utilizing Level 3 inputs, primarily include, but are not limited to, market multiples, control premiums, the discount rate, terminal growth rates, operating income before depreciation and amortization, and capital expenditures forecasts.

As of March 31, 2022 and April 1, 2022, the allocation of the Company’s total goodwill (prior to the reclassification of goodwill to assets held for sale) was as follows: North America $3.61 billion, Europe $4.95 billion, Emerging Markets $1.64 billion, JANZ $0.78 billion and Greater China $0.97 billion.

As of March 31, 2022 and April 1, 2022, the Company determined that the fair value of the North America and Greater China reporting units was substantially in excess of the respective unit’s carrying value.

For the Europe reporting unit, the estimated fair value exceeded its carrying value by approximately $797 million or 5.3% for both the interim and annual goodwill impairment tests. As it relates to the income approach for the Europe reporting unit at March 31, 2022 and April 1, 2022, the Company forecasted cash flows for the next 10 years. During the forecast period, the revenue compound annual growth rate was approximately 0.5%. A terminal year value was calculated with a negative 1.0% revenue growth rate applied. The discount rate utilized was 9.5% and the estimated tax rate was 15.3%. Under the market-based approach, we utilized an estimated range of market multiples of 7.5 to 8.0 times EBITDA plus a control premium of 15.0%. If all other assumptions are held constant, a reduction in the terminal value growth rate by 3.0% or an increase in discount rate by 1.5% would result in an impairment charge for the Europe reporting unit.

For the JANZ reporting unit, the estimated fair value exceeded its carrying value by approximately $231 million or 7.4% for both the interim and annual goodwill impairment tests. As it relates to the income approach for the JANZ reporting unit at March 31, 2022 and April 1, 2022, the Company forecasted cash flows for the next 10 years. During the forecast period, the revenue compound annual growth rate was approximately negative 4.8%. A terminal year value was calculated assuming no revenue growth rate. The discount rate utilized was 6.0% and the estimated tax rate was 30.4%. Under the market-based approach, we utilized an estimated market multiple of 6.0 times EBITDA plus a control premium of 15.0%. If all other assumptions are held constant, a reduction in the terminal value growth rate by 3.5% or an increase in discount rate by 2.0% would result in an impairment charge for the JANZ reporting unit.

For the Emerging Markets reporting unit, the estimated fair value exceeded its carrying value by approximately $816 million or 10.3% for both the interim and annual goodwill impairment tests. As it relates to the income approach for the Emerging Markets reporting unit at March 31, 2022 and April 1, 2022, the Company forecasted cash flows for the next 10 years. During the forecast period, the revenue compound annual growth rate was approximately 1.6%. A terminal year value was calculated with a 0.8% revenue growth rate applied. The discount rate utilized was 10.5% and the estimated tax rate was 18.4%. Under the market-based approach, we utilized an estimated market multiple of 7.5 times EBITDA plus a control premium of 15.0%. If all other assumptions are held constant, a reduction in the terminal value growth rate by approximately 8.5% or an increase in discount rate by 3.0% would result in an impairment charge for the Emerging Markets reporting unit.

Subsequent to the completion of the interim goodwill impairment test and in conjunction with the Biocon Biologics Transaction, the Company allocated goodwill to its biosimilars portfolio using a relative fair value approach and reclassified the amount to assets held for sale. Upon closing of the Biocon Biologics Transaction on November 29, 2022, we derecognized goodwill of $919.7 million allocated to the biosimilars portfolio.

In the fourth quarter of 2022, we determined that our Upjohn Distributor Markets should be classified as held for sale in the December 31, 2022 consolidated balance sheet. The Company allocated goodwill to its Upjohn Distributor Markets using a relative fair value approach and recorded a goodwill impairment charge of $117.0 million within the Emerging Markets reporting unit, which was recorded within SG&A in the consolidated statement of operations. The goodwill impairment charge was the result of the estimated proceeds less selling costs from the disposal of the Upjohn Distributor Markets being below the carrying value of the net assets of the disposal group.

Refer to Note 5 Divestitures for additional information.

Due to the inherent uncertainty involved in making these estimates, actual results could differ from those estimates. In addition, changes in underlying assumptions, especially as they relate to the key assumptions detailed, could have a significant impact on the fair value of the reporting units.

Intangible Assets, Net

Intangible assets consist of the following components at December 31, 2022 and 2021:


(In millions)	Weighted Average Life (Years)	Cost		Accumulated Amortization		Net Book Value
December 31, 2022
Product rights, licenses and other (1)	15	$	37,490.5	$	14,923.6	$	22,566.9
In-process research and development		40.2		—		40.2
		$	37,530.7	$	14,923.6	$	22,607.1
December 31, 2021
Product rights, licenses and other (1)	15	$	39,006.2	$	12,918.5	$	26,087.7
In-process research and development		46.5		—		46.5
		$	39,052.7	$	12,918.5	$	26,134.2

____________

(1)Represents amortizable intangible assets. Other intangibles consist principally of customer lists and contractual rights.

Product rights and licenses are primarily comprised of the products marketed at the time of acquisition. These product rights and licenses relate to numerous individual products, the net book value of which, by product category, is as follows:


(In millions)	Developed Markets		Greater China		JANZ		Emerging Markets		December 31, 2022
Brands	$	8,762.2	$	5,632.3	$	1,061.3	$	3,122.5	$	18,578.3
Complex Gx and Biosimilars	177.5		—		0.9		—		178.4
Generics	3,271.4		10.6		263.3		263.9		3,809.2
Total Product Rights and Licenses	$	12,211.1	$	5,642.9	$	1,325.5	$	3,386.4	$	22,565.9


(In millions)	Developed Markets		Greater China		JANZ		Emerging Markets		December 31, 2021
Brands	$	10,066.6	$	6,102.9	$	1,174.8	$	3,801.7	$	21,146.0
Complex Gx and Biosimilars	226.8		—		1.5		—		228.3
Generics	4,020.2		12.1		319.5		358.4		4,710.2
Total Product Rights and Licenses	$	14,313.6	$	6,115.0	$	1,495.8	$	4,160.1	$	26,084.5

Amortization expense and intangible asset disposal & impairment charges, which are included as a component of amortization expense, are classified primarily within cost of sales in the consolidated statements of operations, and were as follows for the years ended December 31, 2022, 2021 and 2020:


	Year ended December 31,
(In millions)	2022		2021		2020
Intangible asset amortization expense	$	2,504.6	$	2,702.2	$	1,605.8
IPR&D intangible asset impairment charges	0.6		19.4		37.4
Finite-lived intangible asset disposal & impairment charges	172.9		83.4		45.0
Total intangible asset amortization expense (including disposal & impairment charges)	$	2,678.1	$	2,805.0	$	1,688.2

The assessment for impairment of finite-lived intangibles is based on our ability to recover the carrying value of the long-lived assets or asset grouping by analyzing the expected future undiscounted pre-tax cash flows specific to the asset or asset grouping. If the carrying amount is greater than the undiscounted cash flows, the Company recognizes an impairment loss for the excess of the carrying amount over the estimated fair value based on discounted cash flows.

Significant management judgment is involved in estimating the recoverability of these assets and is dependent upon the accuracy of the assumptions used in making these estimates, as well as how the estimates compare to the eventual future operating performance of the specific asset or asset grouping. The fair value of finite-lived intangible assets was calculated as the present value of the estimated future net cash flows using a market rate of return. The assumptions inherent in the estimated future cash flows include, among other things, the impact of the current competitive environment and future market expectations. A discount rate of 9.0% was utilized in the valuations performed during the years ended December 31, 2021 and 2020. Any future long-lived assets impairment charges could have a material impact in the Company’s consolidated financial condition and results of operations.

In the fourth quarter of 2022, the Company recognized an intangible asset charge of approximately $172.9 million, which was recorded within Cost of Sales in the consolidated statement of operations, to write down the disposal group to fair value, less cost to sell, related to our Upjohn Distributor Markets, which was classified as held for sale. The Company has approximately $230.3 million of intangible assets related to the Upjohn Distributor Markets that have been classified as held for sale in the December 31,2022 consolidated balance sheet. Refer to Note 5 Divestitures for additional information.

On April 30, 2021, the Company completed an agreement to divest a group of OTC products in the U.S. As a result of this transaction, the Company recognized an intangible asset impairment charge of approximately $83.4 million during the year ended December 31, 2021.

The Company’s IPR&D assets are tested at least annually for impairment or upon the occurrence of a triggering event. Impairment is determined to exist when the fair value of IPR&D assets, which is based upon updated forecasts and commercial development plans, is less than the carrying value of the assets being tested. The fair value of IPR&D was calculated as the present value of the estimated future net cash flows using a market rate of return. The assumptions inherent in the estimated

future cash flows include, among other things, the impact of changes to the development programs, the projected development and regulatory time frames and the current competitive environment. A discount rate of 10.5% was utilized in the valuations performed during the year ended December 31, 2022. Discount rates ranging between 7.0% and 9.0%, and 9.0% and 11.0% were utilized in the valuations performed during the years ended December 31, 2021 and 2020, respectively.

The fair value of both IPR&D and finite-lived intangible assets was determined based upon detailed valuations employing the income approach which utilized Level 3 inputs, as defined in Note 10, Financial Instruments and Risk Management. Changes to any of the Company’s assumptions including changes to or abandonment of development programs, regulatory timelines, discount rates or the competitive environment related to the assets could lead to future material impairment charges.

Intangible asset amortization expense for the years ending December 31, 2023 through 2027 is estimated to be as follows:


(In millions)
2023	$	2,322
2024	2,230
2025	2,136
2026	2,083
2027	1,871

Financial Instruments and Risk Management (Maturities of Available-for-sale Debt Securities at Fair Value) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Mature within one year	$ 1.0
Mature in one to five years	18.4
Mature in five years and later	15.9
Fair Value	$ 35.3	$ 38.2

Debt (Minimum Repayments on Outstanding Borrowings) (Details) $ in Millions	Dec. 31, 2022 USD ($)
Debt Disclosure [Abstract]
2021	$ 1,250
2022	1,873
2023	1,285
2024	2,555
2025	1,660
Thereafter	10,091
Total	$ 18,714

Balance Sheet Components Balance Sheet Components (Cash and Cash Equivalents) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 1,259.9	$ 701.2	$ 844.4
Restricted cash, included in other current and non-current assets	2.6	5.0	5.6
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 1,262.5	$ 706.2	$ 850.0	$ 491.1

Revenue Recognition and Accounts Receivable (Tables)

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table presents the Company’s net sales by product category for each of our reportable segments for the years ended December 31, 2022, 2021, and 2020, respectively:


(In millions)	2022 Net Sales
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	5,160.4		2,190.7		922.6		1,615.9		9,889.6
Complex Gx and Biosimilars	1,218.0		0.6		44.1		50.7		1,313.4
Generics	3,390.5		9.9		665.7		949.0		5,015.1
Total Viatris	$	9,768.9	$	2,201.2	$	1,632.4	$	2,615.6	$	16,218.1


(In millions)	2021 Net Sales
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	5,759.2		2,207.8		1,197.1		1,677.2		10,841.3
Complex Gx and Biosimilars	1,241.6		0.2		46.5		53.8		1,342.1
Generics	3,427.9		4.8		783.8		1,413.7		5,630.2
Total Viatris	$	10,428.7	$	2,212.8	$	2,027.4	$	3,144.7	$	17,813.6


(In millions)	2020 Net Sales
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	3,920.7		253.9		617.0		443.3		5,234.9
Complex Gx and Biosimilars	1,202.6		0.7		42.8		49.4		1,295.5
Generics	3,387.6		5.3		535.5		1,361.1		5,289.5
Total Viatris	$	8,510.9	$	259.9	$	1,195.3	$	1,853.8	$	11,819.9

____________

(a)Amounts for the year ended December 31, 2022 include the unfavorable impact of foreign currency translations compared to the prior year period.

The following table presents net sales on a consolidated basis for select key products for the years ended December 31, 2022 and 2021, respectively:


	Year Ended December 31,
(In millions)	2022		2021

Select Key Global Products
Lipitor ®	$	1,635.2	$	1,663.2
Norvasc ®	775.1		824.7
Lyrica ®	623.8		728.5
Viagra ®	458.9		533.8
EpiPen® Auto-Injectors	378.0		391.7
Celebrex ®	338.1		344.4
Creon ®	304.0		309.8
Effexor ®	279.6		316.8
Zoloft ®	246.2		284.3
Xalabrands	195.1		226.0

Select Key Segment Products
Influvac ®	$	225.5	$	299.3
Yupelri ®	202.1		161.9
Dymista ®	179.8		168.0
Amitiza ®	167.9		201.5
Xanax ®	156.5		185.9

____________

(a)The Company does not disclose net sales for any products considered competitively sensitive.

(b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.

(c)Amounts for the year ended December 31, 2022 include the unfavorable impact of foreign currency translations compared to the prior year period.

(d)Amounts for the year ended December 31, 2020 are not presented due to the significance of products acquired as part of the Combination.

The following is a rollforward of the categories of variable consideration during 2022:


(In millions)	Balance at December 31, 2021		Current Provision Related to Sales Made in the Current Period		Balances Divested		Checks/ Credits Issued to Third Parties		Effects of Foreign Exchange		Balance at December 31, 2022
Chargebacks	$	591.7	$	6,192.2	$	(53.4)	$	(6,205.6)	$	(1.5)	$	523.4
Rebates, promotional programs and other sales allowances	1,373.0		4,346.2		(215.1)		(4,177.5)		(42.4)		1,284.2
Returns	686.8		296.7		(16.0)		(447.6)		(6.5)		513.4
Governmental rebate programs	399.2		608.9		(34.1)		(602.4)		(5.1)		366.5
Total	$	3,050.7	$	11,444.0	$	(318.6)	$	(11,433.1)	$	(55.5)	$	2,687.5

Schedule of Accounts Receivable, Net

Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2022 and 2021, respectively:


(In millions)	December 31, 2022		December 31, 2021
Accounts receivable, net	$	1,798.7	$	1,688.6
Other current liabilities	888.8		1,362.1
Total	$	2,687.5	$	3,050.7

Accounts receivable, net was comprised of the following at December 31, 2022 and 2021, respectively:


(In millions)	December 31, 2022		December 31, 2021
Trade receivables, net	$	3,243.8	$	3,774.4
Other receivables	570.7		492.0
Accounts receivable, net	$	3,814.5	$	4,266.4

Disaggregation of Revenue, Variable Consideration

The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the years ended December 31, 2022, 2021 and 2020, respectively:


	Year Ended December 31,
(In millions)	2022		2021		2020
Gross sales	$	27,662.1	$	30,553.4	$	19,899.1
Gross to net adjustments:
Chargebacks	(6,192.2)		(5,530.1)		(3,656.2)
Rebates, promotional programs and other sales allowances	(4,346.2)		(6,135.6)		(3,765.5)
Returns	(296.7)		(384.6)		(329.7)
Governmental rebate programs	(608.9)		(689.5)		(327.8)
Total gross to net adjustments	$	(11,444.0)	$	(12,739.8)	$	(8,079.2)
Net sales	$	16,218.1	$	17,813.6	$	11,819.9

Employee Benefit Plans (Plans with PBO in Excess of Plan Assets) (Details) - Pension Benefits - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Projected benefit obligation	$ 1,026.5	$ 1,591.8
Accumulated benefit obligation	999.3	1,546.4
Fair value of plan assets	$ 604.9	$ 904.1

Segment Information (Reconciliation of Segment Information to Total Consolidated Information) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Net sales	$ 16,218.1	$ 17,813.6	$ 11,819.9
Segment Profitability	1,614.9	(34.0)	(210.8)
Intangible asset amortization expense	(2,504.6)	(2,702.2)	(1,605.8)
Impairment of goodwill	(117.0)	0.0	0.0
Acquired IPR&D	36.4	70.1	42.5
Litigation settlements & other contingencies	$ (4.4)	(329.2)	(107.8)
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Goods and Services Sold
Operating Segments
Segment Reporting Information [Line Items]
Net sales	$ 16,218.1	17,813.6
Segment Profitability	8,263.2	8,705.0	5,271.6
Segment Reconciling
Segment Reporting Information [Line Items]
Intangible asset amortization expense	(2,504.6)	(2,702.2)	(1,605.8)
Intangible asset disposal & impairment charges	(173.5)	(102.8)	(82.4)
Globally managed research and development costs	(662.2)	(681.0)	(512.6)
Acquired IPR&D	(36.4)	(70.1)	(42.5)
Litigation settlements & other contingencies	(4.4)	(329.2)	(107.8)
Transaction related and other special items	(1,026.9)	(2,832.2)	(1,739.7)
Corporate (Other)
Segment Reporting Information [Line Items]
Corporate and other unallocated	(2,123.3)	(2,021.5)	(1,391.6)
Developed Markets
Segment Reporting Information [Line Items]
Impairment of goodwill	0.0
Developed Markets \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	9,768.9	10,428.7	8,510.9
Segment Profitability	4,878.1	5,143.1	4,243.9
Greater China
Segment Reporting Information [Line Items]
Impairment of goodwill	0.0
Greater China \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	2,201.2	2,212.8	259.9
Segment Profitability	1,512.5	1,397.1	52.7
JANZ
Segment Reporting Information [Line Items]
Impairment of goodwill	0.0
JANZ \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	1,632.4	2,027.4	1,195.3
Segment Profitability	665.5	762.4	364.6
Emerging Markets \| Operating Segments
Segment Reporting Information [Line Items]
Net sales	2,615.6	3,144.7	1,853.8
Segment Profitability	$ 1,207.1	$ 1,402.4	$ 610.4

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2017
Income Tax Contingency [Line Items]
Effective tax rate	26.10%	(91.00%)	7.10%
Deferred tax liability not recognized, amount of unrecognized deferred tax liability, undistributed earnings of foreign subsidiaries	$ 2,600.0
Statutory tax rate	21.00%	21.00%	21.00%
Valuation allowance, amount	$ 387.0	$ 780.4
Expected foreign tax credits	196.1
Unrecognized tax benefit	296.7	322.9	$ 391.1		$ 92.1
Unrecognized tax benefits that impact effective tax rate	210.7
Accrued interest and penalties	106.4	96.8
Interest expense (income) related to uncertain tax positions	21.1		18.5	$ 6.0
Amount of unrecognized deferred tax liability	55.0
Unrecognized tax benefit — beginning of year	296.7	322.9	$ 391.1		$ 92.1
Reserve for Uncertain Tax Positions, Including Interest And Penalties	298.1	315.6
CARES Act, Income Tax Expense (Benefit)		22.1
Income Tax Examination [Line Items]
Reserve for Uncertain Tax Positions, Including Interest And Penalties	298.1	315.6
PUERTO RICO
Income Tax Contingency [Line Items]
Operating loss carryforwards expired in period	274.4
U.S. Federal Tax Authority
Income Tax Contingency [Line Items]
Net operating loss carryforwards	4.6
U.S. State Tax Authority
Income Tax Contingency [Line Items]
Net operating loss carryforwards	2,900.0
Foreign
Income Tax Contingency [Line Items]
Net operating loss carryforwards	1,010.0
Foreign deductible attributes	37.3
Credit carryforward	213.3
Foreign \| Australian Taxation Office
Income Tax Contingency [Line Items]
Partial payment of anticipated tax expense	5.2	$ 56.0
Indefinite \| Foreign
Income Tax Contingency [Line Items]
Net operating loss carryforwards	810.8
2016 through 2035 \| Foreign
Income Tax Contingency [Line Items]
Net operating loss carryforwards	$ 195.1

Valuation and Qualifying Accounts (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Allowance for doubtful accounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	$ 154.5	$ 159.9	$ 72.8
Additions Charged to Costs and Expenses	21.5	16.0	16.9
Additions Charged to Other Accounts	0.0	0.0	77.3
Deductions	(61.3)	(21.4)	(7.1)
Ending balance	114.7	154.5	159.9
Valuation allowance for deferred tax assets
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Beginning balance	780.4	443.6	603.5
Additions Charged to Costs and Expenses	42.7	82.2	39.0
Additions Charged to Other Accounts	0.0	260.8	0.0
Deductions	(436.1)	(6.2)	(198.9)
Ending balance	$ 387.0	$ 780.4	$ 443.6

Employee Benefit Plans (Net Accrued Benefit Costs Classification on Balance Sheet) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Pension Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Noncurrent assets	$ 118.3	$ 117.2
Current liabilities	(14.6)	(14.6)
Noncurrent liabilities	(415.6)	(682.8)
Net accrued benefit costs	(311.9)	(580.2)
Other Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Noncurrent assets	0.0	0.0
Current liabilities	(15.4)	(16.1)
Noncurrent liabilities	(122.1)	(172.3)
Net accrued benefit costs	$ (137.5)	$ (188.4)

Financial Instruments and Risk Management (Narrative) (Details) € in Millions, ¥ in Millions, $ in Millions		12 Months Ended
	Nov. 29, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 JPY (¥)	Dec. 31, 2021 EUR (€)	Dec. 31, 2021 JPY (¥)	Dec. 31, 2020 USD ($)
Derivative [Line Items]
Pre-tax net losses on cash flow hedges to be reclassified from AOCE into earnings in next twelve months		$ (8.0)
Purchase consideration, contingent consideration		375.0	$ 199.7					$ 223.6
Reclassifications		0.0	0.0
Accretion		8.2	9.0
Contingent consideration payments		(64.1)	(83.2)
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Biocon Biologics
Derivative [Line Items]
Equity consideration	$ 1,000.0
Respiratory delivery platform [Member]
Derivative [Line Items]
Purchase consideration, contingent consideration		132.0
Biocon Biologics
Derivative [Line Items]
Purchase consideration, contingent consideration		221.2
2020 Euro Senior Notes
Derivative [Line Items]
Long-term debt		$ 305.1	347.6
Debt instrument, interest rate, stated percentage		0.816%		0.816%	0.816%
2022 Euro Senior Notes
Derivative [Line Items]
Debt instrument, interest rate, stated percentage		0.816%		0.816%	0.816%
2.125% Euro Senior Notes due 2025
Derivative [Line Items]
Debt instrument, interest rate, stated percentage		1.023%		1.023%	1.023%
2027 Euro Senior Notes
Derivative [Line Items]
Debt instrument, interest rate, stated percentage		1.362%		1.362%	1.362%
Senior Notes 2023 3.125%
Derivative [Line Items]
Debt instrument, interest rate, stated percentage		3.125%		3.125%	3.125%
YEN Term Loan
Derivative [Line Items]
Long-term debt		$ 305.1
Senior Notes \| 2.250% Euro Senior Notes due 2024
Derivative [Line Items]
Long-term debt		$ 1,069.8	1,135.8
Debt instrument, interest rate, stated percentage		2.25%		2.25%	2.25%
Senior Notes \| 2.125% Euro Senior Notes due 2025
Derivative [Line Items]
Long-term debt		$ 813.5	871.6
Senior Notes \| 2025 Euro Senior Notes
Derivative [Line Items]
Long-term debt		$ 534.8	567.8
Debt instrument, interest rate, stated percentage		2.125%		2.125%	2.125%
Senior Notes \| 2028 Senior Notes
Derivative [Line Items]
Long-term debt		$ 748.9	748.7
Debt instrument, interest rate, stated percentage		4.55%		4.55%	4.55%
Senior Notes \| 2027 Euro Senior Notes
Derivative [Line Items]
Long-term debt		$ 945.9	1,013.0
Senior Notes \| 2032 Euro Senior Notes
Derivative [Line Items]
Long-term debt		$ 1,444.4	1,546.6
Debt instrument, interest rate, stated percentage		1.908%		1.908%	1.908%
Senior Notes \| 2028 Euro Senior Notes
Derivative [Line Items]
Long-term debt		$ 798.5	847.4
Debt instrument, interest rate, stated percentage		3.125%		3.125%	3.125%
Senior Notes \| Senior Notes 2023 3.125%
Derivative [Line Items]
Long-term debt		$ 0.0	766.1
Debt instrument, interest rate, stated percentage		3.125%		3.125%	3.125%
Net Investment Hedging
Derivative [Line Items]
Notional amount of derivative				€ 5,100.0	¥ 40,000	€ 5,850.0	¥ 40,000
Long-term debt				5,850.0	40,000
Net Investment Hedging \| 2022 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative \| €				0.0		750.0
Long-term debt \| €				750.0
Net Investment Hedging \| 2.250% Euro Senior Notes due 2024
Derivative [Line Items]
Notional amount of derivative \| €				1,000.0		1,000.0
Long-term debt \| €				1,000.0
Net Investment Hedging \| 2.125% Euro Senior Notes due 2025
Derivative [Line Items]
Notional amount of derivative \| €				750.0		750.0
Long-term debt \| €				750.0
Net Investment Hedging \| 2025 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative \| €				500.0		500.0
Long-term debt \| €				500.0
Net Investment Hedging \| 2028 Senior Notes
Derivative [Line Items]
Notional amount of derivative \| €				750.0		750.0
Long-term debt \| €				750.0
Net Investment Hedging \| 2027 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative \| €				850.0		850.0
Long-term debt \| €				850.0
Net Investment Hedging \| 2032 Euro Senior Notes
Derivative [Line Items]
Notional amount of derivative \| €				1,250.0		€ 1,250.0
Long-term debt \| €				€ 1,250.0
Net Investment Hedging \| YEN Term Loan
Derivative [Line Items]
Notional amount of derivative \| ¥					40,000		¥ 40,000
Long-term debt \| ¥					¥ 40,000
Other Noncurrent Liabilities
Derivative [Line Items]
Purchase consideration, contingent consideration		$ 310.6	133.0					123.1
Reclassifications		(61.8)	(49.4)
Accretion		8.2	9.0
Contingent consideration payments		0.0	0.0
Other current liabilities
Derivative [Line Items]
Purchase consideration, contingent consideration		64.4	66.7					$ 100.5
Reclassifications		61.8	49.4
Accretion		0.0	0.0
Contingent consideration payments		$ (64.1)	$ (83.2)
Measurement Input, Discount Rate \| Contingent consideration \| Minimum
Derivative [Line Items]
Rate used to discount net cash inflows to present values		0.064		0.064	0.064
Measurement Input, Discount Rate \| Contingent consideration \| Maximum
Derivative [Line Items]
Rate used to discount net cash inflows to present values		0.090		0.090	0.090

Income Taxes (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Employee benefits	$ 129.6	$ 271.3
Litigation reserves	20.5	94.4
Accounts receivable allowances	446.2	425.9
Inventory	159.3	187.8
Tax credit and loss carry-forwards	760.3	1,256.0
Operating lease assets	56.2	63.6
Interest expense	94.8	111.6
Intangible assets	149.3	151.1
Other	209.3	327.8
Total deferred tax assets, gross	2,025.5	2,889.5
Less: Valuation allowance	(387.0)	(780.4)
Total deferred tax assets	1,638.5	2,109.1
Deferred tax liabilities:
Plant and equipment	56.6	19.6
Operating lease liabilities	56.2	63.6
Intangible assets and goodwill	2,880.3	3,468.3
Other	151.5	39.9
Total deferred tax liabilities	3,144.6	3,591.4
Deferred tax liabilities, net	$ (1,506.1)	$ (1,482.3)

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives in Fair Value Hedging Relationships) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax	$ (82.1)	$ 39.3	$ (10.1)
Fair value hedging relationships \| Interest Expense \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax	0.0	0.0	22.1
Fair value hedging relationships \| Interest Expense \| Senior Notes 2023 3.125%
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax	$ 0.0	$ 0.0	$ (22.1)

Financial Instruments and Risk Management (Derivatives Not Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Derivatives, Fair Value [Line Items]
Asset Derivatives	$ 134.7	$ 144.6
Liability Derivatives	187.0	61.0
Not designated as hedging instrument
Derivatives, Fair Value [Line Items]
Asset Derivatives	104.3	82.6
Liability Derivatives	160.6	56.7
Not designated as hedging instrument \| Prepaid expenses & other current assets \| Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Asset Derivatives	104.3	82.6
Not designated as hedging instrument \| Other current liabilities \| Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Liability Derivatives	$ 160.6	$ 56.7

Leases (Tables)

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Lease, Cost

Other information related to leases was as follows:


	As of December 31, 2022
Remaining lease terms	1 year to 22 years
Weighted-average remaining lease term	6 years
Weighted-average discount rate	3.0	%

Lessee, Operating Lease, Liability, Maturity

As of December 31, 2022, maturities of lease liabilities were as follows:


(In millions)
Year ending December 31,
2023	$	76.4
2024	63.4
2025	38.6
2026	30.2
2027	23.1
Thereafter	52.3
Total lease payments	$	284.0
Less imputed interest	22.0
Total lease liability	$	262.0

Divestitures (Details) $ in Millions		3 Months Ended	11 Months Ended	12 Months Ended
Divestitures (Details) $ in Millions	Nov. 29, 2022 USD ($)	Dec. 31, 2022 USD ($) Product	Nov. 29, 2022 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($) Product	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of assets and subsidiaries					$ 1,950.0	$ 96.7	$ 20.0
Revenue from disposal group					16,218.1	17,813.6	11,819.9
Impairment of goodwill					$ 117.0	0.0	0.0
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)
Number of insulin analog products \| Product		3			3
Product rights and licenses
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of intangible assets					$ 172.9	$ 83.4	$ 45.0
Biocon Biologics
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue from disposal group					(63.5)
Biocon Biologics \| Scenario, Forecast \| Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Deferred cash consideration				$ 335.0
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Biocon Biologics
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration received on divestiture	$ 3,000.0		$ 3,000.0
Proceeds from sale of assets and subsidiaries	2,000.0
Equity consideration	$ 1,000.0
Ownership percentage	12.90%
Contingent liability (up to)	$ 250.0		250.0
Transition services agreement, revised term	2 years
Gain on divestiture of business	$ 1,750.0
Revenue from disposal group			$ 611.5
Disposal Group, Held-for-sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Possible impairment charges if assets held-for-sale are not sold in next fiscal year (in excess of)		$ 300.0			300.0
Disposal Group, Held-for-sale, Not Discontinued Operations \| Upjohn Distributor Markets
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total impairment charge		374.2
Assets held-for-sale, intangible assets		230.3			230.3
Disposal Group, Held-for-sale, Not Discontinued Operations \| Upjohn Distributor Markets \| Inventories
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total impairment charge		$ 84.3
Disposal Group, Held-for-sale, Not Discontinued Operations \| Upjohn Distributor Markets \| Emerging Markets
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of goodwill					$ 117.0

Equity Method Investments (Balance Sheet) (Details) $ in Millions	Dec. 31, 2021 USD ($)
Clean energy investments
Schedule of Equity Method Investments [Line Items]
Other liabilities	$ 10.9

Equity Method Investments (Net Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Schedule of Equity Method Investments [Line Items]
Assets, Current	$ 10,635.4	$ 10,902.9
Total assets	50,022.2	54,842.8
Current liabilities	6,746.2	9,884.4
Total liabilities	$ 28,949.9	34,350.1
Consolidated Entity
Schedule of Equity Method Investments [Line Items]
Assets, Current		4.2
Noncurrent assets		0.5
Total assets		4.7
Current liabilities		2.8
Total liabilities		2.8
Net assets		$ 1.9

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(18))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

+ Details

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(9))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

+ Details

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.

+ References

+ Details

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

+ Details

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765

Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Divestitures	12 Months Ended
Divestitures	Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]
Divestitures	Divestitures Biocon Biologics Transaction On February 27, 2022, Viatris entered into a definitive agreement with Biocon Biologics to contribute its biosimilars portfolio to Biocon Biologics. The transaction subsequently closed on November 29, 2022, creating what Viatris expects to be a unique fully vertically integrated global biosimilars leader. Under the terms of the Biocon Agreement, Viatris received $3 billion in consideration in the form of a $2 billion cash payment, adjusted as set forth in the Biocon Agreement, and approximately $1 billion of CCPS representing a stake of approximately 12.9% (on a fully diluted basis) in Biocon Biologics. Viatris also is entitled to $335 million of additional cash payments in 2024. In addition, Viatris and Biocon Biologics have agreed to a closing working capital target of $250 million. An amount of cash equal to all or a portion of the closing working capital target may become payable to Biocon Biologics in connection with certain events in the future, depending on the valuations attributable to such events. Refer to Note 6 Balance Sheet Components for additional information on assets and liabilities related to Biocon Biologics. Viatris and Biocon Biologics also entered an agreement pursuant to which Viatris is providing commercialization and certain other transition services on behalf of Biocon Biologics, including billings, collections and the remittance of rebates, to ensure business continuity for patients, customers and colleagues. The term of the transition services agreement is generally up to two years. Under the transition services agreement, Viatris is entitled to be reimbursed for its costs (subject to certain caps) plus a markup. Upon closing, the Company recognized a gain on sale of approximately $1.75 billion for the difference between the consideration received, including the fair value of the CCPS, and the carrying value of the biosimilars portfolio (including an allocation of goodwill). The gain was recognized as a component of Other (income) expense, net in the consolidated statement of operations during the year ended December 31, 2022. The Company has not recognized the results of the business in its consolidated financial statements subsequent to November 29, 2022. For the period from January 1, 2022 to November 29, 2022, total revenues relating to the biosimilars portfolio which was subsequently contributed to Biocon Biologics were approximately $611.5 million. The Company’s CCPS in Biocon Biologics are classified as equity securities and are included in Other assets in the consolidated balance sheet as of December 31, 2022. Refer to Note 10 Financial Instruments and Risk Management for further discussion. The Company had previously entered into an exclusive collaboration with Biocon on the development, manufacturing, supply and commercialization of multiple, high value biosimilar compounds and three insulin analog products for the global marketplace. The collaboration was terminated upon closing of the Biocon Biologics Transaction. Other Potential Divestitures In November 2022, the Company provided an update on the strategic priorities announced in February 2022, including identifying the following businesses no longer considered core to its future strategy that the Company intends to divest: •OTC; •API (while retaining some selective development API capabilities); •Women’s health care, primarily related to our oral and injectable contraceptives. This does not include all of our women’s health care related products; as an example, our Xulane® product in the U.S. is excluded; and •Upjohn Distributor Markets. In the fourth quarter of 2022, we determined that our Upjohn Distributor Markets should be classified as held for sale in the December 31, 2022 consolidated balance sheet. Upon classification as held for sale, we recognized a total charge of $374.2 million. This was comprised of a goodwill impairment charge of $117.0 million, other charges, principally inventory write-offs, of $84.3 million and a charge of approximately $172.9 million to write down the disposal group to fair value, less cost to sell. Assets held for sale associated with the Upjohn Distributor Markets consisted of intangible assets of $230.3 million as of December 31, 2022. If these transactions are not completed during 2023, the distribution arrangements will expire and the Company will wind down operations in these markets, which may result in additional asset write-offs and other costs being incurred. These additional charges could be in excess of $300 million. On April 30, 2021, the Company completed an agreement to divest a group of OTC products in the U.S. As a result of this transaction, the Company recognized an intangible asset impairment charge of approximately $83.4 million during the year ended December 31, 2021.

Revenue Recognition and Accounts Receivable - Disaggregation of Revenue by Key Products (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Net sales	$ 16,218.1	$ 17,813.6	$ 11,819.9
Lipitor ®
Disaggregation of Revenue [Line Items]
Net sales	1,635.2	1,663.2
Norvasc ®
Disaggregation of Revenue [Line Items]
Net sales	775.1	824.7
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	623.8	728.5
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	458.9	533.8
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	378.0	391.7
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	338.1	344.4
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	304.0	309.8
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	279.6	316.8
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	246.2	284.3
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	195.1	226.0
Influvac ®
Disaggregation of Revenue [Line Items]
Net sales	225.5	299.3
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	202.1	161.9
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	179.8	168.0
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	167.9	201.5
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	$ 156.5	$ 185.9

Acquisitions and Other Transactions

12 Months Ended

Dec. 31, 2022

Business Combinations [Abstract]

Acquisitions and Other Transactions

Oyster Point Acquisition

During the first quarter of 2023, the Company completed the acquisition of Oyster Point for approximately $425 million in cash, which includes $11 per share paid to Oyster Point stockholders through a tender offer and the repayment of the principal amount of certain debt of Oyster Point. In addition to the upfront cash consideration, each Oyster Point stockholder received one non-tradeable contingent value right representing up to an additional $2 per share, or approximately $60 million in the aggregate, contingent upon Oyster Point achieving certain metrics based upon full year 2022 performance, which are expected to be determined by the end of the first quarter of 2023. Oyster Point is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.

The Company expects to account for this transaction as a business combination. The accounting impact of this acquisition and the results of the operations for Oyster Point will be included in our consolidated financial statements beginning in the first quarter of 2023. Due to the proximity of the closing date of this acquisition to the date of this filing, the initial accounting for this acquisition is incomplete, pending identification and measurement of the assets acquired and liabilities assumed.

Famy Life Sciences Acquisition

On November 7, 2022, the Company entered into a definitive agreement to acquire the remaining equity shares of Famy Life Sciences, a private-owned research company with a complementary portfolio of ophthalmology therapies under development, for a consideration of $281 million. The Company had previously entered into a Master Development Agreement with Famy Life Sciences on December 20, 2019 to grant the Company rights with respect to acquiring certain pharmaceutical products and had additionally acquired shares representing approximately 13.5% equity interest in Famy Life Sciences for $25.0 million during the year ended December 31, 2020. The investment was accounted for in accordance with ASC 321, Investments - Equity Securities.

The transaction to acquire the remaining equity shares of Famy Life Sciences closed during the first quarter of 2023. The Company expects to recognize a gain of $18.9 million during the first quarter of 2023 as a result of remeasuring its pre-existing 13.5% equity interest in Famy Life Sciences to fair value, which will be recognized as a component of Other (income) expense, net in the consolidated statements of operations.

The Company expects to account for this transaction as a business combination. The accounting impact of this acquisition and the results of the operations for Famy Life Sciences will be included in our consolidated financial statements beginning in the first quarter of 2023. Due to the proximity of the closing date of this acquisition to the date of this filing, the initial accounting for this acquisition is incomplete, pending identification and measurement of the assets acquired and liabilities assumed.

Upjohn Business Combination Agreement

On July 29, 2019, Mylan, Pfizer, Upjohn, a wholly-owned subsidiary of Pfizer, and certain other affiliated entities entered into a Business Combination Agreement pursuant to which Mylan would combine with the Upjohn Business in a Reverse Morris Trust transaction. The Upjohn Business was a global, primarily off-patent branded and generic established medicines business, which includes 20 primarily off-patent oral solid dose legacy brands, such as Lyrica®, Lipitor®, Celebrex® and Viagra®. The Combination was completed on November 16, 2020.

Prior to the Combination and pursuant to a Separation and Distribution Agreement, Pfizer had, among other things, transferred to Viatris substantially all of the assets and liabilities comprising the Upjohn Business (the Separation) and, thereafter, Pfizer had distributed to Pfizer stockholders all of the issued and outstanding shares of Viatris (the Distribution). When the Distribution and Combination were complete, Pfizer stockholders as of the record date of the Distribution owned 57% of the outstanding shares of Viatris common stock and Mylan shareholders as of immediately before the Combination owned 43% of the outstanding shares of Viatris common stock, in each case on a fully diluted basis. Viatris also made a cash payment to Pfizer equal to $12 billion, which was funded with the proceeds of debt incurred by Upjohn prior to the Combination.

The transaction involved multiple legal entity restructuring transactions and a reverse merger acquisition with Viatris representing the legal acquirer and Mylan representing the accounting acquirer of the Upjohn Business. In accordance with ASC 805, Business Combinations, Mylan is considered the accounting acquirer of the Upjohn Business and Viatris applied purchase accounting to the acquired assets and assumed liabilities of the Upjohn Business as of November 16, 2020. The debt incurred by Upjohn prior to the Combination was a liability assumed in purchase accounting. The fair value of the debt as of November 16, 2020 was $13.08 billion.

The purchase price consists of the issuance of approximately 689.9 million Viatris shares of common stock at a fair value of approximately $10.73 billion based on the closing price of Mylan’s ordinary shares on November 13, 2020, as reported by the NASDAQ. In accordance with U.S. GAAP, the Company used the acquisition method of accounting to account for this transaction. Under the acquisition method of accounting, the assets acquired and liabilities assumed in the transaction have been recorded at their respective estimated fair values at the acquisition date. During the twelve months ended December 31, 2021 and 2020, the Company incurred acquisition related costs of approximately $234.6 million and $602.9 million, respectively. Acquisition related costs were recorded primarily in SG&A in the consolidated statements of operations for such periods.


(In millions)	Preliminary Purchase Price Allocation as of December 31, 2020 (a)		Measurement Period and Other Adjustments (b)		Purchase Price Allocation as of December 31, 2021 (as adjusted)
Current assets (excluding inventories and net of cash acquired)	$	2,841.9	$	(38.7)	$	2,803.2
Inventories	2,588.9		(34.2)		2,554.7
Property, plant and equipment	1,394.1		(5.0)		1,389.1
Identified intangible assets	18,040.0		—		18,040.0
Goodwill	2,107.5		295.6		2,403.1
Deferred income tax benefit	1,481.9		196.3		1,678.2
Other assets	792.1		(7.4)		784.7
Total assets acquired	$	29,246.4	$	406.6	$	29,653.0
Current liabilities	2,760.2		419.7		3,179.9
Long-term debt, including current portion	13,076.2		—		13,076.2
Deferred tax liabilities	1,656.9		1.0		1,657.9
Other noncurrent liabilities	1,441.5		(14.1)		1,427.4
Net assets acquired (net of $415.8 of cash acquired)	$	10,311.6	$	—	$	10,311.6

____________

(a)As previously reported in Viatris’ Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

The Combination enhanced each businesses’ ability to serve patients’ needs and expand their capabilities across more than 165 markets. Mylan brought a diverse portfolio across many geographies and key therapeutic areas, such as central nervous system and anesthesia, infectious disease and cardiovascular, as well as a robust pipeline, high-quality manufacturing and supply chain excellence. The Upjohn Business brought trusted, iconic brands, such as Lipitor® (atorvastatin calcium), Celebrex® (celecoxib) and Viagra® (sildenafil), and proven commercialization capabilities, including leadership positions in China and other emerging markets.

The Company recorded a step-up in the fair value of inventory of approximately $1.43 billion at the acquisition date. During the twelve months ended December 31, 2021 and 2020, the Company recorded amortization of the inventory step-up of approximately $1.19 billion and $238.2 million, respectively, which was included in cost of sales in the consolidated statements of operations. The inventory step-up was fully amortized during 2021. In addition, a step-up in the fair value of property, plant and equipment of approximately $385.0 million was recognized. The related depreciation is being expensed over a service life of five years for machinery and equipment and between 10 and 20 years for buildings.

The identified intangible assets of $18.04 billion are comprised of product rights and are being amortized over a weighted average useful life of 15 years. Significant assumptions utilized in the valuation of identified intangible assets were based on company specific information and projections which are not observable in the market and are thus considered Level 3 measurements as defined by U.S. GAAP. The goodwill of $2.40 billion arising from the Combination consisted largely of the value of the employee workforce and products to be sold in new markets leveraging the combined entity. In addition, an allocation of the goodwill was assigned to the respective segments. None of the goodwill recognized in this transaction is expected to be deductible for income tax purposes.

The Company recorded a fair value adjustment of approximately $759.4 million related to the long-term debt assumed as part of the acquisition. The fair value of long-term debt as of the Combination date was determined by broker or dealer quotations, which is classified as Level 2 in the fair value hierarchy. The total fair value adjustment is being amortized as a reduction to interest expense over the maturity dates of the related debt instruments.

The operating results of the Upjohn Business have been included in the Company’s consolidated statements of operations since the acquisition date. The total revenues of the Upjohn Business for the period from the acquisition date to December 31, 2020, were $866.5 million and net loss, net of tax, was approximately $360.9 million. The net loss for the period includes the effect of the purchase accounting adjustments and acquisition related costs.

Unaudited Pro Forma Financial Results

The following table presents supplemental unaudited pro forma information for the Combination, as if it had occurred on January 1, 2019. The unaudited pro forma results reflect certain adjustments related to past operating performance and acquisition accounting adjustments, such as increased depreciation and amortization expense based on the fair value of assets acquired, the impact of transaction costs and the related income tax effects. The unaudited pro forma results do not include any anticipated synergies which may be achievable, or have been achieved, subsequent to the closing of the Combination. Accordingly, the unaudited pro forma results are not necessarily indicative of the results that actually would have occurred had the acquisitions been completed on the stated date above, nor are they indicative of the future operating results of Viatris and its subsidiaries.


	Year Ended December 31,
(Unaudited, in millions, except per share amounts)	2020
Total revenues	$	18,284.8
Net earnings	$	1,483.7
Earnings per share:
Basic	$	1.23
Diluted	$	1.23
Weighted average shares outstanding:
Basic	1,206.8
Diluted	1,207.7

Other Transactions

In December 2020, Viatris and Pfizer terminated their strategic collaboration for generic drugs in Japan pursuant to an amendment and termination agreement. Under the prior collaboration agreement, both parties contributed products, which Pfizer distributed to third-parties in the Japan market. Under the terms of the amendment and termination agreement, Viatris purchased all collaboration related inventory held by Pfizer. As a result of the termination, and the repurchase of collaboration inventory, the Company reduced revenue by $86.5 million during the year ended December 31, 2020.

Share-Based Incentive Plan (Nonvested Restricted Stock, Restricted Stock Units and PSUs Activity) (Details) - Restricted Stock Awards	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of restricted stock awards, nonvested beginning balance \| shares	16,858,128
Weighted average grant-date fair value per share, nonvested beginning balance \| $ / shares	$ 15.12
Number of restricted stock awards, granted \| shares	16,880,145
Weighted average grant-date fair value per share, granted \| $ / shares	$ 10.20
Number of restricted stock awards, released \| shares	(4,790,749)
Weighted average grant-date fair value per share, released \| $ / shares	$ 17.53
Number of restricted stock awards, forfeited \| shares	(1,675,598)
Weighted average grant-date fair value per share, forfeited \| $ / shares	$ 12.30
Number of restricted stock awards, nonvested ending balance \| shares	27,271,926
Weighted average grant-date fair value per share, nonvested ending balance \| $ / shares	$ 11.81

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Treasury Stock	Accumulated Other Comprehensive Loss
Balance at Dec. 31, 2019	$ 11,883.8	$ 6.1	$ 8,643.5	$ 6,031.1	$ (999.7)	$ (1,797.2)
Balance (in shares) at Dec. 31, 2019		540,746,871			24,598,074
Net earnings (loss)	(669.9)			(669.9)
Other comprehensive earnings, net of tax	939.2					939.2
Share-based compensation expense	79.2		79.2
Issuance of restricted stock and stock options exercised, net	0.6		0.6
Issuance of restricted stock and stock options exercised, net (in shares)		872,802
Taxes related to the net share settlement of equity awards	(6.3)		(6.3)
Exchange of Mylan N.V. ordinary shares for Viatris Inc. common stock	0.0	$ (6.1)	6.1
Exchange of Mylan N.V. ordinary shares for Viatris Inc. common stock (in shares)		(541,619,673)
Issuance of common stock to Mylan N.V. shareholders	0.0	$ 5.2	(5.2)
Issuance of common stock to Mylan N.V. shareholders (in shares)		541,619,673
Issuance of common stock	10,727.5	$ 6.9	10,720.6
Issuance of common stock (in shares)		689,874,045
Retirement of Mylan N.V. treasury stock, net	0.0		(999.7)		$ 999.7
Retirement of Mylan N.V. treasury stock, net (in shares)		(24,598,074)			(24,598,074)
Balance at Dec. 31, 2020	22,954.1	$ 12.1	18,438.8	5,361.2	$ 0.0	(858.0)
Balance (in shares) at Dec. 31, 2020		1,206,895,644			0
Net earnings (loss)	(1,269.1)			(1,269.1)
Other comprehensive earnings, net of tax	(886.3)					(886.3)
Share-based compensation expense	111.2		111.2
Taxes related to the net share settlement of equity awards	(13.9)		(13.9)
Issuance of restricted stock, net (in shares)		2,611,819
Cash dividends declared	(403.3)			(403.3)
Balance at Dec. 31, 2021	20,492.7	$ 12.1	18,536.1	3,688.8	$ 0.0
Balance (in shares) at Dec. 31, 2021		1,209,507,463			0
Net earnings (loss)	2,078.6			2,078.6
Other comprehensive earnings, net of tax	(1,016.9)					(1,016.9)
Share-based compensation expense	116.4		116.4
Taxes related to the net share settlement of equity awards	(11.6)		(11.6)
Issuance of common stock	3.3		3.3
Issuance of common stock (in shares)		313,341
Issuance of restricted stock, net	1.6		1.6
Issuance of restricted stock, net (in shares)		3,972,427
Cash dividends declared	(591.8)			(591.8)
Balance at Dec. 31, 2022	$ 21,072.3	$ 12.1	$ 18,645.8	$ 5,175.6	$ 0.0	$ (2,761.2)
Balance (in shares) at Dec. 31, 2022		1,213,793,231			0

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Changes in carrying amount of goodwill

The changes in the carrying amount of goodwill for the years ended December 31, 2022 and 2021 are as follows:


(In millions)	Developed Markets (1)		Greater China		JANZ		Emerging Markets (2)		Total



Balance at December 31, 2020:	$	9,184.5	$	738.3	$	864.0	$	1,560.2	$	12,347.0
Measurement period and other adjustments	67.7		220.4		(30.9)		38.4		295.6
Foreign currency translation	(528.8)		10.8		(56.8)		45.9		(528.9)
Balance at December 31, 2021:	$	8,723.4	$	969.5	$	776.3	$	1,644.5	$	12,113.7




Disposition (3)	(743.9)		(2.7)		(32.6)		(140.5)		(919.7)
Impairment	—		—		—		(117.0)		(117.0)
Foreign currency translation	(518.0)		(26.2)		(54.7)		(52.3)		(651.2)
Balance at December 31, 2022	$	7,461.5	$	940.6	$	689.0	$	1,334.7	$	10,425.8

____________

(1)Balances as of December 31, 2022, 2021 and 2020 include accumulated impairment losses of $385.0 million.

(2)Balance as of December 31, 2022 includes accumulated impairment loss of $117.0 million.

(3)Reflects goodwill relating to the biosimilars portfolio. Refer to Note 5 Divestitures for additional information.

Components of intangible assets

Intangible assets consist of the following components at December 31, 2022 and 2021:


(In millions)	Weighted Average Life (Years)	Cost		Accumulated Amortization		Net Book Value
December 31, 2022
Product rights, licenses and other (1)	15	$	37,490.5	$	14,923.6	$	22,566.9
In-process research and development		40.2		—		40.2
		$	37,530.7	$	14,923.6	$	22,607.1
December 31, 2021
Product rights, licenses and other (1)	15	$	39,006.2	$	12,918.5	$	26,087.7
In-process research and development		46.5		—		46.5
		$	39,052.7	$	12,918.5	$	26,134.2

____________

(1)Represents amortizable intangible assets. Other intangibles consist principally of customer lists and contractual rights.

Product rights and licenses by therapeutic category

These product rights and licenses relate to numerous individual products, the net book value of which, by product category, is as follows:


(In millions)	Developed Markets		Greater China		JANZ		Emerging Markets		December 31, 2022
Brands	$	8,762.2	$	5,632.3	$	1,061.3	$	3,122.5	$	18,578.3
Complex Gx and Biosimilars	177.5		—		0.9		—		178.4
Generics	3,271.4		10.6		263.3		263.9		3,809.2
Total Product Rights and Licenses	$	12,211.1	$	5,642.9	$	1,325.5	$	3,386.4	$	22,565.9


(In millions)	Developed Markets		Greater China		JANZ		Emerging Markets		December 31, 2021
Brands	$	10,066.6	$	6,102.9	$	1,174.8	$	3,801.7	$	21,146.0
Complex Gx and Biosimilars	226.8		—		1.5		—		228.3
Generics	4,020.2		12.1		319.5		358.4		4,710.2
Total Product Rights and Licenses	$	14,313.6	$	6,115.0	$	1,495.8	$	4,160.1	$	26,084.5

Finite-lived Intangible Assets Amortization Expense


	Year ended December 31,
(In millions)	2022		2021		2020
Intangible asset amortization expense	$	2,504.6	$	2,702.2	$	1,605.8
IPR&D intangible asset impairment charges	0.6		19.4		37.4
Finite-lived intangible asset disposal & impairment charges	172.9		83.4		45.0
Total intangible asset amortization expense (including disposal & impairment charges)	$	2,678.1	$	2,805.0	$	1,688.2

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

Intangible asset amortization expense for the years ending December 31, 2023 through 2027 is estimated to be as follows:


(In millions)
2023	$	2,322
2024	2,230
2025	2,136
2026	2,083
2027	1,871

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,259,900	$ 701,200
Accounts receivable, net	3,814,500	4,266,400
Inventories	3,519,500	3,977,700
Prepaid expenses and other current assets	1,811,200	1,957,600
Assets held for sale	230,300	0
Total current assets	10,635,400	10,902,900
Property, plant and equipment, net	3,024,500	3,188,600
Intangible assets, net	22,607,100	26,134,200
Goodwill	10,425,800	12,113,700
Deferred income tax benefit	925,900	1,332,700
Other assets	2,403,500	1,170,700
Total assets	50,022,200	54,842,800
Current liabilities:
Accounts payable	1,766,600	1,657,400
Short-term borrowings	0	1,493,000
Income taxes payable	279,600	236,900
Current portion of long-term debt and other long-term obligations	1,259,100	1,877,500
Other current liabilities	3,440,900	4,619,600
Total current liabilities	6,746,200	9,884,400
Long-term debt	18,015,200	19,717,100
Deferred income tax liability	2,432,000	2,815,000
Other long-term obligations	1,756,500	1,933,600
Total liabilities	28,949,900	34,350,100
Viatris Inc. shareholders’ equity
Common stock: $0.01 par value, 3,000,000,000 shares authorized; shares issued and outstanding: 1,213,793,231 and 1,209,507,463, respectively	12,100	12,100
Additional paid-in capital	18,645,800	18,536,100
Retained earnings	5,175,600	3,688,800
Accumulated other comprehensive loss	(2,761,200)	(1,744,300)
Total equity	21,072,300	20,492,700
Total liabilities and equity	$ 50,022,200	$ 54,842,800

Debt (Senior Notes) (Details) $ in Millions, ¥ in Billions	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jul. 31, 2021 JPY (¥) Rate	Jun. 30, 2021 USD ($)
Debt Instrument [Line Items]
Long-term debt	$ 18,015.2		$ 19,717.1
Long-term Debt, Gross	$ 18,714.0
2020 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	0.816%
Long-term debt	$ 305.1		347.6
YEN Term Loan
Debt Instrument [Line Items]
Long-term debt	$ 305.1
Senior Notes \| Upjohn Inc.
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 7,450.0
Senior Notes \| 2.250% Euro Senior Notes due 2024
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	2.25%
Long-term debt	$ 1,069.8		1,135.8
Senior Notes \| 2028 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	3.125%
Long-term debt	$ 798.5		847.4
Senior Notes \| 2028 Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	4.55%
Long-term debt	$ 748.9		748.7
Senior Notes \| 2048 Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	5.20%
Long-term debt	$ 747.8		747.8
Senior Notes \| 2025 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	2.125%
Long-term debt	$ 534.8		$ 567.8
Senior Notes \| USD Term Loan Facility
Debt Instrument [Line Items]
Debt Instrument, Face Amount					$ 600.0
Revolving Credit Facility \| Twenty Twenty One Revolving Facility
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity					$ 4,000.0
Medium-term Notes \| YEN Term Loan
Debt Instrument [Line Items]
Debt Instrument, Face Amount \| ¥				¥ 40
Medium-term Notes \| Twenty Twenty One Loan Facilities
Debt Instrument [Line Items]
Maximum Leverage Ratio, Period Two \| Rate				400.00%
Maximum Leverage Ratio, Period One \| Rate				425.00%
Maximum Leverage Ratio, Period Three \| Rate				375.00%

Share-Based Incentive Plan (Stock Awards) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of shares under stock awards, outstanding at beginning of period	5,576,490	6,711,731	6,347,709
Weightedaverage exercise price per share, outstanding at beginning of period	$ 37.19	$ 35.36	$ 36.97
Number of shares under stock awards, granted			814,351
Weighted average exercise price per share, granted			$ 17.37
Number of shares under stock awards, exercised			(27,615)
Weighted average exercise price per share, exercised			$ 21.13
Number of shares under stock awards, forfeited	(1,126,848)	(1,135,241)	(422,714)
Weighted average exercise price per share, forfeited	$ 31.91	$ 26.39	$ 25.74
Number of shares under stock awards, outstanding at end of period	4,449,642	5,576,490	6,711,731
Weighted average exercise price per share, outstanding at end of period	$ 38.53	$ 37.19	$ 35.36
Number of shares under stock awards, vested and expected to vest at period end	4,411,052
Weighted average exercise price per share, vested and expected to vest at period end	$ 38.70
Number of shares under stock awards, exercisable at period end	4,216,884
Weighted average exercise price per share, exercisable at period end	$ 39.65

Share-Based Incentive Plan

12 Months Ended

Dec. 31, 2022

Share-Based Payment Arrangement [Abstract]

Share-Based Incentive Plan

Prior to the Distribution, Viatris adopted and Pfizer, in the capacity as Viatris’ sole stockholder at such time, approved the 2020 Incentive Plan (the Viatris Inc. 2020 Stock Incentive Plan) which became effective as of the Distribution. In connection with the Combination, as of November 16, 2020, the Company assumed the 2003 LTIP (Mylan N.V. Amended and Restated 2003 Long-Term Incentive Plan), which had previously been approved by Mylan shareholders. The 2020 Incentive Plan and 2003 LTIP include (i) 72,500,000 shares of Common Stock authorized for grant pursuant to the 2020 Incentive Plan, which may include dividend payments payable in Common Stock on unvested shares granted under awards, (ii) 6,757,640 shares of Common Stock to be issued pursuant to the exercise of outstanding stock options granted to participants under the 2003 LTIP and assumed by Viatris in connection with the Combination and (iii) 13,535,627 shares of Common Stock subject to outstanding equity-based awards, other than stock options, assumed by Viatris in connection with the Combination, or that otherwise remain available for issuance under the 2003 LTIP.

Under the 2020 Incentive Plan and 2003 LTIP, shares are reserved for issuance to key employees, consultants, independent contractors and non-employee directors of the Company through a variety of incentive awards, including: stock options, SARs, restricted stock and units, PSUs, other stock-based awards and short-term cash awards. Stock option awards are granted with an exercise price equal to the fair market value of the shares underlying the stock options at the date of the grant, generally become exercisable over periods ranging from three to four years, and generally expire in ten years.

The following table summarizes stock awards (stock options and SARs) activity under the 2020 Incentive Plan and 2003 LTIP:


	Number of Shares Under Stock Awards	Weighted Average Exercise Price per Share
Outstanding at December 31, 2019	6,347,709	$	36.97
Granted	814,351	17.37
Exercised	(27,615)	21.13
Forfeited	(422,714)	25.74

Outstanding at December 31, 2020	6,711,731	$	35.36


Forfeited	(1,135,241)	26.39
Outstanding at December 31, 2021	5,576,490	$	37.19


Forfeited	(1,126,848)	31.91
Outstanding at December 31, 2022	4,449,642	$	38.53
Vested and expected to vest at December 31, 2022	4,411,052	$	38.70
Exercisable at December 31, 2022	4,216,884	$	39.65

As of December 31, 2022, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had average remaining contractual terms of 4.1 years, 4.1 years and 3.9 years, respectively. Also, at December 31, 2022, stock awards outstanding, stock awards vested and expected to vest and stock awards exercisable had no aggregate intrinsic value.

A rollforward of the changes in the Company’s nonvested Restricted Stock Awards (restricted stock and restricted stock unit awards, including PSUs) from December 31, 2021 to December 31, 2022 is presented below:


	Number of Restricted Stock Awards	Weighted Average Grant-Date Fair Value Per Share
Nonvested at December 31, 2021	16,858,128	$	15.12
Granted	16,880,145	10.20
Released	(4,790,749)	17.53
Forfeited	(1,675,598)	12.30
Nonvested at December 31, 2022	27,271,926	$	11.81

Of the 16,880,145 Restricted Stock Awards granted during the year ended December 31, 2022, 11,471,308 vest ratably in three years or less and are not subject to market or performance conditions. Of the remaining Restricted Stock Awards

granted, 290,173 are not subject to market conditions and will cliff vest within a three-year period, and 5,118,664 are subject to market or performance conditions and will cliff vest in three years or less.

As of December 31, 2022, the Company had $171.2 million of total unrecognized compensation expense, net of estimated forfeitures, related to all of its stock-based awards, which we expect to recognize over the remaining weighted average vesting period of 1.5 years. The total intrinsic value of Restricted Stock Awards released during the years ended December 31, 2022 and 2021 was $51.8 million and $78.1 million, respectively.

With respect to options granted under the 2020 Incentive Plan and 2003 LTIP, the fair value of each option grant was estimated at the date of grant using the Black-Scholes option pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield and employee exercise behavior. Expected volatilities utilized in the model are based mainly on the implied volatility of the Company’s stock price and other factors. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The model incorporates exercise and post-vesting forfeiture assumptions based on an analysis of historical data. The expected lives of the grants are derived from historical and other factors.

There were no options granted during the years ended December 31, 2022 or 2021. The assumptions used for options granted under the 2020 Incentive Plan and 2003 LTIP during the year ended December 31, 2020 are as follows:


															Year Ended December 31,
															2020
Volatility															46.7%
Risk-free interest rate															1.0%
Expected term (years)															6.5
Forfeiture rate															5.5%
Weighted average grant date fair value per option															$8.07
Dividend yield															—%

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Provision

The income tax provision (benefit) consisted of the following components:


	Year Ended December 31,
(In millions)	2022		2021		2020
U.S. Federal:
Current	$	115.3	$	12.6	$	(6.4)
Deferred	263.7		(182.7)		(277.0)
	379.0		(170.1)		(283.4)
U.S. State:
Current	26.5		7.7		(0.1)
Deferred	20.3		(10.8)		7.7
	46.8		(3.1)		7.6
Non-U.S.:
Current	618.7		(91.3)		168.7
Deferred	(309.9)		869.2		55.8
	308.8		777.9		224.5
Income tax provision (benefit)	$	734.6	$	604.7	$	(51.3)
Earnings before income taxes:

United States	794.8		(1,982.5)		(945.5)
Foreign - Other	2,018.4		1,318.1		224.3
Total earnings (loss) before income taxes	$	2,813.2	$	(664.4)	$	(721.2)

Schedule of Deferred Tax Assets and Liabilities

Temporary differences and carry-forwards that result in deferred tax assets and liabilities were as follows:


(In millions)	December 31, 2022		December 31, 2021
Deferred tax assets:
Employee benefits	$	129.6	$	271.3
Litigation reserves	20.5		94.4
Accounts receivable allowances	446.2		425.9
Inventory	159.3		187.8
Tax credit and loss carry-forwards	760.3		1,256.0
Operating lease assets	56.2		63.6
Interest expense	94.8		111.6
Intangible assets	149.3		151.1
Other	209.3		327.8
	2,025.5		2,889.5
Less: Valuation allowance	(387.0)		(780.4)
Total deferred tax assets	1,638.5		2,109.1
Deferred tax liabilities:
Plant and equipment	56.6		19.6
Operating lease liabilities	56.2		63.6
Intangible assets and goodwill	2,880.3		3,468.3
Other	151.5		39.9
Total deferred tax liabilities	3,144.6		3,591.4
Deferred tax liabilities, net	$	(1,506.1)	$	(1,482.3)

Statutory Tax Rate to Effective Tax Rate Reconciliation

Our effective tax rate from continuing operations differs from the applicable United States statutory federal income tax rate of 21.0%, due to the following:


	Year Ended December 31,
	2022		2021		2020
Statutory tax rate	21.0	%	21.0	%	21.0	%


Clean energy and research credits	—	%	9.8	%	12.8	%
Foreign rate differential	(3.6)	%	31.4	%	8.6	%
Expiration of attributes	9.8	%	—	%	—	%
Goodwill impairment	6.5	%	—	%	—	%
State income taxes and credits	1.3	%	(0.6)	%	(1.6)	%
Tax settlements and resolution of certain tax positions	1.0	%	0.9	%	(3.8)	%

Impact of the Combination and divestitures	(6.7)	%	(109.7)	%	(35.5)	%
Incremental U.S. tax on foreign earnings	2.0	%	(36.9)	%	(3.6)	%
Valuation allowance	(13.6)	%	(8.4)	%	24.6	%
Deferred tax impact of tax law changes	5.4	%	7.0	%	—	%
Withholding taxes	1.5	%	(1.3)	%	(1.6)	%
Waived deductions under IRC § 59A	—	%	—	%	(3.3)	%
















Other items	1.5	%	(4.2)	%	(10.5)	%
Effective tax rate	26.1	%	(91.0)	%	7.1	%

Schedule of Unrecognized Tax Benefits

A reconciliation of the unrecognized tax benefits is as follows:


	Year Ended December 31,
(In millions)	2022		2021		2020
Unrecognized tax benefit — beginning of year	$	322.9	$	391.1	$	92.1
Additions for current year tax positions	8.2		—		13.4
Additions for prior year tax positions	1.0		—		35.7
Reductions for prior year tax positions	(5.8)		(9.1)		(5.2)
Settlements	(0.4)		(47.3)		(8.9)
Reductions due to expirations of statute of limitations	(1.9)		(7.0)		—
(Reduction) addition due to acquisition	(27.3)		(4.8)		264.0
Unrecognized tax benefit — end of year	$	296.7	$	322.9	$	391.1

Consolidated Statements of Equity (Parenthetical) - $ / shares								12 Months Ended
	Dec. 16, 2022	Sep. 16, 2022	Jun. 16, 2022	Mar. 16, 2022	Dec. 16, 2021	Sep. 16, 2021	Jun. 16, 2021	Dec. 31, 2022	Dec. 31, 2021
Statement of Stockholders' Equity [Abstract]
Dividends paid per share (in dollars per share)	$ 0.12	$ 0.12	$ 0.12	$ 0.12	$ 0.11	$ 0.11	$ 0.11	$ 0.48	$ 0.33

Acquisitions and Other Transactions (Purchase Price Allocations) (Details) - USD ($) $ in Millions			12 Months Ended
	Dec. 31, 2020	Nov. 13, 2020	Dec. 31, 2022	Dec. 31, 2020	Dec. 31, 2021	Nov. 16, 2020	May 28, 2019
Business Acquisition, Date of Acquisition [Abstract]
Goodwill	$ 12,347.0		$ 10,425.8	$ 12,347.0	$ 12,113.7
Cash Acquired from Acquisition	$ 415.8
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract]
Goodwill				$ 295.6
Other assets			(7.4)
Deferred tax liabilities			1.0
Upjohn Inc. \| Pfizer, Inc.
Business Acquisition, Date of Acquisition [Abstract]
Long-term debt, including current portion						$ 13,080.0
Upjohn Inc.
Business Acquisition, Date of Acquisition [Abstract]
Current assets (excluding inventories and net of cash acquired)			2,803.2		2,841.9
Inventories			2,554.7		2,588.9
Property, plant and equipment			1,389.1		1,394.1
Identified intangible assets		$ 18,040.0	18,040.0		18,040.0
Goodwill		2,400.0	2,403.1		2,107.5
Deferred income tax benefit			1,678.2		1,481.9
Other assets			784.7		792.1
Total assets acquired			29,653.0		29,246.4
Current liabilities			3,179.9		2,760.2
Long-term debt, including current portion			13,076.2		13,076.2
Deferred tax liabilities			1,657.9		1,656.9
Other noncurrent liabilities			1,427.4		1,441.5
Net assets acquired			10,311.6		$ 10,311.6		$ 10,730.0
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract]
Current assets (excluding inventories and net of cash acquired)			(38.7)
Inventories		1,430.0	(34.2)
Property, plant and equipment		$ 385.0	(5.0)
Goodwill			295.6
Deferred income tax benefit			196.3
Total assets acquired			406.6
Current liabilities			419.7
Other noncurrent liabilities			(14.1)
Net assets acquired (net of $415.8 of cash acquired)			$ 0.0

Cover - USD ($)

12 Months Ended

Dec. 31, 2022

Feb. 21, 2023

Jun. 30, 2022

Cover [Abstract]

Document Type

10-K

Document Annual Report

true

Document Period End Date

Dec. 31, 2022

Document Transition Report

false

Entity File Number

001-39695

Entity Registrant Name

VIATRIS INC.

Entity Incorporation, State or Country Code

Entity Tax Identification Number

83-4364296

Entity Address, Address Line One

1000 Mylan Boulevard

Entity Address, City or Town

Canonsburg

Entity Address, State or Province

Entity Address, Postal Zip Code

15317

City Area Code

(724)

Local Phone Number

514-1800

Title of 12(b) Security

Common Stock, par value $0.01 per share

Trading Symbol

VTRS

Security Exchange Name

NASDAQ

Entity Well-known Seasoned Issuer

Yes

Entity Voluntary Filers

Entity Current Reporting Status

Yes

Entity Interactive Data Current

Yes

Entity Filer Category

Large Accelerated Filer

Entity Small Business

false

Entity Emerging Growth Company

false

ICFR Auditor Attestation Flag

true

Entity Shell Company

false

Common Stock, Par or Stated Value Per Share

$ 0.01

Entity Common Stock, Shares Outstanding

1,196,813,959

Entity Public Float

$ 12,662,127,991

Documents Incorporated by Reference


Document			Part of Form 10-K into Which Document is Incorporated
An amendment to this Form 10-K will be filed no later than 120 days after the close of registrant’s fiscal year.			III

Entity Central Index Key

0001792044

Amendment Flag

false

Document Fiscal Year Focus

2022

Document Fiscal Period Focus

Current Fiscal Year End Date

--12-31

Revenue Recognition and Accounts Receivable Variable Consideration Rollforward (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	$ 4,266.4
End of period	3,814.5
Variable Consideration
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	3,050.7
Current Provision Related to Sales Made in the Current Period	11,444.0
Balances Divested	(318.6)
Checks/ Credits Issued to Third Parties	(11,433.1)
Effects of Foreign Exchange	(55.5)
End of period	2,687.5
Variable Consideration \| Chargebacks
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	591.7
Current Provision Related to Sales Made in the Current Period	6,192.2
Balances Divested	(53.4)
Checks/ Credits Issued to Third Parties	(6,205.6)
Effects of Foreign Exchange	(1.5)
End of period	523.4
Variable Consideration \| Rebates, Promotional Programs and Other Sales Allowances
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	1,373.0
Current Provision Related to Sales Made in the Current Period	4,346.2
Balances Divested	(215.1)
Checks/ Credits Issued to Third Parties	(4,177.5)
Effects of Foreign Exchange	(42.4)
End of period	1,284.2
Variable Consideration \| Variable Consideration Returns
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	686.8
Current Provision Related to Sales Made in the Current Period	296.7
Balances Divested	(16.0)
Checks/ Credits Issued to Third Parties	(447.6)
Effects of Foreign Exchange	(6.5)
End of period	513.4
Variable Consideration \| Governmental Rebate Programs
Accounts Receivable, Variable Consideration [Roll Forward]
Beginning of period	399.2
Current Provision Related to Sales Made in the Current Period	608.9
Balances Divested	(34.1)
Checks/ Credits Issued to Third Parties	(602.4)
Effects of Foreign Exchange	(5.1)
End of period	$ 366.5

Employee Benefit Plans (Estimated Future Benefit Payments) (Details) $ in Millions	Dec. 31, 2022 USD ($)
Pension Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2019	$ 93.1
2020	96.1
2021	97.9
2022	98.3
2023	102.0
Thereafter	518.1
Total	1,005.5
Other Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2019	15.4
2020	15.8
2021	15.8
2022	15.7
2023	15.1
Thereafter	64.5
Total	$ 142.3

Debt (Fair Value) (Narrative) (Details) - USD ($) $ in Millions		3 Months Ended
	Nov. 13, 2020	Mar. 31, 2020	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Proceeds from Sale of Securities, Operating Activities		$ 45
Upjohn Inc.
Debt Instrument [Line Items]
Cash paid to acquire asset	$ 12,000
Senior Notes
Debt Instrument [Line Items]
Fair value of long-term debt			$ 15,360	$ 22,010

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues:
Net sales	$ 16,218.1	$ 17,813.6	$ 11,819.9
Total revenues	16,262.7	17,886.3	11,946.0
Cost of sales	9,765.7	12,310.8	8,149.3
Gross profit	6,497.0	5,575.5	3,796.7
Operating expenses:
Research and Development Expense	662.2	681.0	512.6
Acquired IPR&D	36.4	70.1	42.5
Selling, general and administrative	4,179.1	4,529.2	3,344.6
Litigation settlements and other contingencies, net	4.4	329.2	107.8
Total operating expenses	4,882.1	5,609.5	4,007.5
Earnings (loss) from operations	1,614.9	(34.0)	(210.8)
Interest expense	592.4	636.2	497.8
Other (income) expense, net	(1,790.7)	(5.8)	12.6
Earnings (loss) before income taxes	2,813.2	(664.4)	(721.2)
Income tax provision (benefit)	734.6	604.7	(51.3)
Net earnings (loss)	$ 2,078.6	$ (1,269.1)	$ (669.9)
Earnings (loss) per share attributable to Viatris Inc. shareholders
Basic (in USD per share)	$ 1.71	$ (1.05)	$ (1.11)
Diluted (in USD per share)	$ 1.71	$ (1.05)	$ (1.11)
Weighted average shares outstanding:
Basic (in shares)	1,212.1	1,208.8	601.2
Diluted (in shares)	1,217.4	1,208.8	601.2
Net sales
Revenues:
Net sales	$ 16,218.1	$ 17,813.6	$ 11,819.9
Other revenues
Revenues:
Other revenues	$ 44.6	$ 72.7	$ 126.1

Segment Information (Tables)

12 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Reconciliation of Segment Information to Total Consolidated Information

Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.


	Net Sales						Segment Profitability
	Years Ended December 31,						Years Ended December 31,
(in millions)	2022		2021		2020		2022		2021		2020
Reportable Segments:
Developed Markets	$	9,768.9	$	10,428.7	$	8,510.9	$	4,878.1	$	5,143.1	$	4,243.9
Greater China	2,201.2		2,212.8		259.9		1,512.5		1,397.1		52.7
JANZ	1,632.4		2,027.4		1,195.3		665.5		762.4		364.6
Emerging Markets	2,615.6		3,144.7		1,853.8		1,207.1		1,402.4		610.4
Total reportable segments	$	16,218.1	$	17,813.6	$	11,819.9	$	8,263.2	$	8,705.0	$	5,271.6

Reconciling items:
Intangible asset amortization expense							(2,504.6)		(2,702.2)		(1,605.8)
Intangible asset disposal & impairment charges							(173.5)		(102.8)		(82.4)
Impairment of goodwill							(117.0)		—		—
Globally managed research and development costs							(662.2)		(681.0)		(512.6)
Acquired IPR&D							(36.4)		(70.1)		(42.5)
Litigation settlements & other contingencies							(4.4)		(329.2)		(107.8)
Transaction related and other special items							(1,026.9)		(2,832.2)		(1,739.7)
Corporate and other unallocated							(2,123.3)		(2,021.5)		(1,391.6)
Earnings (loss) from operations							$	1,614.9	$	(34.0)	$	(210.8)

Schedule of Revenue by Major Customers by Reporting Segments

The following table represents the percentage of consolidated net sales to Viatris’ major customers during the years ended December 31, 2022, 2021, and 2020:


	Percentage of Consolidated Net Sales
	2022		2021		2020
McKesson Corporation	11	%	9	%	13	%
AmerisourceBergen Corporation	10	%	9	%	10	%
Cardinal Health, Inc.	5	%	5	%	8	%

Net Third Party Sales Classified Based on Geographic Location of Subsidiaries

Net sales by country are presented on the basis of geographic location of our subsidiaries:


	Year Ended December 31,
(In millions)	2022		2021		2020
United States	$	3,946.6	$	4,176.4	$	3,746.1
China	1,951.3		1,981.5		216.1

____________

No other country’s net sales represents more than 10% of consolidated net sales.

Segment Information

12 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Segment Information

Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Company reports segment information on the basis of markets and geography, which reflects its focus on bringing its broad and diversified portfolio of branded, complex generics, including biosimilars prior to the Biocon Biologics Transaction, and generic products to people in markets everywhere. Our Developed Markets segment comprises our operations primarily in North America and Europe. Our Greater China segment includes our operations in China, Taiwan and Hong Kong. Our JANZ segment reflects our operations in Japan, Australia and New Zealand. Our Emerging Markets segment encompasses our presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company’s ARV franchise.

The Company’s chief operating decision maker is the Chief Executive Officer, who evaluates the performance of its segments based on total revenues and segment profitability.

Certain costs are not included in the measurement of segment profitability, such as costs, if any, associated with the following:

◦Intangible asset amortization expense and impairments of goodwill and long-lived assets;

◦R&D expense;

◦Net charges or net gains for litigation settlements and other contingencies;

◦Certain costs related to transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory and property, plant and equipment; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) other significant items, which are substantive and/or unusual, and in some cases recurring, items (such as restructuring) that are evaluated on an individual basis by management and that either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such special items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for asset impairments and disposals of assets or businesses, including costs related to our planned divestitures and the Biocon Biologics Transaction, and, as applicable, any associated transition activities.

◦Corporate and other unallocated costs associated with platform functions (such as digital, facilities, legal, finance, human resources, insurance, public affairs and procurement), patient advocacy activities and certain compensation and other corporate costs (such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing, which include manufacturing variances associated with production) and operations that are not directly assessed to an operating segment as business unit (segment) management does not manage these costs.

The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker.

The accounting policies of the segments are the same as those described in Note 2 Summary of Significant Accounting Policies.

Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.


	Net Sales						Segment Profitability
	Years Ended December 31,						Years Ended December 31,
(in millions)	2022		2021		2020		2022		2021		2020
Reportable Segments:
Developed Markets	$	9,768.9	$	10,428.7	$	8,510.9	$	4,878.1	$	5,143.1	$	4,243.9
Greater China	2,201.2		2,212.8		259.9		1,512.5		1,397.1		52.7
JANZ	1,632.4		2,027.4		1,195.3		665.5		762.4		364.6
Emerging Markets	2,615.6		3,144.7		1,853.8		1,207.1		1,402.4		610.4
Total reportable segments	$	16,218.1	$	17,813.6	$	11,819.9	$	8,263.2	$	8,705.0	$	5,271.6

Reconciling items:
Intangible asset amortization expense							(2,504.6)		(2,702.2)		(1,605.8)
Intangible asset disposal & impairment charges							(173.5)		(102.8)		(82.4)
Impairment of goodwill							(117.0)		—		—
Globally managed research and development costs							(662.2)		(681.0)		(512.6)
Acquired IPR&D							(36.4)		(70.1)		(42.5)
Litigation settlements & other contingencies							(4.4)		(329.2)		(107.8)
Transaction related and other special items							(1,026.9)		(2,832.2)		(1,739.7)
Corporate and other unallocated							(2,123.3)		(2,021.5)		(1,391.6)
Earnings (loss) from operations							$	1,614.9	$	(34.0)	$	(210.8)

The following table represents the percentage of consolidated net sales to Viatris’ major customers during the years ended December 31, 2022, 2021, and 2020:


	Percentage of Consolidated Net Sales
	2022		2021		2020
McKesson Corporation	11	%	9	%	13	%
AmerisourceBergen Corporation	10	%	9	%	10	%
Cardinal Health, Inc.	5	%	5	%	8	%

Sales by Country Information

Net sales by country are presented on the basis of geographic location of our subsidiaries:


	Year Ended December 31,
(In millions)	2022		2021		2020
United States	$	3,946.6	$	4,176.4	$	3,746.1
China	1,951.3		1,981.5		216.1

____________

No other country’s net sales represents more than 10% of consolidated net sales.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

Revenue Recognition and Accounts Receivable Variable Consideration (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Gross sales	$ 27,662.1	$ 30,553.4	$ 19,899.1
Chargebacks	(6,192.2)	(5,530.1)	(3,656.2)
Rebates, promotional programs and other sales allowances	(4,346.2)	(6,135.6)	(3,765.5)
Returns	(296.7)	(384.6)	(329.7)
Medicaid and other governmental rebates	(608.9)	(689.5)	(327.8)
Sales Revenue, Gross to net adjustments	11,444.0	12,739.8	8,079.2
Net sales	16,218.1	17,813.6	11,819.9
Net sales
Disaggregation of Revenue [Line Items]
Net sales	$ 16,218.1	$ 17,813.6	$ 11,819.9

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Leases (Lease Information) (Details)	Dec. 31, 2022
Lessee, Lease, Description [Line Items]
Weighted-average remaining lease term	6 years
Weighted-average discount rate	3.00%
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease terms	22 years
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease terms	1 year

Debt (Revolving Facilities and Term Facilities) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Line of Credit Facility [Line Items]
Debt, Current	$ 1,250.5	$ 1,860.3

Balance Sheet Components (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Balance Sheet Components [Abstract]
Net realizable value of inventory recognized as expense	$ 326.1	$ 474.9	$ 206.1
Inventory reserves	484.8	519.0
Capitalized software costs	121.5	62.3
Depreciation	$ 349.5	$ 509.5	$ 289.7

Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	$ 199.7	$ 223.6
Payments	64.1	83.2
Biocon Biologics Transaction	220.0
Accretion	8.2	9.0
Reclassifications	0.0	0.0
Fair value loss (gain)	11.2	50.3
Balance at end of period	375.0	199.7
Other current liabilities
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	66.7	100.5
Payments	64.1	83.2
Biocon Biologics Transaction	0.0
Accretion	0.0	0.0
Reclassifications	61.8	49.4
Fair value loss (gain)	0.0	0.0
Balance at end of period	64.4	66.7
Other Noncurrent Liabilities
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	133.0	123.1
Payments	0.0	0.0
Biocon Biologics Transaction	220.0
Accretion	8.2	9.0
Reclassifications	(61.8)	(49.4)
Fair value loss (gain)	11.2	50.3
Balance at end of period	$ 310.6	$ 133.0

Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Future amortization expense) (Details) $ in Millions	Dec. 31, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 2,322
2024	2,230
2025	2,136
2026	2,083
2027	$ 1,871

Balance Sheet Components (Prepaids and other current assets) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid expenses	$ 194.6	$ 256.7
Available-for-sale fixed income securities	35.3	38.2
Fair value of financial instruments	134.7	144.6
Equity securities	42.6	51.0
Other current assets	1,404.0	1,467.1
Prepaid expenses and other current assets	$ 1,811.2	$ 1,957.6

Revenue Recognition and Accounts Receivable (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts, Notes, Loans and Financing Receivable [Line Items]
Derecognized accounts receivables	$ 34.7	$ 29.6
Three Customers \| Accounts Receivable \| Credit Concentration Risk
Accounts, Notes, Loans and Financing Receivable [Line Items]
Concentration risk, percentage	23.00%	18.00%
Allowance for doubtful accounts
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowances for doubtful accounts	$ 114.7	$ 154.5	$ 159.9	$ 72.8

Employee Benefit Plans (Tables)

12 Months Ended

Dec. 31, 2022

Retirement Benefits [Abstract]

Accumulated Other Comprehensive Income (Loss) Pretax Amounts Not Yet Reclassified in Net Periodic Benefit Cost

Included in accumulated other comprehensive loss as of December 31, 2022 and 2021 are:


	Pension Benefits				Other Postretirement Benefits
	December 31,				December 31,
(In millions)	2022		2021		2022		2021
Unrecognized actuarial (gain) loss	$	(293.6)	$	(59.9)	$	(22.0)	$	21.7
Unrecognized prior service cost (credit)	4.0		6.6		(3.7)		(3.7)
Total	$	(289.6)	$	(53.3)	$	(25.7)	$	18.0

Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits

The change in accumulated other comprehensive loss in 2022 relating to pension benefits and other postretirement benefits consists of:


(In millions)	Pension Benefits		Other Postretirement Benefits
Unrecognized actuarial (gain) loss	$	(236.9)	$	(43.4)
Amortization of actuarial gain/(loss)	3.5		(0.3)
Unrecognized prior service credit (cost)	(1.4)		(0.5)
Amortization of prior service costs	(0.9)		0.5
Impact of foreign currency translation	(0.6)		—
Net change	$	(236.3)	$	(43.7)

Net Periodic Benefit Cost

Components of net periodic benefit cost for the years ended December 31, 2022, 2021 and 2020 were as follows:


	Pension Benefits						Other Postretirement Benefits
	December 31,						December 31,
(In millions)	2022		2021		2020		2022		2021		2020
Service cost	$	32.6	$	38.6	$	23.5	$	3.4	$	3.4	$	1.2
Interest cost	36.8		31.6		13.5		3.7		2.6		1.4
Expected return on plan assets	(64.6)		(66.1)		(19.9)		—		—		—
Plan curtailment, settlement and termination	2.3		(16.5)		1.1		(3.9)		—		—
Amortization of prior service costs	0.9		0.9		—		(0.6)		—		—
Recognized net actuarial losses (gains)	(0.2)		1.3		0.4		0.3		0.2		0.3
Net periodic benefit cost	$	7.8	$	(10.2)	$	18.6	$	2.9	$	6.2	$	2.9

During the year ended December 31, 2021, the Company recognized a settlement gain as a result of cash payments from lump sum elections related to the U.S. and Puerto Rico pension plans.

Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan

The table below presents components of the change in projected benefit obligation, change in plan assets and funded status at December 31, 2022 and 2021.


	Pension Benefits				Other Postretirement Benefits
(In millions)	2022		2021		2022		2021
Change in Projected Benefit Obligation
Projected benefit obligation, beginning of year	$	1,946.6	$	2,145.8	$	188.4	$	188.8
Service cost	32.6		38.6		3.4		3.4
Interest cost	36.8		31.6		3.7		2.6
Participant contributions	3.3		2.0		4.5		2.4
Acquisitions	2.8		4.0		—		—

Plan settlements and terminations	(82.0)		(128.6)		(4.5)		(4.3)
Actuarial (gains) losses	(439.4)		(26.1)		(43.3)		16.2
Benefits paid	(54.1)		(52.8)		(14.7)		(20.7)
Impact of foreign currency translation	(67.6)		(67.9)		—		—
Projected benefit obligation, end of year	$	1,379.0	$	1,946.6	$	137.5	$	188.4

Change in Plan Assets
Fair value of plan assets, beginning of year	$	1,366.4	$	1,354.6	$	—	$	—
Actual return on plan assets	(138.1)		141.7		—		—
Company contributions	25.6		97.0		10.2		18.3
Participant contributions	3.3		2.0		4.5		2.4
Acquisitions	—		(2.1)		—		—

Plan settlements	(85.9)		(128.9)		—		—
Benefits paid	(54.1)		(52.8)		(14.7)		(20.7)

Impact of foreign currency translation	(50.1)		(45.1)		—		—
Fair value of plan assets, end of year	1,067.1		1,366.4		—		—
Funded status of plans	$	(311.9)	$	(580.2)	$	(137.5)	$	(188.4)

Net Accrued Benefit Costs Classification on Balance Sheet

Net accrued benefit costs for pension plans and other postretirement benefits are reported in the following components of the Company’s consolidated balance sheets at December 31, 2022 and 2021:


	Pension Benefits				Other Postretirement Benefits
	December 31,				December 31,
(In millions)	2022		2021		2022		2021
Noncurrent assets	$	118.3	$	117.2	$	—	$	—
Current liabilities	(14.6)		(14.6)		(15.4)		(16.1)
Noncurrent liabilities	(415.6)		(682.8)		(122.1)		(172.3)
Net accrued benefit costs	$	(311.9)	$	(580.2)	$	(137.5)	$	(188.4)

Plans with Accumulated Benefit Obligation in Excess of Plan Assets


	December 31,
(In millions)	2022		2021
Plans with accumulated benefit obligation in excess of plan assets:
Projected benefit obligation	$	1,026.5	$	1,591.8
Accumulated benefit obligation	999.3		1,546.4
Fair value of plan assets	604.9		904.1

Schedule of Allocation of Plan Assets

The table below presents total plan assets by investment category as of December 31, 2022 and 2021 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value:


	December 31, 2022
(In millions)	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	34.2	$	0.9	$	—	$	35.1
Equity securities	42.9		353.4		—		396.3
Fixed income securities	181.6		271.5		—		453.1
Assets held by insurance companies and other	76.9		97.9		7.8		182.6
Total	$	335.6	$	723.7	$	7.8	$	1,067.1


	December 31, 2021
(In millions)	Level 1		Level 2		Level 3		Total
Cash and cash equivalents	$	63.1	$	1.9	$	—	$	65.0
Equity securities	53.9		497.2		—		551.1
Fixed income securities	211.4		405.5		—		616.9
Assets held by insurance companies and other	10.2		41.6		81.6		133.4
Total	$	338.6	$	946.2	$	81.6	$	1,366.4

Schedule of Assumptions Used

The following weighted average assumptions were used to determine the benefit obligations for the Company’s defined benefit pension and other postretirement plans as of December 31, 2022 and 2021:


	Pension Benefits				Other Postretirement Benefits
	2022		2021		2022		2021
Discount rate	4.8	%	2.3	%	5.4	%	2.5	%
Expected return on plan assets	5.0	%	5.1	%	—	%	—	%
Rate of compensation increase	3.7	%	3.1	%	—	%	—	%


	Pension Benefits						Other Postretirement Benefits
	2022		2021		2020		2022		2021		2020
Discount rate	2.3	%	1.9	%	1.6	%	2.5	%	1.9	%	3.3	%
Expected return on plan assets	5.0	%	5.1	%	4.3	%	—	%	—	%	—	%
Rate of compensation increase	3.1	%	2.9	%	2.7	%	—	%	—	%	—	%

Schedule of Expected Benefit Payments

Estimated benefit payments over the next ten years for the Company’s pension plans and retiree health plan are as follows:


(In millions)	Pension Benefits		Other Postretirement Benefits
2023	$	93.1	$	15.4
2024	96.1		15.8
2025	97.9		15.8
2026	98.3		15.7
2027	102.0		15.1
Thereafter	518.1		64.5
Total	$	1,005.5	$	142.3

Balance Sheet Components (Tables)

12 Months Ended

Dec. 31, 2022

Balance Sheet Components [Abstract]

Cash and Restricted Cash

Cash and restricted cash


(In millions)	December 31, 2022		December 31, 2021		December 31, 2020
Cash and cash equivalents	$	1,259.9	$	701.2	$	844.4
Restricted cash, included in other current and non-current assets	2.6		5.0		5.6
Cash, cash equivalents and restricted cash	$	1,262.5	$	706.2	$	850.0

Inventories


(In millions)	December 31, 2022		December 31, 2021
Raw materials	$	571.5	$	922.4
Work in process	755.4		993.3
Finished goods	2,192.6		2,062.0
Inventories	$	3,519.5	$	3,977.7

Prepaid expenses and other current assets


(In millions)	December 31, 2022		December 31, 2021
Prepaid expenses	$	194.6	$	256.7

Available-for-sale fixed income securities	35.3		38.2
Fair value of financial instruments	134.7		144.6
Equity securities	42.6		51.0
Other current assets	1,404.0		1,467.1
Prepaid expenses and other current assets	$	1,811.2	$	1,957.6

Property, plant and equipment, net


(In millions)	December 31, 2022		December 31, 2021
Machinery and equipment	$	2,936.7	$	3,054.0
Buildings and improvements	1,539.7		1,808.5
Construction in progress	474.0		588.7
Land and improvements	133.4		137.9
Gross property, plant and equipment	5,083.8		5,589.1
Accumulated depreciation	2,059.3		2,400.5
Property, plant and equipment, net	$	3,024.5	$	3,188.6

Other assets


(In millions)	December 31, 2022		December 31, 2021

CCPS in Biocon Biologics	$	997.4	$	—
Operating lease right-of-use assets	259.3		290.8

Non-marketable equity investments	94.0		81.4
Deferred consideration due from Biocon Biologics	299.5		—
Other long-term assets	753.3		798.5
Other assets	$	2,403.5	$	1,170.7

Accounts payable


(In millions)	December 31, 2022		December 31, 2021
Trade accounts payable	$	1,158.0	$	1,056.1
Other payables	608.6		601.3
Accounts payable	$	1,766.6	$	1,657.4

Other current liabilities


(In millions)	December 31, 2022		December 31, 2021
Accrued sales allowances	$	888.8	$	1,362.1
Payroll and employee benefit liabilities	746.8		741.9
Legal and professional accruals, including litigation accruals	297.2		715.6
Contingent consideration	64.4		66.7
Accrued restructuring	95.3		233.5
Accrued interest	80.2		86.6
Fair value of financial instruments	187.0		61.0
Operating lease liability	80.6		86.7
Due to Biocon Biologics	22.5		—
Other	978.1		1,265.5
Other current liabilities	$	3,440.9	$	4,619.6

Other long-term obligations


(In millions)	December 31, 2022		December 31, 2021
Employee benefit liabilities	$	544.6	$	876.4

Contingent consideration (1)	310.6		133.0
Tax related items, including contingencies	414.6		426.1
Operating lease liability	181.4		200.9
Accrued restructuring	60.4		64.3
Other	244.9		232.9
Other long-term obligations	$	1,756.5	$	1,933.6

(1) Includes a total of $221.2 million due to Biocon Biologics. Refer to Note 10 Financial Instruments and Risk Management for additional information.

Balance Sheet Components

12 Months Ended

Dec. 31, 2022

Balance Sheet Components [Abstract]

Balance Sheet Components

Selected balance sheet components consist of the following:

Cash and restricted cash


(In millions)	December 31, 2022		December 31, 2021		December 31, 2020
Cash and cash equivalents	$	1,259.9	$	701.2	$	844.4
Restricted cash, included in other current and non-current assets	2.6		5.0		5.6
Cash, cash equivalents and restricted cash	$	1,262.5	$	706.2	$	850.0

Inventories


(In millions)	December 31, 2022		December 31, 2021
Raw materials	$	571.5	$	922.4
Work in process	755.4		993.3
Finished goods	2,192.6		2,062.0
Inventories	$	3,519.5	$	3,977.7

Inventory reserves totaled $484.8 million and $519.0 million at December 31, 2022 and 2021, respectively. Included as a component of cost of sales is expense related to the net realizable value of inventories of $326.1 million, $474.9 million and $206.1 million for the years ended December 31, 2022, 2021 and 2020, respectively.

Prepaid expenses and other current assets


(In millions)	December 31, 2022		December 31, 2021
Prepaid expenses	$	194.6	$	256.7

Available-for-sale fixed income securities	35.3		38.2
Fair value of financial instruments	134.7		144.6
Equity securities	42.6		51.0
Other current assets	1,404.0		1,467.1
Prepaid expenses and other current assets	$	1,811.2	$	1,957.6

Prepaid expenses consist primarily of prepaid rent, insurance and other individually insignificant items.

Property, plant and equipment, net


(In millions)	December 31, 2022		December 31, 2021
Machinery and equipment	$	2,936.7	$	3,054.0
Buildings and improvements	1,539.7		1,808.5
Construction in progress	474.0		588.7
Land and improvements	133.4		137.9
Gross property, plant and equipment	5,083.8		5,589.1
Accumulated depreciation	2,059.3		2,400.5
Property, plant and equipment, net	$	3,024.5	$	3,188.6

Capitalized software costs included in our consolidated balance sheets were $121.5 million and $62.3 million, net of accumulated depreciation, at December 31, 2022 and 2021, respectively. The Company periodically reviews the estimated useful lives of assets and makes adjustments when appropriate. Depreciation expense was approximately $349.5 million, $509.5 million and $289.7 million for the years ended December 31, 2022, 2021 and 2020, respectively.

Other assets


(In millions)	December 31, 2022		December 31, 2021

CCPS in Biocon Biologics	$	997.4	$	—
Operating lease right-of-use assets	259.3		290.8

Non-marketable equity investments	94.0		81.4
Deferred consideration due from Biocon Biologics	299.5		—
Other long-term assets	753.3		798.5
Other assets	$	2,403.5	$	1,170.7

Accounts payable


(In millions)	December 31, 2022		December 31, 2021
Trade accounts payable	$	1,158.0	$	1,056.1
Other payables	608.6		601.3
Accounts payable	$	1,766.6	$	1,657.4

Other current liabilities


(In millions)	December 31, 2022		December 31, 2021
Accrued sales allowances	$	888.8	$	1,362.1
Payroll and employee benefit liabilities	746.8		741.9
Legal and professional accruals, including litigation accruals	297.2		715.6
Contingent consideration	64.4		66.7
Accrued restructuring	95.3		233.5
Accrued interest	80.2		86.6
Fair value of financial instruments	187.0		61.0
Operating lease liability	80.6		86.7
Due to Biocon Biologics	22.5		—
Other	978.1		1,265.5
Other current liabilities	$	3,440.9	$	4,619.6

Other long-term obligations


(In millions)	December 31, 2022		December 31, 2021
Employee benefit liabilities	$	544.6	$	876.4

Contingent consideration (1)	310.6		133.0
Tax related items, including contingencies	414.6		426.1
Operating lease liability	181.4		200.9
Accrued restructuring	60.4		64.3
Other	244.9		232.9
Other long-term obligations	$	1,756.5	$	1,933.6

(1) Includes a total of $221.2 million due to Biocon Biologics. Refer to Note 10 Financial Instruments and Risk Management for additional information.

Balance Sheet Components (Inventories) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Inventory, Net [Abstract]
Raw materials	$ 571.5	$ 922.4
Work in process	755.4	993.3
Finished goods	2,192.6	2,062.0
Inventories	$ 3,519.5	$ 3,977.7

Collaboration and Licensing Agreements (Narrative) (Details) $ in Millions		12 Months Ended
	Jan. 30, 2015 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jan. 08, 2016 drugs
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent consideration liability		$ 375.0	$ 199.7	$ 223.6
Proceeds from sale of assets and subsidiaries		1,950.0	96.7	$ 20.0
Momenta
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of drugs \| drugs					6
Theravance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments		18.5
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Revance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development			$ 30.0
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement \| Theravance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development		50.0
Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments		347.0
Maximum \| Theravance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments	$ 293.0
Fiscal Year 2017 \| Maximum \| Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development and sales milestone payments		38.0
Respiratory delivery platform [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent consideration liability		$ 132.0

Financial Instruments and Risk Management (Derivatives Designated as Hedging Instruments Fair Values of Derivative Instruments) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Derivatives, Fair Value [Line Items]
Asset Derivatives	$ 134.7	$ 144.6
Liability Derivatives	187.0	61.0
Designated as hedging instrument
Derivatives, Fair Value [Line Items]
Asset Derivatives	30.4	62.0
Liability Derivatives	26.4	4.3
Designated as hedging instrument \| Prepaid expenses & other current assets \| Foreign Exchange Forward
Derivatives, Fair Value [Line Items]
Asset Derivatives	30.4	62.0
Designated as hedging instrument \| Other current liabilities \| Foreign Exchange Forward
Derivatives, Fair Value [Line Items]
Liability Derivatives	$ 26.4	$ 4.3

Debt Debt (Receivables Facility and Commercial Paper Program) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Jun. 06, 2017
Debt Instrument [Line Items]
Short-term borrowings	$ 0	$ 1,493,000
Securitized accounts receivable	474,900	388,900
Commercial Paper Program [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$ 1,650,000
Receivables Facility
Debt Instrument [Line Items]
Short-term borrowings	0	$ 318,500
Accounts receivable securitization facility maximum borrowing capacity	400,000
Note Securitization Facility [Member]
Debt Instrument [Line Items]
Accounts receivable securitization facility maximum borrowing capacity	$ 200,000
London Interbank Offered Rate (LIBOR) [Member] \| Receivables Facility
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.775%
London Interbank Offered Rate (LIBOR) [Member] \| Note Securitization Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.85%

Income Taxes (Schedule of Components of Income Tax Provision) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Contingency [Line Items]
Income tax provision (benefit)	$ 734.6	$ 604.7	$ (51.3)
Earnings (loss) before income taxes and noncontrolling interest:
Operating and non-operating expense	2,813.2	(664.4)	(721.2)
Foreign Tax Authority
Income Tax Contingency [Line Items]
U.S. Federal Current	115.3	12.6	(6.4)
U.S. Federal Deferred	263.7	(182.7)	(277.0)
Income tax provision (benefit), U.S. Federal	379.0	(170.1)	(283.4)
Earnings (loss) before income taxes and noncontrolling interest:
Earnings before income taxes and noncontrolling interest, United States	794.8	(1,982.5)	(945.5)
U.S. State Tax Authority
Income Tax Contingency [Line Items]
U.S. State Current	26.5	7.7	(0.1)
U.S. State Deferred	20.3	(10.8)	7.7
Income tax provision (benefit), U.S. State	46.8	(3.1)	7.6
Non-U.S. state tax authority
Income Tax Contingency [Line Items]
Non-U.S. Current	618.7	(91.3)	168.7
Non-U.S. Deferred	(309.9)	869.2	55.8
Income tax provision (benefit), Non-U.S.	308.8	777.9	224.5
Other Foreign Operations
Earnings (loss) before income taxes and noncontrolling interest:
Earnings before income taxes and noncontrolling interest, foreign	$ 2,018.4	$ 1,318.1	$ 224.3

Equity Method Investments (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Schedule of Equity Method Investments [Line Items]
Equity Method Investments Net Gain (Loss) From Impairment and Reduction In Obligations	$ 5.7	$ 21.4
Loss from equity method investments	$ 0.0	$ 61.9	$ 48.4
Clean energy investments
Schedule of Equity Method Investments [Line Items]
Number of equity method investments	3

Comprehensive Earnings (Components of Other Comprehensive Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity	$ 21,072.3	$ 20,492.7	$ 22,954.1	$ 11,883.8
Net unrealized gains on marketable securities, net of tax, beginning of period	0.0
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, beginning of period	32.2
Foreign currency translation adjustment, beginning of period	(1,802.4)
Accumulated other comprehensive loss, net of tax, beginning of period	(1,744.3)
Other comprehensive earnings (loss) before reclassifications, before tax	(2.8)
Net sales	16,218.1	17,813.6	11,819.9
Interest expense	(592.4)	(636.2)	(497.8)
Amortization of prior service costs included in SG&A			0.0
Other comprehensive (loss) earnings, before tax	(884.0)	(775.2)	912.6
Income tax related to items of other comprehensive (loss) earnings, derivatives	(734.6)	(604.7)	51.3
Net unrealized gains on marketable securities, net of tax, end of period	(2.3)	0.0
Net unrealized gains on marketable securities, net of tax, end of period	268.5	32.2
Foreign currency translation adjustment, end of period	(3,385.9)	(1,802.4)
Accumulated other comprehensive loss, net of tax, end of period	(2,761.2)	(1,744.3)
Net unrealized (loss) gain on marketable securities	(2.8)	(1.1)	0.6
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax	(279.1)	(73.9)	14.0
Income tax provision (benefit)	132.9	111.1	(26.6)
Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax related to items of other comprehensive (loss) earnings, derivatives	0.5
Gains and Losses on Derivatives in Cash Flow Hedging Relationships
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized gains (losses) on derivatives, net of tax, beginning of period		(18.0)	(31.6)
Other comprehensive earnings (loss) before reclassifications, before tax			18.5
Income tax related to items of other comprehensive (loss) earnings, derivatives		(8.9)
Net unrecognized gains (losses) on derivatives, net of tax, end of period			(18.0)
Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales			(4.8)
Interest expense			4.5
Income tax related to items of other comprehensive (loss) earnings, derivatives			4.6
Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Foreign Exchange Contract \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(89.2)	(30.9)	(4.8)
Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Interest rate swaps \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	(4.5)	(4.3)	4.5
Gains and Losses on Marketable Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrealized gains on marketable securities, net of tax, beginning of period		1.2	0.6
Other comprehensive earnings (loss) before reclassifications, before tax		(1.1)	0.6
Net unrealized gains on marketable securities, net of tax, end of period			1.2
Net unrealized (loss) gain on marketable securities			0.6
Gains and Losses on Marketable Securities \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax related to items of other comprehensive (loss) earnings, derivatives		(0.1)	0.0
Defined Pension Plan Items
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net unrecognized losses and prior service cost related to defined benefit plans, net of tax, beginning of period		(26.1)	(17.4)
Other comprehensive earnings (loss) before reclassifications, before tax	276.3	67.0	(12.1)
Net unrealized gains on marketable securities, net of tax, end of period			(26.1)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax			(14.0)
Defined Pension Plan Items \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs included in SG&A	(0.4)	(0.5)	0.0
Amortization of actuarial loss included in SG&A	3.2	7.4	(1.9)
Income tax related to items of other comprehensive (loss) earnings, derivatives	(42.8)	15.6	(5.3)
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Foreign currency translation adjustment, beginning of period		(461.5)	(1,674.5)
Other comprehensive earnings (loss) before reclassifications, before tax	(1,583.5)	(1,340.9)	1,213.0
Income tax related to items of other comprehensive (loss) earnings, derivatives		0.0
Foreign currency translation adjustment, end of period			(461.5)
Foreign currency translation adjustment	(1,583.5)	(1,340.9)	1,213.0
Foreign Currency Translation Adjustment \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income tax related to items of other comprehensive (loss) earnings, derivatives	0.0		0.0
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total equity	(2,761.2)		(858.0)	(1,797.2)
Accumulated other comprehensive loss, net of tax, beginning of period		(858.0)	(1,797.2)
Other comprehensive earnings (loss) before reclassifications, before tax	(802.1)	(755.5)	914.8
Other comprehensive (loss) earnings, before tax		(775.2)	912.6
Accumulated other comprehensive loss, net of tax, end of period			(858.0)
Accumulated Other Comprehensive Loss \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Amortization of prior service costs included in SG&A	(0.4)	(0.5)	0.0
Amortization of actuarial loss included in SG&A	3.2	7.4	(1.9)
Income tax provision (benefit)	132.9	111.1	(26.6)
Accumulated Other Comprehensive Loss \| Foreign Exchange Contract \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(89.2)	(30.9)	(4.8)
Accumulated Other Comprehensive Loss \| Interest rate swaps \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	(4.5)	(4.3)	4.5
Cash flow hedging relationships \| Gains and Losses on Derivatives in Cash Flow Hedging Relationships
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive earnings (loss) before reclassifications, before tax	47.8	62.7
Other comprehensive (loss) earnings, before tax	(36.9)
Income tax related to items of other comprehensive (loss) earnings, derivatives	9.2
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax			18.2
Cash flow hedging relationships \| Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Foreign Exchange Contract
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales	(89.2)
Cash flow hedging relationships \| Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Foreign Exchange Contract \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net sales		(30.9)
Cash flow hedging relationships \| Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Interest rate swaps
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense	(4.5)
Cash flow hedging relationships \| Gains and Losses on Derivatives in Cash Flow Hedging Relationships \| Interest rate swaps \| Reclassification out of Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Interest expense		(4.3)
Net Investment Hedging
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax	377.0	16.7	(353.6)	$ (74.3)
Other comprehensive earnings (loss) before reclassifications, before tax	460.1	456.8	(305.2)
Income tax related to items of other comprehensive (loss) earnings, derivatives	$ (99.8)	$ (86.5)	$ 25.9

Commitments (Details) - Pfizer, Inc. - USD ($) $ in Millions	12 Months Ended		14 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2021
Other Commitments [Line Items]
Reimbursement amount, tranche one	$ 380.0
Amounts incurred	54.5	$ 30.4	$ 138.0
Amounts accrued	$ 26.9
Transition Service Agreements
Other Commitments [Line Items]
Limited transition services period	24 months

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Condensed Consolidated Statements of Comprehensive Earnings Derivatives in Net Investment Hedging Relationship) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax	$ (82.1)	$ 39.3	$ (10.1)
Foreign currency borrowings and forward contracts \| Not designated as hedging instrument \| Other income
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax	$ (82.1)	$ 39.3	$ (10.1)

Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2022

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Schedule II - Valuation and Qualifying Accounts

VIATRIS INC. AND SUBSIDIARIES

SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS

(In millions)


Description	Beginning Balance		Additions Charged to Costs and Expenses	Additions Charged to Other Accounts (1)	Deductions	Ending Balance
Allowance for doubtful accounts:
Year ended December 31, 2022	$	154.5	21.5	—	(61.3)	$	114.7
Year ended December 31, 2021	$	159.9	16.0	—	(21.4)	$	154.5
Year ended December 31, 2020	$	72.8	16.9	77.3	(7.1)	$	159.9
Valuation allowance for deferred tax assets:
Year ended December 31, 2022	$	780.4	42.7	—	(436.1)	$	387.0
Year ended December 31, 2021	$	443.6	82.2	260.8	(6.2)	$	780.4
Year ended December 31, 2020	$	603.5	39.0	—	(198.9)	$	443.6

Debt (Tables)

12 Months Ended

Dec. 31, 2022

Debt Instrument [Line Items]

Schedule of Short-term Debt

Short-Term Borrowings

The Company did not have any short-term borrowings as of December 31, 2022 and had $1.49 billion of short-term borrowings as of December 31, 2021.


(In millions)	December 31, 2022		December 31, 2021
Commercial paper notes	$	—	$	1,173.4
Receivables Facility	—		318.5

Other	—		1.1
Short-term borrowings	$	—	$	1,493.0

Summary of Long-Term Debt

A summary of long-term debt is as follows:


($ in millions)	Interest Rate as of December 31, 2022		December 31, 2022		December 31, 2021
Current portion of long-term debt:

2022 Euro Senior Notes (a) ****	0.816	%	—		856.6
2022 Senior Notes (b) ***	1.125	%	—		1,002.9
2023 Senior Notes (c) *	3.125	%	750.6		—
2023 Senior Notes *	4.200	%	499.8		—
Other			0.7		0.9
Deferred financing fees			(0.6)		(0.1)
Current portion of long-term debt			$	1,250.5	$	1,860.3

Non-current portion of long-term debt:






2023 Senior Notes (c) *	3.125	%	—		766.1
2023 Senior Notes *	4.200	%	—		499.6
2024 Euro Senior Notes **	2.250	%	1,069.8		1,135.8
2024 Euro Senior Notes ****	1.023	%	813.5		871.6
2025 Euro Senior Notes *	2.125	%	534.8		567.8
2025 Senior Notes ***	1.650	%	759.6		763.4
2026 Senior Notes **	3.950	%	2,243.2		2,241.4
2027 Euro Senior Notes ****	1.362	%	945.9		1,013.0
2027 Senior Notes ***	2.300	%	775.3		780.8
2028 Euro Senior Notes **	3.125	%	798.5		847.4
2028 Senior Notes *	4.550	%	748.9		748.7
2030 Senior Notes ***	2.700	%	1,512.8		1,520.5
2032 Euro Senior Notes ****	1.908	%	1,444.4		1,546.6
2040 Senior Notes ***	3.850	%	1,650.6		1,657.1
2043 Senior Notes *	5.400	%	497.4		497.3
2046 Senior Notes **	5.250	%	999.9		999.9
2048 Senior Notes *	5.200	%	747.8		747.8
2050 Senior Notes ***	4.000	%	2,200.8		2,205.1
YEN Term Loan Facility	Variable		305.1		347.6

Other			2.0		1.9
Deferred financing fees			(35.1)		(42.3)
Long-term debt			$	18,015.2	$	19,717.1

____________

(a) The 2022 Euro Senior Notes were repaid at maturity in the second quarter of 2022.

(b) The 2022 Senior Notes were repaid at maturity in the second quarter of 2022.

(c) In the first quarter of 2020, the Company terminated interest rate swaps designated as a fair value hedge resulting in net proceeds of approximately $45 million. The fair value adjustment is being amortized to interest expense over the remaining term of the notes.

* Instrument was issued by Mylan Inc.

** Instrument was originally issued by Mylan N.V.; now held by Utah Acquisition Sub Inc.

*** Instrument was issued by Viatris Inc.

**** Instrument was issued by Upjohn Finance B.V.

Minimum Repayments on Outstanding Borrowings

Mandatory minimum repayments remaining on the notional amount of outstanding long-term debt at December 31, 2022 were as follows for each of the periods ending December 31:


(In millions)	Total
2023	$	1,250
2024	1,873
2025	1,285
2026	2,555
2027	1,660
Thereafter	10,091
Total	$	18,714

Revenue Recognition and Accounts Receivable Revenue Disaggregation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Net sales	$ 16,218.1	$ 17,813.6	$ 11,819.9
Biocon Biologics
Disaggregation of Revenue [Line Items]
Net sales	(63.5)
Brands
Disaggregation of Revenue [Line Items]
Net sales	9,889.6	10,841.3	5,234.9
Complex Gx and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	1,313.4	1,342.1	1,295.5
Generics
Disaggregation of Revenue [Line Items]
Net sales	5,015.1	5,630.2	5,289.5
Net sales
Disaggregation of Revenue [Line Items]
Net sales	16,218.1	17,813.6	11,819.9
Developed Markets \| Brands
Disaggregation of Revenue [Line Items]
Net sales	5,160.4	5,759.2	3,920.7
Developed Markets \| Complex Gx and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	1,218.0	1,241.6	1,202.6
Developed Markets \| Generics
Disaggregation of Revenue [Line Items]
Net sales	3,390.5	3,427.9	3,387.6
Greater China \| Brands
Disaggregation of Revenue [Line Items]
Net sales	2,190.7	2,207.8	253.9
Greater China \| Complex Gx and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	0.6	0.2	0.7
Greater China \| Generics
Disaggregation of Revenue [Line Items]
Net sales	9.9	4.8	5.3
JANZ \| Brands
Disaggregation of Revenue [Line Items]
Net sales	922.6	1,197.1	617.0
JANZ \| Complex Gx and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	44.1	46.5	42.8
JANZ \| Generics
Disaggregation of Revenue [Line Items]
Net sales	665.7	783.8	535.5
Emerging Markets \| Brands
Disaggregation of Revenue [Line Items]
Net sales	1,615.9	1,677.2	443.3
Emerging Markets \| Complex Gx and Biosimilars
Disaggregation of Revenue [Line Items]
Net sales	50.7	53.8	49.4
Emerging Markets \| Generics
Disaggregation of Revenue [Line Items]
Net sales	949.0	1,413.7	1,361.1
Operating Segments
Disaggregation of Revenue [Line Items]
Net sales	16,218.1	17,813.6
Operating Segments \| Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	9,768.9	10,428.7	8,510.9
Operating Segments \| Greater China
Disaggregation of Revenue [Line Items]
Net sales	2,201.2	2,212.8	259.9
Operating Segments \| JANZ
Disaggregation of Revenue [Line Items]
Net sales	1,632.4	2,027.4	1,195.3
Operating Segments \| Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	$ 2,615.6	$ 3,144.7	$ 1,853.8

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net earnings (loss)	$ 2,078.6	$ (1,269.1)	$ (669.9)
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	3,027.6	4,506.5	2,216.1
Deferred income tax expense (benefit)	(25.9)	675.7	(213.2)
Litigation settlements and other contingencies, net	(1.7)	323.7	101.1
Loss from equity method investments	0.0	61.9	48.4
Gain on disposal of business	(1,754.1)	0.0	0.0
Share-based compensation expense	116.4	111.2	79.2
Other non-cash items	434.3	411.8	366.4
Changes in operating assets and liabilities:
Accounts receivable	(240.3)	59.3	78.7
Inventories	(259.5)	(427.6)	(741.9)
Trade accounts payable	170.2	(70.4)	(82.7)
Income taxes	25.3	(699.6)	3.6
Other operating assets and liabilities, net	(618.3)	(666.5)	46.0
Net cash provided by operating activities	2,952.6	3,016.9	1,231.8
Cash flows from investing activities:
Cash received (paid) for acquisitions, net of cash acquired	0.0	277.0	415.8
Capital expenditures	(406.0)	(457.2)	(243.0)
Payments for product rights and other, net	(37.0)	(52.2)	(438.2)
Proceeds from sale of property, plant and equipment	13.8	18.3	2.1
Proceeds from sale of assets and subsidiaries	1,950.0	96.7	20.0
Purchase of marketable securities	(30.2)	(30.2)	(104.8)
Proceeds from the sale of marketable securities	29.9	29.8	47.0
Net cash provided by (used in) investing activities	1,520.5	(117.8)	(301.1)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	1,875.6	1,710.1	983.3
Payments of long-term debt	(3,662.5)	(4,201.3)	(2,484.2)
Payments of financing fees	(1.9)	(7.0)	(2.0)
Change in short-term borrowings, net	(1,493.2)	392.1	1,099.6
Proceeds from exercise of stock options	0.0	0.0	0.6
Taxes paid related to net share settlement of equity awards	(17.3)	(17.4)	(7.9)
Contingent consideration payments	(18.9)	(28.6)	(48.5)
Cash dividends paid	(581.6)	(399.0)	0.0
Non-contingent payments for product rights	0.0	(456.0)	(143.3)
Issuance of common stock	3.3	0.0	0.0
Other items, net	18.6	(4.9)	(3.3)
Net cash used in financing activities	(3,877.9)	(3,012.0)	(605.7)
Effect on cash of changes in exchange rates	(38.9)	(30.9)	33.8
Net increase (decrease) in cash, cash equivalents and restricted cash	556.3	(143.8)	358.8
Cash, cash equivalents and restricted cash — beginning of period	706.2	850.0	491.1
Cash, cash equivalents and restricted cash — end of period	1,262.5	706.2	850.0
Non-cash transactions:
Common stock issued for the Combination	0.0	0.0	10,727.5
Cash paid during the period for:
Income taxes	735.2	641.7	324.4
Interest	$ 642.5	$ 684.8	$ 555.4

Financial Instruments and Risk Management (Effect of Derivative Instruments on the Consolidated Statements of Operations Derivatives Not Designated as Hedging Instruments) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	$ 390.8	$ 479.0	$ (325.8)
Net Investment Hedging \| Foreign Exchange Contract \| Gains and Losses on Derivatives in Cash Flow Hedging Relationships
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	$ 360.1	$ 436.6	$ (346.4)

Debt (Summary of Long-term Debt) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt, Current		$ 1,250.5	$ 1,860.3
Unamortized Debt Issuance Expense		(35.1)	(42.3)
Long-term debt		18,015.2	19,717.1
Proceeds from Sale of Securities, Operating Activities	$ 45.0
Other Current Portion of Long-term Debt
Debt Instrument [Line Items]
Debt, Current		0.7	0.9
2020 Euro Senior Notes
Debt Instrument [Line Items]
Debt, Current		$ 0.0	856.6
Debt instrument, interest rate, stated percentage		0.816%
Long-term debt		$ 305.1	347.6
2020 Senior Notes (3.750% coupon)
Debt Instrument [Line Items]
Debt, Current		$ 0.0	1,002.9
Debt instrument, interest rate, stated percentage		1.125%
Senior Notes 2023 3.125%
Debt Instrument [Line Items]
Debt, Current		$ 750.6	0.0
Debt instrument, interest rate, stated percentage		3.125%
2023 Senior Notes (4.200%)
Debt Instrument [Line Items]
Debt, Current		$ 499.8	0.0
Debt instrument, interest rate, stated percentage		4.20%
Other Long Term Debt
Debt Instrument [Line Items]
Long-term debt		$ 2.0	1.9
2022 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		0.816%
2.125% Euro Senior Notes due 2025
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		1.023%
2027 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		1.362%
2027 Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		2.30%
Senior Notes \| Senior Notes 2023 3.125%
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		3.125%
Long-term debt		$ 0.0	766.1
Senior Notes \| 2023 Senior Notes (4.200%)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		4.20%
Long-term debt		$ 0.0	499.6
Senior Notes \| 2.250% Euro Senior Notes due 2024
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		2.25%
Long-term debt		$ 1,069.8	1,135.8
Senior Notes \| 2025 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		2.125%
Long-term debt		$ 534.8	567.8
Senior Notes \| 2026 Senior Notes (3.950%)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		3.95%
Long-term debt		$ 2,243.2	2,241.4
Senior Notes \| 2028 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		3.125%
Long-term debt		$ 798.5	847.4
Senior Notes \| 2028 Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		4.55%
Long-term debt		$ 748.9	748.7
Senior Notes \| 2043 Senior Notes (5.400%)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		5.40%
Long-term debt		$ 497.4	497.3
Senior Notes \| 2046 Senior Notes (5.250%)
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		5.25%
Long-term debt		$ 999.9	999.9
Senior Notes \| 2048 Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		5.20%
Long-term debt		$ 747.8	747.8
Senior Notes \| 2.125% Euro Senior Notes due 2025
Debt Instrument [Line Items]
Long-term debt		813.5	871.6
Senior Notes \| 2027 Euro Senior Notes
Debt Instrument [Line Items]
Long-term debt		945.9	1,013.0
Senior Notes \| 2027 Senior Notes
Debt Instrument [Line Items]
Long-term debt		$ 775.3	780.8
Senior Notes \| 2030 Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		2.70%
Long-term debt		$ 1,512.8	1,520.5
Senior Notes \| 2032 Euro Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		1.908%
Long-term debt		$ 1,444.4	1,546.6
Senior Notes \| 2040 Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		3.85%
Long-term debt		$ 1,650.6	1,657.1
Senior Notes \| 2050 Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		4.00%
Long-term debt		$ 2,200.8	2,205.1
Senior Notes \| 2025 Senior Notes
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		1.65%
Long-term debt		$ 759.6	763.4
Current portion of long-term debt
Debt Instrument [Line Items]
Unamortized Debt Issuance Expense		$ (0.6)	$ (0.1)

Leases (Lease Maturities) (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Leases [Abstract]
2023	$ 76,400
2024	63,400
2025	38,600
2026	30,200
2027	23,100
Thereafter	52,300
Total lease payments	284,000
Less imputed interest	22,000
Total lease liability	$ 262,000

Comprehensive Earnings (Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Total equity	$ 21,072.3	$ 20,492.7	$ 22,954.1	$ 11,883.8
Net unrealized (loss) on marketable securities, net of tax	(2.3)	0.0
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax	(268.5)	(32.2)
Foreign currency translation adjustment	(3,385.9)	(1,802.4)
Accumulated Other Comprehensive Income (Loss), Net of Tax	(2,761.2)	(1,744.3)
Net unrealized (loss) on marketable securities, net of tax	(2.3)	0.0
Net unrecognized gain and prior service cost related to defined benefit plans, net of tax	268.5	32.2
Foreign currency translation adjustment	(3,385.9)	(1,802.4)
Accumulated Other Comprehensive Income (Loss), Net of Tax	(2,761.2)	(1,744.3)
AOCI Attributable to Parent [Member]
Total equity	(2,761.2)		(858.0)	(1,797.2)
Accumulated Other Comprehensive Income (Loss), Net of Tax			(858.0)	(1,797.2)
Accumulated Other Comprehensive Income (Loss), Net of Tax			(858.0)	(1,797.2)
Foreign Currency Translation Adjustment
Foreign currency translation adjustment			(461.5)	(1,674.5)
Foreign currency translation adjustment	(1,583.5)	(1,340.9)	1,213.0
Foreign currency translation adjustment			(461.5)	(1,674.5)
Cash flow hedging relationships \| Gains and Losses on Derivatives in Cash Flow Hedging Relationships
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax	(18.5)	9.2
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax	(18.5)	9.2
Net Investment Hedging
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax	377.0	16.7	(353.6)	(74.3)
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax	$ 377.0	$ 16.7	$ (353.6)	$ (74.3)

Employee Benefit Plans (Net Periodic Benefit Costs) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Service cost			$ 1.2
Interest cost			1.4
Expected return on plan assets			0.0
Plan curtailment, settlement and termination			0.0
Amortization of prior service costs included in SG&A			0.0
Recognized net actuarial losses			0.3
Net periodic benefit cost			2.9
Other Pension, Postretirement and Supplemental Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 3.4	$ 3.4
Interest cost	3.7	2.6
Expected return on plan assets	0.0	0.0
Plan curtailment, settlement and termination	(3.9)	0.0
Amortization of prior service costs included in SG&A	(0.6)	0.0
Recognized net actuarial losses	0.3	0.2
Net periodic benefit cost	2.9	6.2
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	32.6	38.6	23.5
Interest cost	36.8	31.6	13.5
Expected return on plan assets	(64.6)	(66.1)	(19.9)
Plan curtailment, settlement and termination	2.3	(16.5)	1.1
Amortization of prior service costs included in SG&A	0.9	0.9	0.0
Recognized net actuarial losses	(0.2)	1.3	0.4
Net periodic benefit cost	7.8	(10.2)	$ 18.6
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	3.4	3.4
Interest cost	$ 3.7	$ 2.6

Debt (Upjohn Senior Notes) (Details) - Upjohn Inc. - Senior Notes € in Millions, $ in Millions	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 EUR (€)
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 7,450
Upjohn Euro Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount \| €			€ 3,600
Unregistered Upjohn U.S. Dollar Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 7,450

Litigation	12 Months Ended
Litigation	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Litigation	Litigation The Company is involved in various disputes, governmental and/or regulatory inquiries, investigations and proceedings, tax proceedings and litigation matters, both in the U.S. and abroad, that arise from time to time, some of which could result in losses, including damages, fines and/or civil penalties, and/or criminal charges against the Company. These matters are often complex and have outcomes that are difficult to predict. In addition, in connection with the Combination, the Company has generally assumed liability for, and control of, pending and threatened legal matters relating to the Upjohn Business – including certain matters initiated against Pfizer described below – and has agreed to indemnify Pfizer for liabilities arising out of such assumed legal matters. Pfizer, however, has agreed to retain various matters – including certain specified competition law matters – to the extent they arise from conduct during the pre-Distribution period and has agreed to indemnify the Company for liabilities arising out of such matters. While the Company believes that it has meritorious defenses with respect to the claims asserted against it and the assumed legal matters referenced above, and intends to vigorously defend its position, the process of resolving these matters is inherently uncertain and may develop over a long period of time, and so it is not possible to predict the ultimate resolution of any such matter. It is possible that an unfavorable resolution of any of the ongoing matters could have a material effect on the Company’s business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price. Some of these governmental inquiries, investigations, proceedings and litigation matters with which the Company is involved are described below, and unless otherwise disclosed, the Company is unable to predict the outcome of the matter or to provide an estimate of the range of reasonably possible material losses. The Company records accruals for loss contingencies to the extent we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company is also involved in other pending proceedings for which, in the opinion of the Company based upon facts and circumstances known at the time, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s business, financial position, results of operations, cash flows, ability to pay dividends and/or stock price. If and when any reasonably possible losses associated with the resolution of such other pending proceedings, in the opinion of the Company, become material, the Company will disclose such matters. Legal costs are recorded as incurred and are classified in SG&A in the Company’s consolidated statements of operations. EpiPen® Auto-Injector Litigation The Company and a former Mylan N.V. officer (collectively the “Mylan Defendants”) were named as defendants in indirect purchaser class actions relating to the pricing and/or marketing of the EpiPen® Auto-Injector. The plaintiffs in these cases asserted violations of various federal and state antitrust and consumer protection laws, RICO as well as common law claims. Plaintiffs’ sought monetary damages, attorneys’ fees and costs. These lawsuits were filed in various federal and state courts and were either dismissed or transferred into a MDL in the U.S. District Court for the District of Kansas and were consolidated or centralized. An antitrust class consisting of certain states was ultimately certified. On June 23, 2021, the Court granted – in substantial part – the Mylan Defendants’ motion for summary judgment by dismissing certain antitrust claims and the RICO claims, which included RICO claims asserted against the former Mylan N.V. officer. In February 2022, the parties reached an agreement to fully resolve this matter for $264 million, which was accrued for during the year ended December 31, 2021. During the first quarter of 2022, $5.0 million of the settlement was paid and the remaining amount of the settlement was paid in July 2022. The settlement was approved by the Court on July 11, 2022 and contains an express provision disclaiming and denying any wrongdoing or liability by the Mylan Defendants. This matter is resolved. On February 14, 2020, the Company, together with other non-Viatris affiliated companies, were named as defendants in a putative direct purchaser class action filed in the U.S. District Court for the District of Kansas relating to the pricing and/or marketing of the EpiPen® Auto-Injector. On September 21, 2021, after Plaintiffs’ then operative complaint was dismissed with an option to file a limited amended complaint, Plaintiffs filed an amended complaint asserting federal antitrust claims which are based on allegations concerning a patent settlement between Pfizer and Teva and other alleged actions regarding the launch of Teva’s generic epinephrine auto-injector. Plaintiffs’ seek monetary damages, declaratory relief, attorneys’ fees and costs. Beginning in March 2020, the Company, together with other non-Viatris affiliated companies, were named as defendants in putative direct purchaser class actions filed in the U.S. District Court for the District of Minnesota relating to contracts with certain pharmacy benefit managers concerning EpiPen® Auto-Injector. The plaintiffs claim that the alleged conduct resulted in the exclusion or restriction of competing products and the elimination of pricing constraints in violation of RICO and federal antitrust law. These actions have been consolidated. Plaintiffs’ seek monetary damages, attorneys’ fees and costs. On April 24, 2017, Sanofi Aventis U.S., LLC (“Sanofi”) filed a lawsuit against the Company in the U.S. District Court for the District of New Jersey. This lawsuit has been transferred into the aforementioned MDL and alleges exclusive dealing and anti-competitive marketing practices in violation of the antitrust laws in connection with the sale and marketing of the EpiPen® Auto-Injector. Sanofi seeks monetary damages, declaratory relief, attorneys’ fees and costs. The Court granted the Company’s motion for summary judgment and dismissed Sanofi’s claims. Sanofi’s appeal was denied. Sanofi has filed a petition seeking review by the U.S. Supreme Court. The Company has a total accrual of approximately $5.5 million related to these matters at December 31, 2022, which is included in other current liabilities in the consolidated balance sheets. Although it is reasonably possible that the Company may incur additional losses from these matters, any amount cannot be reasonably estimated at this time. In addition, the Company expects to incur additional legal and other professional service expenses associated with such matters in future periods and will recognize these expenses as services are received. The Company believes that the ultimate amount paid for these services and claims could have a material effect on the Company's business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price in future periods. Drug Pricing Matters Department of Justice On December 3, 2015, the Company received a subpoena from the Antitrust Division of the DOJ seeking information relating to the marketing, pricing, and sale of certain of our generic products and any communications with competitors about such products. On September 8, 2016, the Company, as well as certain employees and a member of senior management, received subpoenas from the DOJ seeking similar information. Related search warrants also were executed. On May 10, 2018, the Company received a civil investigative demand from the Civil Division of the DOJ seeking information relating to the pricing and sale of its generic drug products. We are fully cooperating with these investigations, which we believe are related to a broader industry-wide investigation of the generic pharmaceutical industry. Civil Litigation Beginning in 2016, the Company, along with other manufacturers, has been named as a defendant in lawsuits filed in the United States and Canada generally alleging anticompetitive conduct with respect to generic drugs. The lawsuits have been filed by plaintiffs, including putative classes of direct purchasers, indirect purchasers, and indirect resellers, as well as individual direct and indirect purchasers and certain cities and counties. The lawsuits allege harm under federal laws and the United States lawsuits also allege harm under state laws, including antitrust laws, state consumer protection laws and unjust enrichment claims. Some of the United States lawsuits also name as defendants the Company’s President, including allegations against him with respect to a single drug product, and one of the Company’s sales employees, including allegations against him with respect to certain generic drugs. The vast majority of the lawsuits have been consolidated in an MDL proceeding in the Eastern District of Pennsylvania (“EDPA”). Plaintiffs generally seek monetary damages, restitution, declaratory and injunctive relief, attorneys’ fees and costs. The EDPA Court has ordered certain plaintiffs’ complaints regarding two single-drug product cases to proceed as bellwethers. The Company is named in those plaintiffs’ complaints that regard one of the two individual drug products. Attorneys General Litigation On December 21, 2015, the Company received a subpoena and interrogatories from the Connecticut Office of the Attorney General seeking information relating to the marketing, pricing and sale of certain of the Company’s generic products and communications with competitors about such products. On December 14, 2016, attorneys general of certain states filed a complaint in the United States District Court for the District of Connecticut against several generic pharmaceutical drug manufacturers, including the Company, alleging anticompetitive conduct with respect to, among other things, a single drug product. The complaint has subsequently been amended, including on June 18, 2018, to add attorneys general alleging violations of federal and state antitrust laws, as well as violations of various states’ consumer protection laws. This lawsuit has been transferred to the aforementioned MDL proceeding in the EDPA. The operative complaint includes attorneys general of forty-six states, the District of Columbia and the Commonwealth of Puerto Rico. The Company is alleged to have engaged in anticompetitive conduct with respect to four generic drug products. The amended complaint also includes claims asserted by attorneys general of thirty-six states and the Commonwealth of Puerto Rico against certain individuals, including the Company’s President, with respect to a single drug product. The amended complaint seeks declaratory and injunctive relief, disgorgement, attorneys’ fees and costs, and certain states seek monetary damages, civil penalties, restitution, and other equitable monetary relief. The States’ claim for disgorgement and restitution under federal law in this case has been dismissed. On May 10, 2019, certain attorneys general filed a new complaint in the United States District Court for the District of Connecticut against various drug manufacturers and individuals, including the Company and one of its sales employees, alleging anticompetitive conduct with respect to additional generic drugs. On November 1, 2019, the complaint was amended, adding additional states as plaintiffs. The operative complaint is brought by attorneys general of forty-seven states, certain territories and the District of Columbia. The amended complaint also includes claims asserted by attorneys general of forty-two states and certain territories against several individuals, including a Company sales employee. The amended complaint seeks declaratory and injunctive relief, disgorgement, attorneys’ fees and costs, and certain states seek monetary damages, civil penalties, restitution, and other equitable monetary relief. This lawsuit has been transferred to the aforementioned MDL proceeding in the EDPA. On June 10, 2020, certain attorneys general filed a new complaint in the United States District Court for the District of Connecticut against drug manufacturers, including the Company, and individual defendants (none from the Company), alleging anticompetitive conduct with respect to additional generic drugs. On September 9, 2021, the complaint was amended, adding an additional state as a plaintiff. The operative complaint is brought by attorneys general of forty-six states, certain territories and the District of Columbia. The amended complaint seeks declaratory and injunctive relief, disgorgement, attorneys’ fees and costs, and certain states seek monetary damages, civil penalties, restitution, and other equitable monetary relief. This lawsuit has been transferred to the aforementioned MDL proceeding in the EDPA and has been ordered to proceed as a bellwether. Securities Related Litigation Purported class action complaints were filed in October 2016 against Mylan N.V. and Mylan Inc. (collectively “Mylan”), certain of Mylan’s former directors and officers, and certain of the Company’s current directors and officers (collectively, for purposes of this paragraph, the “defendants”) in the United States District Court for the Southern District of New York (“SDNY”) on behalf of certain purchasers of securities of Mylan on the NASDAQ. The complaints alleged that defendants made false or misleading statements and omissions of purportedly material fact, in violation of federal securities laws, in connection with disclosures relating to the classification of their EpiPen® Auto-Injector as a non-innovator drug for purposes of the Medicaid Drug Rebate Program. On March 20, 2017, a consolidated amended complaint was filed alleging substantially similar claims, but adding allegations that defendants made false or misleading statements and omissions of purportedly material fact in connection with allegedly anticompetitive conduct with respect to EpiPen® Auto-Injector and certain generic drugs. The operative complaint is the third amended consolidated complaint, which was filed on June 17, 2019, and contains the allegations as described above against Mylan, certain of Mylan’s former directors and officers, and certain of the Company’s current directors, officers, and employees (collectively, for purposes of this paragraph, the “defendants”). A class has been certified covering all persons or entities that purchased Mylan common stock between February 21, 2012 and May 24, 2019 excluding defendants, certain of the Company’s current directors and officers, former directors and officers of Mylan, members of their immediate families and their legal representatives, heirs, successors or assigns, and any entity in which defendants have or had a controlling interest. Plaintiffs seek damages and costs and expenses, including attorneys’ fees and expert costs. A decision on Defendants’ motion for summary judgment seeking to dismiss the case in its entirety and Plaintiffs’ cross-motion for partial summary judgment as to portions of certain claims is pending. On April 30, 2017, a similar lawsuit was filed in the Tel Aviv District Court (Economic Division) in Israel, which has been stayed pending a decision in the SDNY class action litigation. On February 14, 2020, the Abu Dhabi Investment Authority filed a complaint against Mylan in the SDNY asserting allegations pertaining to EpiPen® Auto-Injector and certain generic drugs under the federal securities laws that overlap with those asserted in the third amended complaint identified above. The Abu Dhabi Investment Authority’s complaint seeks monetary damages as well as the plaintiff’s fees and costs. On June 26, 2020, a putative class action complaint was filed by the Public Employees Retirement System of Mississippi, which was subsequently amended on November 13, 2020, against Mylan N.V., certain of Mylan N.V.’s former directors and officers, and an officer and director of the Company (collectively for the purposes of this paragraph, the “defendants”) in the U.S. District Court for the Western District of Pennsylvania on behalf of certain purchasers of securities of Mylan N.V. The amended complaint alleges that defendants made false or misleading statements and omissions of purportedly material fact, in violation of federal securities laws, in connection with disclosures relating to the Morgantown manufacturing plant and inspections at the plant by the FDA. Plaintiff seeks certification of a class of purchasers of Mylan N.V. securities between February 16, 2016 and May 7, 2019. The complaint seeks monetary damages, as well as the plaintiff’s fees and costs. On February 15, 2021, a complaint was filed by Skandia Mutual Life Ins. Co., Lansforsakringar AB, KBC Asset Management N.V., and GIC Private Limited, against the Company, certain of Mylan N.V.’s former directors and officers, a current director and officer of the Company, and current employees of the Company. The Complaint asserts claims which are based on allegations that are similar to those in the SDNY and the Western District of Pennsylvania complaints identified above. Plaintiffs seek compensatory damages, costs and expenses and attorneys’ fees. On October 28, 2021, the Company and certain of its then officers and directors were named as defendants in a putative class action lawsuit filed in the Court of Common Pleas of Allegheny County, Pennsylvania on behalf of former Mylan shareholders who received Company common stock in connection with the Combination. A non-Viatris affiliated company and persons were also named as defendants. The complaint alleges violations of Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 for purportedly failing to disclose or misrepresenting material information in the registration statement and related prospectus issued in connection with the Combination. On January 3, 2023, an amended complaint was filed naming the same defendants and alleging the same violations as the original complaint. Plaintiffs seek monetary damages, reasonable costs and expenses, and certain other equitable and injunctive relief. Opioids The Company, along with other manufacturers, distributors, pharmacies, pharmacy benefit managers, and individual healthcare providers is a defendant in more than 1,000 cases in the United States and Canada filed by various plaintiffs, including counties, cities and other local governmental entities, asserting civil claims related to sales, marketing and/or distribution practices with respect to prescription opioid products. In addition, lawsuits have been filed as putative class actions including on behalf of children with Neonatal Abstinence Syndrome due to alleged exposure to opioids. The lawsuits generally seek equitable relief and monetary damages (including punitive and/or exemplary damages) based on a variety of legal theories, including various statutory and/or common law claims, such as negligence, public nuisance and unjust enrichment. The vast majority of these lawsuits have been consolidated in an MDL in the U.S. District Court for the Northern District Court of Ohio. On January 13, 2023, the Company received a civil subpoena from the Attorney General of the State of New York seeking information relating to opioids manufactured, marketed, or sold by the Company and related subject matter. The Company is fully cooperating with this subpoena request. Meda Sweden Commercial Dispute On August 30, 2021, Ocular AS and other related entities (“Claimants”) initiated an arbitration in Sweden against Meda OTC AB and Meda AB (collectively, “Meda” or the “Company”) alleging breach of a 2013 sale and purchase agreement between Claimants and Meda concerning commercialization of a dental hygiene product. Claimants are seeking approximately $155 million in purported damages, plus interest and costs. The Company believes that it acted lawfully and vigorously contested all aspects of Claimants’ case – including their asserted damages – at an arbitration hearing that took place in February 2023. Product Liability Like other pharmaceutical companies, the Company is involved in a number of product liability lawsuits related to alleged personal injuries arising out of certain products manufactured/or distributed by the Company, including but not limited to those discussed below. Plaintiffs in these cases generally seek damages and other relief on various grounds for alleged personal injury and economic loss. The Company has accrued approximately $65.3 million as of December 31, 2022 for its product liability matters. It is reasonably possible that we will incur additional losses and fees above the amount accrued but we cannot estimate a range of such reasonably possible losses or legal fees related to these claims at this time. There are no assurances, however, that settlements reached and/or adverse judgments received, if any, will not exceed amounts accrued. Nitrosamines The Company, along with numerous other manufacturers, retailers, and others, are parties to litigation relating to alleged trace amounts of nitrosamine impurities in certain products, including valsartan and ranitidine. The vast majority of these lawsuits naming the Company in the United States are pending in two MDLs, namely an MDL pending in the United States District Court for the District of New Jersey concerning valsartan and an MDL pending in the United States District Court for the Southern District of Florida concerning ranitidine. The lawsuits against the Company in the MDLs include putative and certified classes seeking the refund of the purchase price and other economic and punitive damages allegedly sustained by consumers and end payors as well as individuals seeking compensatory and punitive damages for personal injuries allegedly caused by ingestion of the medications. Similar lawsuits pertaining to valsartan have been filed in other countries. Third party payor, consumer and medical monitoring classes were certified in the valsartan MDL and a Rule 23(f) petition to appeal the certification decision is pending. The Company has also received claims and inquiries related to these products, as well as requests to indemnify purchasers of the Company’s API and/ or finished dose forms of these products. The original master complaints concerning ranitidine were dismissed on December 31, 2020. The end-payor plaintiff immediately appealed to the U.S. Court of Appeals for the Eleventh Circuit, which affirmed the dismissal. The personal injury and consumer putative class plaintiffs filed amended master complaints. The Company was not named as a defendant in the amended master complaints, though it was still named in certain short form complaints filed by personal injury plaintiffs. The trial court has dismissed all remaining claims against the generic defendants. Certain of the personal injury plaintiffs appealed this dismissal, which remains pending. Lipitor A number of individual and multi-plaintiff lawsuits have been filed against Pfizer in various federal and state courts alleging that the plaintiffs developed type 2 diabetes purportedly as a result of the ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to an MDL in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the MDL were remanded to certain state courts. In 2017, the District Court granted Pfizer’s motion for summary judgment, dismissing all of the cases pending in the MDL. In June 2018, this dismissal was affirmed by the U.S. Court of Appeals for the Fourth Circuit. The state court proceedings remain pending in various jurisdictions, including in California, Missouri, and New York. On January 27, 2021, the California Court granted Pfizer’s motion to exclude the opinions of plaintiffs’ only general causation expert in connection with his opinions involving the three lowest doses of Lipitor (10, 20 and 40 mg). The Company’s motion for summary judgment in connection with the 10, 20, and 40 mg plaintiffs was granted, resulting in their dismissal. On November 3, 2021, the Court granted the Company’s motion seeking the dismissal of the remaining cases involving the highest dose of Lipitor (80 mg). Viagra Since April 2016, an MDL has been pending in the U.S. District Court for the Northern District of California, in which plaintiffs allege that they developed melanoma and/or the exacerbation of melanoma purportedly as a result of the ingestion of Viagra. Additional cases filed against Eli Lilly and Company (“Lilly”) with respect to Cialis have also been consolidated in the MDL. Plaintiffs seek compensatory and punitive damages. In January 2020, the District Court granted Pfizer’s and Lilly’s motion to exclude all of plaintiffs’ general causation opinions. As a result, in April 2020, the District Court entered summary judgment in favor of defendants and dismissed all of plaintiffs’ claims. The parties have settled this matter. Intellectual Property The Company is involved in a number of patent litigation lawsuits involving the validity and/or infringement of patents held by branded pharmaceutical manufacturers including but not limited to the matters described below. The Company uses its business judgment to decide to market and sell certain products, in each case based on its belief that the applicable patents are invalid and/or that its products do not infringe, notwithstanding the fact that allegations of patent infringement(s) or other potential third party rights have not been finally resolved by the courts. The risk involved in doing so can be substantial because the remedies available to the owner of a patent for infringement may include, a reasonable royalty on sales or damages measured by the profits lost by the patent owner. If there is a finding of willful infringement, damages may be increased up to three times. Moreover, because of the discount pricing typically involved with bioequivalent products, patented branded products generally realize a substantially higher profit margin than generic and biosimilar products. The Company also faces challenges to its patents, including suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments, or other parties are seeking damages for allegedly causing delay of generic entry. An adverse decision in any of these matters could have an adverse effect that is material to our business, financial condition, results of operations, cash flows, ability to pay dividends and/or stock price. The Company has accrued approximately $107.9 million as of December 31, 2022 for its intellectual property matters. It is reasonably possible that we will incur additional losses and fees above the amount accrued but we cannot estimate a range of such reasonably possible losses or legal fees related to these claims at this time. There are no assurances, however, that settlements reached and/or adverse judgments received, if any, will not exceed amounts accrued. Dimethyl Fumarate On June 30, 2017, Biogen MA Inc. and Biogen International GmbH (collectively, “Biogen”) sued MPI in the U.S. District Court for the Northern District of West Virginia asserting that MPI’s abbreviated new drug application for dimethyl fumarate delayed-release capsules containing 120 mg and 240 mg of dimethyl fumarate (generic for Tecfidera®) infringed six U.S. patents that Biogen had listed in the Orange Book: 6,509,376, 7,320,999, 7,619,001, 7,803,840, 8,759,393, and 8,399,514. All patents except for the ‘514 expired during the litigation and were dismissed from the case. After a trial involving only the ’514 patent on June 18, 2020, the District Court issued a judgment finding all claims of the ’514 patent invalid for lack of adequate written description. On appeal, the Federal Circuit affirmed the District Court’s judgment. Biogen’s petition for rehearing was denied. Biogen’s petition seeking review by the U.S. Supreme Court was also denied. On July 13, 2018, MPI filed an IPR petition challenging the ’514 patent based only on obviousness. On February 5, 2020, the PTAB issued a final written decision finding the claims not obvious. MPI’s appeal of the PTAB decision is moot in light of the U.S. Supreme Court denying review of the Federal Circuit’s affirmance of the District Court’s invalidity judgment. These matters are resolved. On August 17, 2020, the FDA approved MPI’s dimethyl fumarate delayed-release capsules, which MPI began selling on August 18, 2020. Lyrica - United Kingdom Beginning in 2014, Pfizer was involved in patent litigation in the English courts concerning the validity of its Lyrica pain use patent. In 2015, the High Court of Justice in London ordered that the NHS England issue guidance for prescribers and pharmacists directing the prescription and dispensing of Lyrica by brand when pregabalin was prescribed for the treatment of neuropathic pain and entered a preliminary injunction against certain Sandoz group companies preventing the sale of Sandoz’s full label pregabalin product. Pfizer undertook to compensate certain generic companies and NHS entities for losses caused by these orders, which remained in effect until patent expiration in July 2017. In November 2018, the U.K. Supreme Court ruled that all the relevant claims directed to neuropathic pain were invalid. Dr. Reddy’s Laboratories filed a claim for monetary damages, interest, and costs in May 2020, followed by the Scottish Ministers and fourteen Scottish Health Boards (together, NHS Scotland) in July 2020. In September 2020, Teva, Sandoz, Ranbaxy, Actavis, and the Secretary of State for Health and Social Care, together with 32 other NHS entities (together, NHS England, Wales, and Northern Ireland) filed their claims. All of the claims except for those filed by Dr. Reddy’s Laboratories and NHS Scotland have been resolved. A trial on the remaining claims has been set for November 2023. Yupelri Beginning in January 2023, certain generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Yupelri® with associated Paragraph IV certifications. The companies assert the invalidity and/or non-infringement of polymorph patents expiring in 2030 and 2031, and a method of use patent expiring in 2039. The companies have not filed Paragraph IV certifications to our compound patents, which currently expire in December 2025, with one compound patent subject to a patent term extension to October 2028. In February 2023, we brought patent infringement actions against the generic filers in federal district courts, including the U.S. District Court for the District of New Jersey, the U.S. District Court for the District of Delaware, and the U.S. District Court for the Middle District of North Carolina, asserting infringement of the patents by the generic companies. Other Litigation The Company is involved in various other legal proceedings including commercial, contractual, employment, or other similar matters that are considered normal to its business. The Company has approximately $24.5 million accrued related to these various other legal proceedings at December 31, 2022.

Goodwill and Other Intangible Assets (Components of Intangible Assets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-lived intangible asset, estimated useful life, in years	15 years	15 years
Finite-lived intangible assets, original cost	$ 37,490.5	$ 39,006.2
Finite-lived intangible assets, accumulated amortization	14,923.6	12,918.5
Finite-lived intangible assets, net book value	22,566.9	26,087.7
In-process research and development	40.2	46.5
Intangible assets, gross, excluding goodwill	37,530.7	39,052.7
Intangible assets, net book value, excluding goodwill	$ 22,607.1	$ 26,134.2

Summary of Significant Accounting Policies (Basic And Diluted Earnings Per Ordinary Share Attributable To Mylan N.V.) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ 2,078.6	$ (1,269.1)	$ (669.9)
Weighted average common shares outstanding	1,212.1	1,208.8	601.2
Basic earnings (loss) per share attributable to Viatris Inc. shareholders	$ 1.71	$ (1.05)	$ (1.11)
Weighted average number diluted shares outstanding adjustment, stock-based awards and warrants	5.3	0.0	0.0
Total dilutive shares outstanding	1,217.4	1,208.8	601.2
Diluted earnings (loss) per share attributable to Viatris Inc. shareholders	$ 1.71	$ (1.05)	$ (1.11)
Retained Earnings
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ 2,078.6	$ (1,269.1)	$ (669.9)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

+ Details

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Earnings Per Common Share Attributable To Mylan

Basic and diluted earnings per share attributable to Viatris Inc. are calculated as follows:


	Year Ended December 31,
(In millions, except per share amounts)	2022		2021		2020
Basic earnings (loss) attributable to Viatris Inc. common shareholders (numerator):
Net earnings (loss) attributable to Viatris Inc. common shareholders	$	2,078.6	$	(1,269.1)	$	(669.9)
Shares (denominator):
Weighted average shares outstanding	1,212.1		1,208.8		601.2
Basic earnings (loss) per share attributable to Viatris Inc. shareholders	$	1.71	$	(1.05)	$	(1.11)

Diluted earnings (loss) attributable to Viatris Inc. common shareholders (numerator):
Net earnings (loss) attributable to Viatris Inc. common shareholders	$	2,078.6	$	(1,269.1)	$	(669.9)
Shares (denominator):
Weighted average shares outstanding	1,212.1		1,208.8		601.2
Share-based awards	5.3		—		—
Total dilutive shares outstanding	1,217.4		1,208.8		601.2
Diluted earnings (loss) per share attributable to Viatris Inc. shareholders	$	1.71	$	(1.05)	$	(1.11)

Balance Sheet Components (Other noncurrent liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Other Noncurrent Liabilities [Line Items]
Employee benefit liabilities	$ 544.6	$ 876.4
Contingent consideration	375.0	199.7	$ 223.6
Tax related items, including contingencies	414.6	426.1
Operating lease liability	181.4	200.9
Accrued restructuring	60.4	64.3
Other	244.9	232.9
Other Liabilities, Noncurrent	1,756.5	1,933.6
Biocon Biologics
Schedule of Other Noncurrent Liabilities [Line Items]
Contingent consideration	221.2
Other Noncurrent Liabilities
Schedule of Other Noncurrent Liabilities [Line Items]
Contingent consideration	$ 310.6	$ 133.0	$ 123.1

Litigation (Narrative) (Details) $ in Millions			3 Months Ended	12 Months Ended
Litigation (Narrative) (Details) $ in Millions	Aug. 30, 2021	Jun. 30, 2017 agreement	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022	Dec. 31, 2022 state	Dec. 31, 2021 USD ($)	Sep. 30, 2020 healthBoard entity
Loss Contingencies [Line Items]
Litigation settlement paid			$ 5.0
Number of cases					1,000
Number of patents allegedly infringed \| agreement		6
Scottish Health Boards \| healthBoard								14
NHS Entities \| entity								32
Ocular AS
Loss Contingencies [Line Items]
Damages sought in lawsuit	155 million
Product Liability
Loss Contingencies [Line Items]
Loss contingency accrual				$ 65.3
Intellectual Property
Loss Contingencies [Line Items]
Loss contingency accrual				107.9
Other Foreign Operations
Loss Contingencies [Line Items]
Loss contingency accrual				24.5
MDL
Loss Contingencies [Line Items]
Number of states					46	46
Anticompetitive Conduct with Generic Drugs
Loss Contingencies [Line Items]
Number of states					47
Amended Anticompetitive Conduct with Generic Drugs
Loss Contingencies [Line Items]
Number of states					42
EpiPen Auto-Injector Litigation
Loss Contingencies [Line Items]
Loss contingency accrual							$ 264.0
EpiPen Auto-Injector Litigation \| Other current liabilities
Loss Contingencies [Line Items]
Litigation accrual				$ 5.5
Amended Multi District Litigation
Loss Contingencies [Line Items]
Number of states					36

Debt

12 Months Ended

Dec. 31, 2022

Debt Disclosure [Abstract]

Debt

Short-Term Borrowings

The Company did not have any short-term borrowings as of December 31, 2022 and had $1.49 billion of short-term borrowings as of December 31, 2021.


(In millions)	December 31, 2022		December 31, 2021
Commercial paper notes	$	—	$	1,173.4
Receivables Facility	—		318.5

Other	—		1.1
Short-term borrowings	$	—	$	1,493.0

The following provides an overview of the Company’s short-term credit facilities.

Receivables Facility and Note Securitization Facility

The Company has a $400 million Receivables Facility which expires in April 2025 and a $200 million Note Securitization Facility which expires in August 2023. Under the terms of each of the Receivables Facility and Note Securitization Facility, certain of our accounts receivable secure the amounts borrowed and cannot be used to pay our other debts or liabilities. The amount that we may borrow at a given point in time is determined based on the amount of qualifying accounts receivable that are present at such point in time.

Borrowings outstanding under the Receivables Facility bear interest at the applicable base rate plus 0.775% and under the Note Securitization Facility at the relevant base rate plus 0.85% and are included as a component of short-term borrowings, while the accounts receivable securing these obligations remain as a component of accounts receivable, net, in our consolidated balance sheets. In addition, the agreements governing the Receivables Facility and Note Securitization Facility contain various customary affirmative and negative covenants, and customary default and termination provisions with which the Company was compliant as of December 31, 2022. As of December 31, 2022 and 2021, the Company had $474.9 million and $388.9 million, respectively, of accounts receivable balances sold to its subsidiary Mylan Securitization under the Receivables Facility.

Long-Term Debt

A summary of long-term debt is as follows:


($ in millions)	Interest Rate as of December 31, 2022		December 31, 2022		December 31, 2021
Current portion of long-term debt:

2022 Euro Senior Notes (a) ****	0.816	%	—		856.6
2022 Senior Notes (b) ***	1.125	%	—		1,002.9
2023 Senior Notes (c) *	3.125	%	750.6		—
2023 Senior Notes *	4.200	%	499.8		—
Other			0.7		0.9
Deferred financing fees			(0.6)		(0.1)
Current portion of long-term debt			$	1,250.5	$	1,860.3

Non-current portion of long-term debt:






2023 Senior Notes (c) *	3.125	%	—		766.1
2023 Senior Notes *	4.200	%	—		499.6
2024 Euro Senior Notes **	2.250	%	1,069.8		1,135.8
2024 Euro Senior Notes ****	1.023	%	813.5		871.6
2025 Euro Senior Notes *	2.125	%	534.8		567.8
2025 Senior Notes ***	1.650	%	759.6		763.4
2026 Senior Notes **	3.950	%	2,243.2		2,241.4
2027 Euro Senior Notes ****	1.362	%	945.9		1,013.0
2027 Senior Notes ***	2.300	%	775.3		780.8
2028 Euro Senior Notes **	3.125	%	798.5		847.4
2028 Senior Notes *	4.550	%	748.9		748.7
2030 Senior Notes ***	2.700	%	1,512.8		1,520.5
2032 Euro Senior Notes ****	1.908	%	1,444.4		1,546.6
2040 Senior Notes ***	3.850	%	1,650.6		1,657.1
2043 Senior Notes *	5.400	%	497.4		497.3
2046 Senior Notes **	5.250	%	999.9		999.9
2048 Senior Notes *	5.200	%	747.8		747.8
2050 Senior Notes ***	4.000	%	2,200.8		2,205.1
YEN Term Loan Facility	Variable		305.1		347.6

Other			2.0		1.9
Deferred financing fees			(35.1)		(42.3)
Long-term debt			$	18,015.2	$	19,717.1

____________

(a) The 2022 Euro Senior Notes were repaid at maturity in the second quarter of 2022.

(b) The 2022 Senior Notes were repaid at maturity in the second quarter of 2022.

* Instrument was issued by Mylan Inc.

** Instrument was originally issued by Mylan N.V.; now held by Utah Acquisition Sub Inc.

*** Instrument was issued by Viatris Inc.

**** Instrument was issued by Upjohn Finance B.V.

Senior Notes

Upjohn Senior Notes

In connection with the Combination, in June 2020, Viatris and Upjohn Finance B.V. completed privately placed debt offerings of $7.45 billion aggregate principal amount of the Unregistered Upjohn U.S. Dollar Notes and €3.60 billion aggregate principal amount of the Upjohn Euro Notes, respectively.

The Unregistered Upjohn U.S. Dollar Notes were issued pursuant to an indenture dated June 22, 2020 in a private offering exempt from the registration requirements of the Securities. In October 2021, substantially all of the then-outstanding $7.45 billion aggregate principal amount of Unregistered Upjohn U.S. Dollar Notes were exchanged for Registered Upjohn Notes registered under the Securities Act in the same aggregate principal amount and with terms substantially identical in all material respects with the corresponding series of Unregistered Upjohn U.S. Dollar Notes.

The Upjohn Euro Notes were issued pursuant to an indenture dated June 23, 2020 in a private offering exempt from the registration requirements of the Securities Act. Viatris and Upjohn Finance B.V. are U.S. dollar functional entities.

The net proceeds from the offerings of the Upjohn Senior Notes, together with the proceeds from the $600 million USD Term Loan Facility, were utilized to fund the $12 billion cash payment by Viatris to Pfizer as partial consideration for Pfizer’s contribution of the Upjohn Business to Viatris and related transaction fees and expenses.

Assumptions and Guarantees of Senior Unsecured Notes

Viatris Inc. is the issuer of the Upjohn U.S. Dollar Notes, which are fully and unconditionally guaranteed on a senior unsecured basis by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc.

Upjohn Finance B.V. is the issuer of the Upjohn Euro Notes, which are fully and unconditionally guaranteed on a senior unsecured basis by Viatris Inc., Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc.

Following the Combination, Utah Acquisition Sub Inc. is the issuer of the Utah U.S. Dollar Notes and the Utah Euro Notes, which are each fully and unconditionally guaranteed on a senior unsecured basis by Mylan Inc., Viatris Inc. and Mylan II B.V.

Mylan Inc. is the issuer of the Mylan Inc. U.S. Dollar Notes and the Mylan Inc. Euro Notes, which are each fully and unconditionally guaranteed on a senior unsecured basis by Mylan II B.V., Viatris Inc. and Utah Acquisition Sub Inc.

YEN Term Loan Facility and 2021 Revolving Facility

In July 2021, Viatris entered into (i) the ¥40 billion YEN Term Loan Facility and (ii) the $4.0 billion 2021 Revolving Facility with various syndicates of banks. The YEN Term Loan Facility and the 2021 Revolving Facility will mature in July 2026 and contain customary affirmative covenants for facilities of this type, including covenants pertaining to the delivery of financial statements, notices of default and certain material events, maintenance of corporate existence and rights, property, and insurance and compliance with laws, as well as customary negative covenants for facilities of this type, including a financial covenant, which set the Maximum Leverage Ratio as of the end of any quarter at 4.25 to 1.00 for each quarter ending after June 30, 2021 through and including June 30, 2022, 4.0 to 1.00 for each quarter ending after June 30, 2022 through and including December 31, 2022 and 3.75 to 1.00 thereafter, except in circumstances as defined in the related credit agreement, and other limitations on the incurrence of subsidiary indebtedness, liens, mergers and certain other fundamental changes, investments and loans, acquisitions, transactions with affiliates, payments of dividends and other restricted payments and changes in our lines of business. Up to $1.65 billion of the 2021 Revolving Facility will be available to repay outstanding borrowings under our Commercial Paper Program if necessary.

Fair Value

At December 31, 2022 and 2021, the aggregate fair value of the Company’s outstanding notes was approximately $15.36 billion and $22.01 billion, respectively. The fair values of the outstanding notes were valued at quoted market prices from broker or dealer quotations and were classified as Level 2 in the fair value hierarchy.

Mandatory minimum repayments remaining on the notional amount of outstanding long-term debt at December 31, 2022 were as follows for each of the periods ending December 31:


(In millions)	Total
2023	$	1,250
2024	1,873
2025	1,285
2026	2,555
2027	1,660
Thereafter	10,091
Total	$	18,714

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2022
Audit Information [Abstract]
Auditor Name	DELOITTE & TOUCHE LLP
Auditor Location	Pittsburgh, Pennsylvania
Auditor Firm ID	34

Segment Information (Net Third Party Sales Classified Based on Geographic Location of Entity) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 16,218.1	$ 17,813.6	$ 11,819.9
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	3,946.6	4,176.4	3,746.1
CHINA
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 1,951.3	$ 1,981.5	$ 216.1

- Definition

+ References

+ Details

Balance Sheet Components (Trade Accounts Payable) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Accounts Payable, Current [Abstract]
Trade accounts payable	$ 1,158.0	$ 1,056.1
Other payables	608.6	601.3
Accounts payable	$ 1,766.6	$ 1,657.4

Equity Method Investments (Income Statement) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Total revenues	$ 16,262.7	$ 17,886.3	$ 11,946.0
Gross loss	6,497.0	5,575.5	3,796.7
Operating and non-operating expense	2,813.2	(664.4)	(721.2)
Net loss	$ 2,078.6	(1,269.1)	(669.9)
Consolidated Entity
Schedule of Equity Method Investments [Line Items]
Total revenues		326.7	374.5
Gross loss		(4.6)	(4.6)
Operating and non-operating expense		16.8	19.0
Net loss		$ (21.4)	$ (23.6)

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

+ Details

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Principles of Consolidation Policy

Use of Estimates in the Preparation of Financial Statements Policy

Foreign Currencies Policy

Cash and Cash Equivalents Policy

Cash and Cash Equivalents. Cash and cash equivalents are comprised of highly liquid investments with an original maturity of three months or less at the date of purchase.

Debt and Equity Securities Policy

Concentrations of Credit Risk Policy

Concentrations of Credit Risk. Financial instruments that potentially subject the Company to credit risk consist principally of interest-bearing investments, derivatives and accounts receivable.

Inventories Policy

Property, Plant and Equipment Policy

Intangible Assets and Goodwill Policy

Purchases of developed products and licenses that are accounted for as asset acquisitions are capitalized as intangible assets and amortized over an estimated useful life.

Contingent Consideration Policy

Impairment of Long-Lived Assets Policy

Divestitures Policy

Short-Term Borrowings

Revenue Recognition Policy

Receivables, including deferred consideration, with terms in excess of one year are initially recorded at their net present value using discount rates reflecting the relative credit risk.

Research and Development Policy

Research and Development. R&D expenses are charged to operations as incurred.

Income Taxes Policy

Earnings Per Common Share Policy

Basic and diluted earnings per share attributable to Viatris Inc. are calculated as follows:


	Year Ended December 31,
(In millions, except per share amounts)	2022		2021		2020
Basic earnings (loss) attributable to Viatris Inc. common shareholders (numerator):
Net earnings (loss) attributable to Viatris Inc. common shareholders	$	2,078.6	$	(1,269.1)	$	(669.9)
Shares (denominator):
Weighted average shares outstanding	1,212.1		1,208.8		601.2
Basic earnings (loss) per share attributable to Viatris Inc. shareholders	$	1.71	$	(1.05)	$	(1.11)

Diluted earnings (loss) attributable to Viatris Inc. common shareholders (numerator):
Net earnings (loss) attributable to Viatris Inc. common shareholders	$	2,078.6	$	(1,269.1)	$	(669.9)
Shares (denominator):
Weighted average shares outstanding	1,212.1		1,208.8		601.2
Share-based awards	5.3		—		—
Total dilutive shares outstanding	1,217.4		1,208.8		601.2
Diluted earnings (loss) per share attributable to Viatris Inc. shareholders	$	1.71	$	(1.05)	$	(1.11)

Stock-Based Compensation Policy

Share-Based Compensation. The fair value of share-based compensation is recognized as expense in the consolidated statements of operations over the vesting period.

Derivatives Policy

Financial Instruments Policy

Level 2: Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Recent Accounting Pronouncements

Recent Accounting Pronouncements.

Adoption of New Accounting Standards

Accounting Standards Issued Not Yet Adopted

Balance Sheet Components (Property, Plant and Equipment) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 5,083.8	$ 5,589.1
Accumulated depreciation	2,059.3	2,400.5
Property, plant and equipment, net	3,024.5	3,188.6
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,936.7	3,054.0
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,539.7	1,808.5
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	474.0	588.7
Land and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 133.4	$ 137.9

Employee Benefit Plans (Changes in Projected Benefit Obligations, Plan Assets and Funded Status) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Projected benefit obligation, beginning of year
Service cost			$ 1.2
Interest cost			1.4
Change in Plan Assets
Fair value of plan assets, beginning of year	$ 1,366.4
Fair value of plan assets, end of year	1,067.1	$ 1,366.4
Pension Benefits
Projected benefit obligation, beginning of year
Projected benefit obligation, beginning of year	1,946.6	2,145.8
Service cost	32.6	38.6	23.5
Interest cost	36.8	31.6	13.5
Participant contributions	3.3	2.0
Acquisitions	2.8	4.0
Plan settlements and terminations	(82.0)	(128.6)
Actuarial (gains) losses	(439.4)	(26.1)
Benefits paid	(54.1)	(52.8)
Impact of foreign currency translation	(67.6)	(67.9)
Projected benefit obligation, end of year	1,379.0	1,946.6	2,145.8
Change in Plan Assets
Fair value of plan assets, beginning of year	1,366.4	1,354.6
Actual return on plan assets	(138.1)	141.7
Company contributions	25.6	97.0
Participant contributions	3.3	2.0
Transferred assets	0.0	(2.1)
Plan settlements	(85.9)	(128.9)
Impact of foreign currency translation	(50.1)	(45.1)
Fair value of plan assets, end of year	1,067.1	1,366.4	1,354.6
Funded status of plans	(311.9)	(580.2)
Other Postretirement Benefits
Projected benefit obligation, beginning of year
Projected benefit obligation, beginning of year	188.4	188.8
Service cost	3.4	3.4
Interest cost	3.7	2.6
Participant contributions	4.5	2.4
Acquisitions	0.0	0.0
Plan settlements and terminations	(4.5)	(4.3)
Actuarial (gains) losses	(43.3)	16.2
Benefits paid	(14.7)	(20.7)
Impact of foreign currency translation	0.0	0.0
Projected benefit obligation, end of year	137.5	188.4	188.8
Change in Plan Assets
Fair value of plan assets, beginning of year	0.0	0.0
Actual return on plan assets	0.0	0.0
Company contributions	10.2	18.3
Participant contributions	4.5	2.4
Defined Benefit Plan, Plan Assets, Business Combination	0.0	0.0
Plan settlements	0.0	0.0
Impact of foreign currency translation	0.0	0.0
Fair value of plan assets, end of year	0.0	0.0	$ 0.0
Funded status of plans	$ (137.5)	$ (188.4)

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions									2 Months Ended	12 Months Ended
	Feb. 24, 2023	Dec. 16, 2022	Sep. 16, 2022	Jun. 16, 2022	Mar. 16, 2022	Dec. 16, 2021	Sep. 16, 2021	Jun. 16, 2021	Feb. 27, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Mar. 17, 2023	Feb. 28, 2022
Accounting Policies [Line Items]
Finite-lived intangible asset, estimated useful life, in years										15 years	15 years
Anti-dilutive securities excluded from computation of earnings per share										11,800	12,700	10,300
Dividends paid per share (in dollars per share)		$ 0.12	$ 0.12	$ 0.12	$ 0.12	$ 0.11	$ 0.11	$ 0.11		$ 0.48	$ 0.33
Share repurchase program, authorized amount														$ 1,000
The Combination
Accounting Policies [Line Items]
Shares issued in Combination												689,900
Cumulative Effect, Period of Adoption, Adjustment
Accounting Policies [Line Items]
Percent of net sales										100.00%
Percent of total assets										100.00%
Subsequent Event
Accounting Policies [Line Items]
Dividends declared (in dollars per share)	$ 0.12
Dividends payable (in dollars per share)													$ 0.12
Shares repurchased during the period (in shares)									21,200
Shares repurchased during the period									$ 250
Minimum
Accounting Policies [Line Items]
Finite-lived intangible asset, estimated useful life, in years										3 years
Maximum
Accounting Policies [Line Items]
Finite-lived intangible asset, estimated useful life, in years										20 years
Machinery and equipment \| Minimum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)										3 years
Machinery and equipment \| Maximum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)										18 years
Buildings and improvements \| Minimum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)										15 years
Buildings and improvements \| Maximum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)										39 years
Capitalized software \| Minimum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)										3 years
Capitalized software \| Maximum
Accounting Policies [Line Items]
Property, plant and equipment, estimated service life (years)										7 years

Comprehensive Earnings

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Comprehensive Earnings

Comprehensive (Loss) Earnings

Accumulated other comprehensive loss, as reflected in the consolidated balance sheets, is comprised of the following:


(In millions)	December 31, 2022		December 31, 2021
Accumulated other comprehensive loss:
Net unrealized (loss) on marketable securities, net of tax	$	(2.3)	$	—
Net unrecognized gain and prior service cost related to defined benefit plans, net of tax	268.5		32.2
Net unrecognized (loss)/gain on derivatives in cash flow hedging relationships, net of tax	(18.5)		9.2
Net unrecognized gain on derivatives in net investment hedging relationships, net of tax	377.0		16.7
Foreign currency translation adjustment	(3,385.9)		(1,802.4)
	$	(2,761.2)	$	(1,744.3)

Components of accumulated other comprehensive (loss) earnings, before tax, consist of the following:


	Year Ended December 31, 2022
	Gains and Losses on Derivatives in Cash Flow Hedging Relationships				Gains and Losses on Net Investment Hedges		Gains and Losses on Marketable Securities		Defined Pension Plan Items		Foreign Currency Translation Adjustment		Totals
(In millions)	Foreign Currency Forward Contracts	Interest Rate Swaps	Total
Balance at December 31, 2021, net of tax			$	9.2	$	16.7	$	—	$	32.2	$	(1,802.4)	$	(1,744.3)
Other comprehensive earnings (loss) before reclassifications, before tax			47.8		460.1		(2.8)		276.3		(1,583.5)		(802.1)
Amounts reclassified from accumulated other comprehensive earnings (loss), before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales	(89.2)		(89.2)										(89.2)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense		4.5	4.5										4.5
Amortization of prior service costs included in SG&A									(0.4)				(0.4)
Amortization of actuarial loss included in SG&A									3.2				3.2
Net other comprehensive earnings (loss), before tax			(36.9)		460.1		(2.8)		279.1		(1,583.5)		(884.0)
Income tax provision			(9.2)		99.8		(0.5)		42.8		—		132.9

Balance at December 31, 2022, net of tax			$	(18.5)	$	377.0	$	(2.3)	$	268.5	$	(3,385.9)	$	(2,761.2)


	Year Ended December 31, 2021
	Gains and Losses on Derivatives in Cash Flow Hedging Relationships				Gains and Losses on Net Investment Hedges		Gains and Losses on Marketable Securities		Defined Pension Plan Items		Foreign Currency Translation Adjustment		Totals
(In millions)	Foreign Currency Forward Contracts	Interest Rate Swaps	Total
Balance at December 31, 2020, net of tax			$	(18.0)	$	(353.6)	$	1.2	$	(26.1)	$	(461.5)	$	(858.0)
Other comprehensive earnings (loss) before reclassifications, before tax			62.7		456.8		(1.1)		67.0		(1,340.9)		(755.5)
Amounts reclassified from accumulated other comprehensive earnings (loss), before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales	(30.9)		(30.9)										(30.9)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense		4.3	4.3										4.3
Amortization of prior service costs included in SG&A									(0.5)				(0.5)
Amortization of actuarial loss included in SG&A									7.4				7.4
Net other comprehensive earnings (loss), before tax			36.1		456.8		(1.1)		73.9		(1,340.9)		(775.2)
Income tax provision			8.9		86.5		0.1		15.6		—		111.1

Balance at December 31, 2021, net of tax			$	9.2	$	16.7	$	—	$	32.2	$	(1,802.4)	$	(1,744.3)


	Year Ended December 31, 2020
	Gains and Losses on Derivatives in Cash Flow Hedging Relationships				Gains and Losses on Net Investment Hedges		Gains and Losses on Marketable Securities		Defined Pension Plan Items		Foreign Currency Translation Adjustment		Totals
(In millions)	Foreign Currency Forward Contracts	Interest Rate Swaps	Total
Balance at December 31, 2019, net of tax			$	(31.6)	$	(74.3)	$	0.6	$	(17.4)	$	(1,674.5)	$	(1,797.2)
Other comprehensive (loss) earnings before reclassifications, before tax			18.5		(305.2)		0.6		(12.1)		1,213.0		914.8
Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales	(4.8)		(4.8)										(4.8)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense		4.5	4.5										4.5
Amortization of prior service costs included in SG&A									—				—
Amortization of actuarial loss included in SG&A									(1.9)				(1.9)
Net other comprehensive (loss) earnings, before tax			18.2		(305.2)		0.6		(14.0)		1,213.0		912.6
Income tax provision (benefit)			4.6		(25.9)		—		(5.3)		—		(26.6)

Balance at December 31, 2020, net of tax			$	(18.0)	$	(353.6)	$	1.2	$	(26.1)	$	(461.5)	$	(858.0)

Employee Benefit Plans (Change in Accumulated Income (Loss) Relating to Defined Benefit Pension and Other Postretirement Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net change	$ 279.1	$ 73.9	$ (14.0)
Pension Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized actuarial (gain) loss	(236.9)
Amortization of actuarial gain/(loss)	3.5
Unrecognized prior service credit (cost)	1.4
Amortization of prior service costs	(0.9)
Impact of foreign currency translation	(0.6)
Net change	(236.3)
Other Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Unrecognized actuarial (gain) loss	(43.4)
Amortization of actuarial gain/(loss)	(0.3)
Unrecognized prior service credit (cost)	0.5
Amortization of prior service costs	0.5
Impact of foreign currency translation	0.0
Net change	$ (43.7)

Share-Based Incentive Plan (Tables)

12 Months Ended

Dec. 31, 2022

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock Awards Activity

The following table summarizes stock awards (stock options and SARs) activity under the 2020 Incentive Plan and 2003 LTIP:


	Number of Shares Under Stock Awards	Weighted Average Exercise Price per Share
Outstanding at December 31, 2019	6,347,709	$	36.97
Granted	814,351	17.37
Exercised	(27,615)	21.13
Forfeited	(422,714)	25.74

Outstanding at December 31, 2020	6,711,731	$	35.36


Forfeited	(1,135,241)	26.39
Outstanding at December 31, 2021	5,576,490	$	37.19


Forfeited	(1,126,848)	31.91
Outstanding at December 31, 2022	4,449,642	$	38.53
Vested and expected to vest at December 31, 2022	4,411,052	$	38.70
Exercisable at December 31, 2022	4,216,884	$	39.65

Nonvested Restricted Stock and Restricted Stock Unit, Including Performance Units, Activity


	Number of Restricted Stock Awards	Weighted Average Grant-Date Fair Value Per Share
Nonvested at December 31, 2021	16,858,128	$	15.12
Granted	16,880,145	10.20
Released	(4,790,749)	17.53
Forfeited	(1,675,598)	12.30
Nonvested at December 31, 2022	27,271,926	$	11.81

Long Term Incentive Plan 2003

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-Based Compensation Plans, Valuation Assumptions


															Year Ended December 31,
															2020
Volatility															46.7%
Risk-free interest rate															1.0%
Expected term (years)															6.5
Forfeiture rate															5.5%
Weighted average grant date fair value per option															$8.07
Dividend yield															—%

Goodwill and Other Intangible Assets (Amortization Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Intangible Assets Excluding Goodwill [Line Items]
Intangible asset amortization expense	$ 2,504.6	$ 2,702.2	$ 1,605.8
Total intangible asset amortization expense (including disposal & impairment charges)	$ 2,678.1	2,805.0	1,688.2
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Goods and Services Sold
In-process research and development
Intangible Assets Excluding Goodwill [Line Items]
IPR&D intangible asset impairment charges	$ 0.6	$ 19.4	$ 37.4

Collaboration and Licensing Agreements	12 Months Ended
Collaboration and Licensing Agreements	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative and Licensing Agreements	Licensing and Other Partner Agreements We periodically enter into licensing and other partner agreements with other pharmaceutical companies for the development, manufacture, marketing and/or sale of pharmaceutical products. Our significant licensing and other partner agreements are primarily focused on the development, manufacturing, supply and commercialization of multiple complex products. Under these agreements, we have future potential milestone payments and co-development expenses payable to third parties as part of our licensing, development and co-development programs. Payments under these agreements generally become due and are payable upon the satisfaction or achievement of certain developmental, regulatory or commercial milestones or as development expenses are incurred on defined projects. Milestone payment obligations are uncertain, including the prediction of timing and the occurrence of events triggering a future obligation and are not reflected as liabilities in the consolidated balance sheets, except for obligations reflected as acquisition related contingent consideration. Refer to Note 10 Financial Instruments and Risk Management for further discussion of contingent consideration. Our potential maximum development milestones not accrued for at December 31, 2022 totaled approximately $347 million. We estimate that the amounts that may be paid during the next twelve months to be approximately $38 million. These agreements may also include potential sales-based milestones and call for us to pay a percentage of amounts earned from the sale of the product as a royalty or a profit share. The amounts disclosed do not include sales-based milestones or royalty or profit share obligations on future sales of product as the timing and amount of future sales levels and costs to produce products subject to these obligations is not reasonably estimable. These sales-based milestones or royalty or profit share obligations may be significant depending upon the level of commercial sales for each product. Revance On February 28, 2018, the Company and Revance entered into an agreement with Revance pursuant to which the Company and Revance are collaborating exclusively, on a world-wide basis (excluding Japan), to develop, manufacture and commercialize a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX®. Under the agreement, the Company is primarily responsible for (a) clinical development activities outside of North America (excluding Japan) (b) regulatory activities, and (c) commercialization for any approved product. Revance is primarily responsible for (a) non-clinical development activities, (b) clinical development activities in North America, and (c) manufacturing and supply of clinical drug substance and drug product; Revance is solely responsible for an initial portion of non-clinical development costs. The remaining portion of any non-clinical development costs and clinical development costs for obtaining approval in the U.S. and Europe is being shared equally between the parties, and the Company is responsible for all other clinical development costs and commercialization expenses. During the year ended December 31, 2020, the Company recorded $30 million of Acquired IPR&D expense for a milestone payment that was due upon the decision to continue the development program. Momenta On January 8, 2016, the Company entered into an agreement with Momenta to develop, manufacture and commercialize up to six of Momenta’s biosimilar candidates. Under the terms of the agreement, the Company and Momenta were jointly responsible for product development and equally shared in the costs and profits of the products with Viatris leading the worldwide commercialization efforts. In January 2019, the parties agreed to the termination of all collaboration activities, except for the continued development of M710, a proposed biosimilar to EYLEA®. In October 2020, Momenta was acquired by Johnson & Johnson. M710 was divested as part of the Biocon Biologics Transaction. Theravance Biopharma On January 30, 2015, the Company entered into a development and commercialization collaboration with Theravance Biopharma, for revefenacin. On November 9, 2018, the Company announced that the FDA approved the NDA for YUPELRI® (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. YUPELRI®, a LAMA, is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the U.S. Viatris is responsible for commercial manufacturing and commercialization. Theravance Biopharma is co-promoting the product in the hospital channel under a profit-sharing arrangement. In 2019, the Company acquired exclusive development and commercialization rights to nebulized revefenacin in China and adjacent territories, which include Hong Kong SAR, the Macau SAR and Taiwan. Theravance Biopharma received an upfront payment of $18.5 million and will be eligible to receive additional potential development and sales milestones together with tiered royalties on net sales of nebulized revefenacin, if approved. Viatris is responsible for all aspects of development and commercialization in the partnered regions, including pre- and post-launch activities and product registration and all associated costs. Under the terms of the agreements, Theravance Biopharma is eligible to receive potential development and sales milestone payments totaling approximately $293 million in the aggregate. As of December 31, 2022, the Company has paid a total of $50.0 million in milestone payments to Theravance Biopharma. FKB On February 22, 2018, the Company entered into a collaboration license and distribution agreement with FKB for the distribution of Hulio®, a biosimilar to AbbVie's Humira® (adalimumab). Under the agreement, the Company has exclusive commercialization rights for the product in the EU and the European Economic Area countries and FKB is responsible for development, manufacturing and supply of the product. On February 27, 2019, the Company amended its agreements with FKB for the commercialization of Hulio®. Under the amended agreements, the Company received the exclusive global commercialization rights for Hulio®. In addition, FKB is eligible to receive additional commercial milestones and royalty payments under the amended agreements. On July 9, 2020, the Company announced that the FDA approved Hulio® (adalimumab-fkjp), a biosimilar to AbbVie's Humira® (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis (4 years and older), psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis, in both prefilled syringe and auto-injector presentations. Hulio® was divested as part of the Biocon Biologics Transaction. Biocon The Company had previously entered into an exclusive collaboration with Biocon on the development, manufacturing, supply and commercialization of multiple, high value biosimilar compounds and three insulin analog products for the global marketplace. The collaboration was terminated upon closing of the Biocon Biologics Transaction. Other Development Agreements We are actively pursuing, and are currently involved in, joint projects related to the development, distribution and marketing of both generic and branded products. Many of these arrangements provide for payments by us upon the attainment of specified milestones. While these arrangements help to reduce the financial risk for unsuccessful projects, fulfillment of specified milestones or the occurrence of other obligations may result in fluctuations in cash flows and Acquired IPR&D expense.

Consolidated Balance Sheets (Parenthetical)	Dec. 31, 2022 $ / shares shares
Ordinary shares, par value, in USD per share \| $ / shares	$ 0.01
Ordinary shares, number of shares authorized	3,000,000,000
Common Stock
Shares issued	1,213,793,231

Balance Sheet Components (Other Current Liabilities) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of other current liabilities [Line Items]
Accrued sales allowances	$ 570.7	$ 492.0
Payroll and employee benefit liabilities	746.8	741.9
Legal and professional accruals, including litigation accruals	297.2	715.6
Contingent consideration	375.0	199.7	$ 223.6
Accrued restructuring	95.3	233.5
Accrued interest	80.2	86.6
Fair value of financial instruments	187.0	61.0
Operating lease liability	80.6	86.7
Due to Biocon Biologics	22.5	0.0
Other	978.1	1,265.5
Other current liabilities	3,440.9	4,619.6
Variable Consideration
Schedule of other current liabilities [Line Items]
Accrued sales allowances	888.8	1,362.1
Other current liabilities
Schedule of other current liabilities [Line Items]
Contingent consideration	$ 64.4	$ 66.7	$ 100.5

Acquisitions and Other Transactions (Other Transactions) (Narrative) (Details) $ / shares in Units, shares in Millions, $ in Millions				1 Months Ended	2 Months Ended	3 Months Ended	12 Months Ended
	Nov. 07, 2022 USD ($)	Nov. 13, 2020 USD ($) shares	Jul. 29, 2019 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)	Mar. 31, 2023 USD ($) right $ / shares	Dec. 31, 2022 USD ($) market	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Nov. 16, 2020 USD ($)
Business Acquisition [Line Items]
Contingent consideration liability				$ 223.6	$ 223.6		$ 375.0	$ 199.7	$ 223.6
Equity securities							42.6	51.0
Goodwill				12,347.0	12,347.0		10,425.8	12,113.7	12,347.0
Famy Life Sciences
Business Acquisition [Line Items]
Equity securities				$ 25.0	$ 25.0				$ 25.0
Subsequent Event \| Famy Life Sciences
Business Acquisition [Line Items]
Gain (Loss) on Sale of Equity Investments						$ 18.9
Viatris Inc. \| Famy Life Sciences
Business Acquisition [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners				13.50%	13.50%				13.50%
Machinery and equipment
Business Acquisition [Line Items]
Acquired intangible assets, weighted average useful life, in years		5 years
Finite-Lived Intangible Assets
Business Acquisition [Line Items]
Acquired intangible assets, weighted average useful life, in years		15 years
Maximum \| Building
Business Acquisition [Line Items]
Acquired intangible assets, weighted average useful life, in years		20 years
Minimum \| Building
Business Acquisition [Line Items]
Acquired intangible assets, weighted average useful life, in years		10 years
Upjohn Inc.
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired			43.00%
Long-term debt, including current portion							$ 13,076.2	13,076.2
Shares issued in Combination \| shares		689.9
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable		$ 10,730.0
Business Combination, Acquisition Related Costs								234.6	$ 602.9
Number Of Markets \| market							165
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory		1,430.0					$ (34.2)
Amortization of Inventory Step Up							1,190.0	238.2
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment		385.0					(5.0)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		18,040.0					18,040.0	18,040.0
Goodwill		2,400.0					2,403.1	$ 2,107.5
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Long-Term Debt		$ 759.4
Business Acquisition, Pro Forma Revenue					$ 866.5		18,284.8
Business Acquisition, Pro Forma Net Income (Loss)					$ 360.9		$ 1,483.7
Oyster Point Pharma, Inc. \| Subsequent Event
Business Acquisition [Line Items]
Business Acquisition, Share Price \| $ / shares						$ 11
Business Acquisition, Non-Transferable Contingent Value Right, Number Of Rights \| right						1
Business Acquisition, Contingent Consideration Per Share \| $ / shares						$ 2
Oyster Point Pharma, Inc. \| Subsequent Event \| Scenario, Forecast
Business Acquisition [Line Items]
Acquisition purchase price						$ 425.0
Contingent consideration liability						$ 60.0
Famy Life Sciences
Business Acquisition [Line Items]
Acquisition purchase price	$ 281.0
Net sales \| Upjohn Inc.
Business Acquisition [Line Items]
Number Of Products			20
Pfizer, Inc.
Business Acquisition [Line Items]
Inventory, Firm Purchase Commitment, Loss				$ 86.5
Pfizer, Inc. \| Upjohn Inc.
Business Acquisition [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent			57.00%
Upjohn Inc. \| Pfizer, Inc.
Business Acquisition [Line Items]
Payments for Business Separation			$ 12,000.0
Long-term debt, including current portion										$ 13,080.0

Comprehensive Earnings (Tables)

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss, as reflected in the consolidated balance sheets, is comprised of the following:


(In millions)	December 31, 2022		December 31, 2021
Accumulated other comprehensive loss:
Net unrealized (loss) on marketable securities, net of tax	$	(2.3)	$	—
Net unrecognized gain and prior service cost related to defined benefit plans, net of tax	268.5		32.2
Net unrecognized (loss)/gain on derivatives in cash flow hedging relationships, net of tax	(18.5)		9.2
Net unrecognized gain on derivatives in net investment hedging relationships, net of tax	377.0		16.7
Foreign currency translation adjustment	(3,385.9)		(1,802.4)
	$	(2,761.2)	$	(1,744.3)

Components of Other Comprehensive Loss

Components of accumulated other comprehensive (loss) earnings, before tax, consist of the following:


	Year Ended December 31, 2022
	Gains and Losses on Derivatives in Cash Flow Hedging Relationships				Gains and Losses on Net Investment Hedges		Gains and Losses on Marketable Securities		Defined Pension Plan Items		Foreign Currency Translation Adjustment		Totals
(In millions)	Foreign Currency Forward Contracts	Interest Rate Swaps	Total
Balance at December 31, 2021, net of tax			$	9.2	$	16.7	$	—	$	32.2	$	(1,802.4)	$	(1,744.3)
Other comprehensive earnings (loss) before reclassifications, before tax			47.8		460.1		(2.8)		276.3		(1,583.5)		(802.1)
Amounts reclassified from accumulated other comprehensive earnings (loss), before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales	(89.2)		(89.2)										(89.2)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense		4.5	4.5										4.5
Amortization of prior service costs included in SG&A									(0.4)				(0.4)
Amortization of actuarial loss included in SG&A									3.2				3.2
Net other comprehensive earnings (loss), before tax			(36.9)		460.1		(2.8)		279.1		(1,583.5)		(884.0)
Income tax provision			(9.2)		99.8		(0.5)		42.8		—		132.9

Balance at December 31, 2022, net of tax			$	(18.5)	$	377.0	$	(2.3)	$	268.5	$	(3,385.9)	$	(2,761.2)


	Year Ended December 31, 2021
	Gains and Losses on Derivatives in Cash Flow Hedging Relationships				Gains and Losses on Net Investment Hedges		Gains and Losses on Marketable Securities		Defined Pension Plan Items		Foreign Currency Translation Adjustment		Totals
(In millions)	Foreign Currency Forward Contracts	Interest Rate Swaps	Total
Balance at December 31, 2020, net of tax			$	(18.0)	$	(353.6)	$	1.2	$	(26.1)	$	(461.5)	$	(858.0)
Other comprehensive earnings (loss) before reclassifications, before tax			62.7		456.8		(1.1)		67.0		(1,340.9)		(755.5)
Amounts reclassified from accumulated other comprehensive earnings (loss), before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales	(30.9)		(30.9)										(30.9)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense		4.3	4.3										4.3
Amortization of prior service costs included in SG&A									(0.5)				(0.5)
Amortization of actuarial loss included in SG&A									7.4				7.4
Net other comprehensive earnings (loss), before tax			36.1		456.8		(1.1)		73.9		(1,340.9)		(775.2)
Income tax provision			8.9		86.5		0.1		15.6		—		111.1

Balance at December 31, 2021, net of tax			$	9.2	$	16.7	$	—	$	32.2	$	(1,802.4)	$	(1,744.3)


	Year Ended December 31, 2020
	Gains and Losses on Derivatives in Cash Flow Hedging Relationships				Gains and Losses on Net Investment Hedges		Gains and Losses on Marketable Securities		Defined Pension Plan Items		Foreign Currency Translation Adjustment		Totals
(In millions)	Foreign Currency Forward Contracts	Interest Rate Swaps	Total
Balance at December 31, 2019, net of tax			$	(31.6)	$	(74.3)	$	0.6	$	(17.4)	$	(1,674.5)	$	(1,797.2)
Other comprehensive (loss) earnings before reclassifications, before tax			18.5		(305.2)		0.6		(12.1)		1,213.0		914.8
Amounts reclassified from accumulated other comprehensive (loss) earnings, before tax:
Gain on foreign exchange forward contracts classified as cash flow hedges, included in net sales	(4.8)		(4.8)										(4.8)
Loss on interest rate swaps classified as cash flow hedges, included in interest expense		4.5	4.5										4.5
Amortization of prior service costs included in SG&A									—				—
Amortization of actuarial loss included in SG&A									(1.9)				(1.9)
Net other comprehensive (loss) earnings, before tax			18.2		(305.2)		0.6		(14.0)		1,213.0		912.6
Income tax provision (benefit)			4.6		(25.9)		—		(5.3)		—		(26.6)

Balance at December 31, 2020, net of tax			$	(18.0)	$	(353.6)	$	1.2	$	(26.1)	$	(461.5)	$	(858.0)

Acquisitions and Other Transactions (Unaudited Pro Forma Financial Results) (Details) - Upjohn Inc. - USD ($) $ / shares in Units, shares in Millions, $ in Millions	2 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2022
Business Acquisition [Line Items]
Total revenues	$ 866.5	$ 18,284.8
Net earnings	$ 360.9	$ 1,483.7
Basic (in usd per share)		$ 1.23
Diluted (in usd per share)		$ 1.23
Basic (in shares)		1,206.8
Diluted (in shares)		1,207.7

Restructuring (2020 Restructuring Plan) (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Restructuring Cost and Reserve [Line Items]

Charges

^[1]

$ 50.5

Cash payment

(25.7)

Restructuring Incurred Cost Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag

true

Reimbursable restructuring charges

26.4

Utilization

(32.9)

Foreign currency translation

1.7

Restructuring Reserve, Ending Balance

22.8

$ 29.2

Corporate (Other)

Restructuring Cost and Reserve [Line Items]

Charges

$ 0.3

30.4

Emerging Markets | Operating Segments

Restructuring Cost and Reserve [Line Items]

Charges

8.2

94.1

8.4

Greater China | Operating Segments

Restructuring Cost and Reserve [Line Items]

Charges

2.5

5.8

18.4

JANZ | Operating Segments

Restructuring Cost and Reserve [Line Items]

Charges

0.9

138.1

2.9

Developed Markets | Operating Segments

Restructuring Cost and Reserve [Line Items]

Charges

74.6

623.8

292.1

Employee Severance

Restructuring Cost and Reserve [Line Items]

Charges

^[1]

9.9

Cash payment

(18.1)

Reimbursable restructuring charges

26.4

Utilization

0.0

Foreign currency translation

1.8

Restructuring Reserve, Ending Balance

20.0

26.4

Other Restructuring

Restructuring Cost and Reserve [Line Items]

Charges

^[1]

40.6

Cash payment

(7.6)

Reimbursable restructuring charges

0.0

Utilization

(32.9)

Foreign currency translation

(0.1)

Restructuring Reserve, Ending Balance

2.8

2020 Restructuring Plan

Restructuring Cost and Reserve [Line Items]

Charges

86.5

892.2

271.3

Acquired in the Combination

92.0

Cash payment

(185.4)

(537.2)

(25.5)

Utilization

(34.9)

(345.0)

(70.8)

Foreign currency translation

(5.4)

(7.1)

0.4

Restructuring Reserve, Ending Balance

$ 157.5

157.5

296.7

267.4

2020 Restructuring Plan | Maximum

Restructuring Cost and Reserve [Line Items]

Charges

1,400.0

2020 Restructuring Plan | Employee Severance

Restructuring Cost and Reserve [Line Items]

Charges

38.2

396.1

195.6

Acquired in the Combination

91.7

Cash payment

(170.1)

(385.5)

(25.1)

Utilization

0.0

Foreign currency translation

(5.1)

(7.0)

0.4

Restructuring Reserve, Ending Balance

155.6

292.6

262.6

2020 Restructuring Plan | Other Restructuring

Restructuring Cost and Reserve [Line Items]

Charges

48.3

496.1

75.7

Acquired in the Combination

0.3

Cash payment

(15.3)

(151.7)

(0.4)

Utilization

(34.9)

(345.0)

(70.8)

Foreign currency translation

(0.3)

(0.1)

0.0

Restructuring Reserve, Ending Balance

$ 1.9

$ 4.1

$ 4.8

[1]

Goodwill and Other Intangible Assets (Product Rights and License by Therapeutic Category) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	$ 22,566.9	$ 26,087.7
Product rights and licenses
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	22,565.9	26,084.5
Product rights and licenses \| Developed Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	12,211.1	14,313.6
Product rights and licenses \| Greater China
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	5,642.9	6,115.0
Product rights and licenses \| JANZ
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	1,325.5	1,495.8
Product rights and licenses \| Emerging Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	3,386.4	4,160.1
Product rights and licenses \| Brands
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	18,578.3	21,146.0
Product rights and licenses \| Brands \| Developed Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	8,762.2	10,066.6
Product rights and licenses \| Brands \| Greater China
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	5,632.3	6,102.9
Product rights and licenses \| Brands \| JANZ
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	1,061.3	1,174.8
Product rights and licenses \| Brands \| Emerging Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	3,122.5	3,801.7
Product rights and licenses \| Complex Gx and Biosimilars
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	178.4	228.3
Product rights and licenses \| Complex Gx and Biosimilars \| Developed Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	177.5	226.8
Product rights and licenses \| Complex Gx and Biosimilars \| Greater China
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	0.0	0.0
Product rights and licenses \| Complex Gx and Biosimilars \| JANZ
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	0.9	1.5
Product rights and licenses \| Complex Gx and Biosimilars \| Emerging Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	0.0	0.0
Product rights and licenses \| Generics
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	3,809.2	4,710.2
Product rights and licenses \| Generics \| Developed Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	3,271.4	4,020.2
Product rights and licenses \| Generics \| Greater China
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	10.6	12.1
Product rights and licenses \| Generics \| JANZ
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	263.3	319.5
Product rights and licenses \| Generics \| Emerging Markets
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]
Finite-lived intangible assets, net	$ 263.9	$ 358.4